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Effects of Adoptive Transfer of Beta-Amyloid Sensitive Immune Cells in a Mouse
Model for Alzheimer’s Disease
Daniel Shippy
ABSTRACT

One major therapeutic target for preventing and treating Alzheimer’s Disease (AD) is removal
of excess β-amyloid (Aβ) from the brain. Both active and passive immunotherapies targeting Aβ
have proven effective in reducing brain Aβ levels and improving cognitive function in mouse
transgenic models of AD. However, these approaches can induce adverse neuropathologic effects
and immunologic over-activation. Indeed, clinical trials of active Aβ immunotherapy in AD patients
were halted due to development of meningoencephalitis, apparently resulting from wide-spread
neuroinflammation. Here we show that a more restricted and specific immune re-activation through
a single adoptive transfer of Aβ-specific T cells can provide long-term benefits to APPsw+PS1
transgenic mice that last at least 1½ months. Aβ-sensitive splenocytes and lymphocytes were
generated in normal mice, re-stimulated with Aβ in vitro, and then adoptively transferred into
cognitively-impaired APPsw+PS1 mice. Compared to control transgenic mice through 1½ month
post-infusion, those mice that received Aβ-sensitive T cells exhibited a reversal of pre-infusion
working memory impairment and demonstrated superior basic mnemonic processing. Step-wise
forward Discriminant Function Analysis of behavioral results clearly demonstrated that T cell
infused mice performed comparably to wild-type non-transgenics, further emphasizing the extent of
vi

cognitive benefit this therapeutic technique afforded. Importantly, a global inflammatory response
did not accompany these benefits. Though no overall reductions in Aβ deposition were noted for T
cell recipient mice, a subset of T cell infused mice that benefited most in cognitive function had
reduced hippocampal burdens, suggesting that hippocampal Aβ burdes did play a role in determining
performance capabilities of these mice. Since chronically high levels of Aβ such as those found in
APPsw+PS1 mice cause immune hypo-responsive/tolerance to Aβ, our results indicate that adoptive
transfer of Aβ-sensitive T-cells can supercede such immune tolerance to Aβ, and may provide a safe,
long-lasting therapy for AD.

vii

Alzheimer’s Disease

Alzheimer’s Disease Background
It is estimated that by the year 2050, 13.2 million individuals in the United
States will be living with a diagnosis of Alzheimer’s Disease, further reinforcing its
position as the most common neurodegenerative disorder and leading cause of
dementia therein (Hebert et al. 2003). Alzheimer’s is characterized by a progressive
loss of cognition and retention accompanied by varied disruptions in behavior and in
many cases extreme psychological disturbances. These symptoms lead to eventual
loss of social integration while at the same time stripping the affected individual of
the ability to care for his or her self. Death is the eventual end result of the disease,
though it is often preceded by an extensive period of complete mobility loss and a
comatose state. The resulting widespread social and economic impact of caring for
such afflicted individuals, already devastating today for many families affected by the
disease, will undoubtedly continue to grow as Alzheimer’s becomes more prevalent.
Though treatments for Alzheimer’s have been approved by the FDA, none
provide long-term reversal or delay of the disease and none serve as a cure (Doody et
al. 2001, Areosa et al. 2005). This, despite the fact that the disease was characterized
nearly a century ago in 1907 by Dr. Alois Alzheimer, who correlated some of the
behavioral impacts of the disease to the most noteworthy aspects of its pathology,
8

including dramatic loss of brain mass and development of both neuritic plaques and
neurofibrillary tangles as well as gliosis (Alzheimer et al. 1995). Even with the surge
of research activity which has occurred within this field over the past several decades
resulting from both its increased prevalence and from increased exposure due to
diagnosis of Alzheimer’s Disease in such noteworthy figures as President Ronald
Reagan, progress in developing treatments and determining preventative measures
has been slow at best. Recent innovative studies involving varied immunotherapeutic
approaches have explored outside the field of typical pharmacological treatments and
have shown promise, however have at the same time been a source of major
disappointment in human applications. With increased understanding of the faults of
such treatments, it is possible that alternate immunological approaches may lead to
valid treatments for Alzheimer’s.
Behavioral Characterization of AD
Due to the progressive nature of Alzheimer’s Disease and to the incomplete
understanding of its development, it has proven useful for clinicians to establish a
staging sequence for Alzheimer’s behavioral impacts. Prior to development of
dementia, it is thought that most individuals enter a transition state termed Mild
Cognitive Impairment (MCI). It is estimated that up to 15% of individuals diagnosed
with MCI proceed to Alzheimer’s development each year, though many are
diagnosed with AD without a prior MCI diagnosis (Feldman et al. 2004). Using
mainly the extent of cognitive impairment present, Alzheimer’s patients can then be
grouped as early, moderate, or advanced phase. Only after death can a true
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verification of AD diagnosis occur via correlation with specific Alzheimer’s
pathology.
A diagnosis of Mild Cognitive Impairment does not always correlate to
development of AD, though the term was specifically developed to describe a state of
lesser impairment preceding Alzheimer’s. It is thought that some limitations of MCI
application may be due to variations in symptom sets used to define it and reliance on
the testimonies of patients and relatives for establishing a history of memory
disruption (Davis and Rockwood 2003). Still, MCI is considered a strong risk factor
for AD development and is therefore clinically relevant. MCI is characterized by
reported working memory deficits, verified to be more significant than is normal for a
patient’s age, with no loss of other functions. Recent studies have also found that
certain patterns of neuropsychiatric symptoms are present in up to 59% of subjects
diagnosed with MCI, including various mood abnormalities and psychosis. In fact,
there appears to be a correlation between presence of neuropsychiatric symptoms
common in AD and progression from MCI to early Alzheimer’s (Feldman et al 2004,
Hwang et al 2004).
During the initial phase of AD, mild to moderate cognitive impairment with
respect to short-term memory is present and is definitive for diagnosis during the life
of the patient (McKhann et al. 1984). Specific behavioral deficits and abnormalities
are present throughout AD and may show some correlation to staging determined by
working memory deficits, though it should be noted that many of these symptoms are
not consistently present on an individual basis. Other major clinical features often
associated with the disease include language and visuospatial deficits, though the
10

former may not appear until mid or often late phase AD. Behavioral symptoms such
as depression, agitation, anxiety, aggression, and insomnia, as well as psychological
symptoms such as delusions and hallucinations have been found to accompany these
deficits during early phase AD, though again these symptom sets are more prevalent
in later AD phases (Moran et al. 2003). These symptoms are often coupled with
functional behavioral impacts such as errors in judgment, untidiness, and transient
confusion as the disease progresses. Not all symptoms are present in all patients, they
occur in widely varied percentages of individuals in this phase of the disease. Moran
et al. recently described three classes of early phase AD patients based on observed
symptom sets, the first with little to no symptoms outside of memory deficits, the
second with additional symptoms related mostly to anxiety and depression, and the
third with additional aggression-based symptoms. Such grouping methodologies
could prove useful in understanding the basis of these symptoms if correlation to
neuropathology can be made.
Entry into moderate phase AD is established based on continued loss of shortterm memory coupled with new, progressive loss of long-term memory. Other
symptoms described for MCI and early phase AD are common to moderate phase AD
as well. Language deficits, which tend to develop later than visuospatial disruptions,
become especially prevalent by the time a patient enters moderate AD. Finally, it is
not uncommon for both behavioral and psychological disturbances developed during
MCI or early phase AD to become even more severe before being lost to immobility
and stupor common to advanced phase AD (Hart et al. 2003). Advanced phase AD
involves an almost complete loss of all memory forms and entry into a vegetative
11

state which continues until death due to illness or systemic loss of bodily functions
occurs.
In a retrospective study, Hart et al. showed that depression, delusions, and
anxiety are the most prevalent of the psychological symptoms present throughout AD,
although hallucinations, elation, and disinhibition may also occur. Numerous studies
have also shown that apathy, motor disturbance, aggression, irritability, appetite
changes, and sleep disturbances are all relatively common behavioral symptoms for
AD (Hart et al 2003, Moran et al 2003, Lyketsos et al 2001). Of these, apathy
appears to be the most prevalent form of behavioral change which occurs.
From the time of diagnosis of AD, an individual may often live as long as
twenty years. With further development of correlations between certain forms of
MCI and progression to AD, the time with which an individual and his or her family
may live with such a diagnosis is ever increasing, further reinforcing the importance
of developing a treatment for the disease.
Pathological Characterization of AD
Although it was Dr. Alois Alzheimer who first described the general
pathological characteristics of AD, an understanding of the true molecular nature of
these markers could not be gained until the 1960s when electron microscopy allowed
for more detailed analysis of neuritic plaques and neurofibrillary tangles (NFT’s), the
two hallmark brain pathologies of the disease (Kidd 1964). In the decades since,
numerous hypotheses regarding the cause of this pathology and its correlation to
behavioral impacts as well as other AD pathological characteristics have been
formulated. Perhaps the most widely acknowledged of these focuses on the presence
12

of a particular protein fragment, Beta-amyloid (Aβ), in the brain and has thus been
termed the amyloid hypothesis. Other AD pathologies such as brain atrophy,
neuronal dystrophy, synaptic loss, and NFT formation are thought to be tied in some
way to Aβ peptide formation in the CNS under this hypothesis.
Aβ is formed from proteolytic processing of the Amyloid Precursor Protein
(APP), a 695-770 amino acid protein typically found in membranes of many cell
types throughout the body. APP contains three relevant cleavage sites which are
discriminately cleaved by the α, β, and γ-secretase complexes. α-Secretase cleaves
within the Aβ domain of the APP molecule, preventing formation of Aβ, while
sequential cleavage by β and γ secretases is needed for amyloidogenesis. The activity
of these latter two enzymatic complexes appears to be increased in later life and even
more so in AD (Canevari et al. 2004). While Aβ is produced in and can be found in
fairly low concentrations throughout the body, it is its activity within the CNS which
appears to be relevant to AD, both in regards to formation of neuritic plaques as well
as through its presence in a soluble form. This is not to suggest that peripheral Aβ is
not relevant to the disease, however, as it has been shown that Aβ is capable of
passing through the blood brain barrier (BBB) (Zlokovic 2004). Some studies in
animal models have even suggested that Aβ may be able to trigger disruptions in the
BBB, which is commonly disrupted in AD patients (Farkas et al. 2003).
Two isoforms of the Aβ peptide can be found within neuritic plaques. Most
contain the 42 amino acid isoform (Aβ1-42), though this isoform is actually less
common elsewhere in the CNS than the second Aβ1-40 peptide. The Aβ1-42 peptide is
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thought to be one of the initiating factors for neuritic plaque formation, originally
aggregating to form what are known as low density or diffuse plaques (Lemere et al.
1996). Inflammatory proteins such as APOE and α-ACT, along with a number of
other proteins produced by various cells of the CNS, are also thought to contribute to
formation of these plaques (Nilsson et al. 2004).
Though the exact nature of plaque formation progression is not understood, it
appears that these diffuse plaques are precursors to the compact plaques noted by Dr.
Alois Alzheimer. It is further acknowledged that as these plaques form there is an
activation of microglial cells which, via secretion of various cytokines, induce
activation of adjacent astrocytic cells, resulting in a co-stimulatory inflammatory
response which may accelerate plaque maturation (D’Andrea et al. 2004). Other
immune cells such as B and T-cells appear to be involved in regulation of this
response. Cytokines such as IL-1 and TNF-α also act by inducing APP messenger
RNA translation, resulting in further increase in Aβ production (Rogers et al 1999).
Inflammatory proteins such as APOE and α-ACT are produced as part of the
response and may be involved in further Aβ deposition by catalyzing conversion of
Aβ to a β-pleated sheet form which is prone to aggregation (Nilsson 2001).
Degradation of adjacent neuronal dendritic and axonal processes further increases the
local inflammatory response via release of intercellular inflammatory factors as well
as additional degrading lysosomal and cytoplasmic enzymes, resulting in even further
damage to surrounding cells. This form of damage elicited by Aβ plaques has caused
this peptide to be termed “neurotoxic”. During this process, Aβ1-42 deposition
14

continues coupled with Aβ1-40 incorporation, finally resulting in formation of compact
(mature) neuritic plaques, each of which is composed of a dense Aβ core surrounded
by reactive microglia and astrocytes and associated with inflammatory proteins such
as APOE and α-ACT. (Selkoe 2001, Nilsson et al. 2004).
Diffuse versions of the neuritic plaque can be found in various regions of the
brain, both inside and outside of the hippocampus and association cortices, which are
the regions most affected with regard to neuronal loss and NFT formation as well as
neuritic dystrophy associated with Aβ pathology. Neuronal loss and other AD
pathologies, including various forms of neuroarchitectural rearrangements in these
regions, are thought to correlate to the losses in working memory noted in AD. It is
primarily in these regions that high levels of compact neuritic plaques can be found,
further reinforcing the importance of these plaques with regards to AD pathology.
It is important to note that Cerebral Amyloid Angiopathy (CAA) is a
pathological feature common in AD which is also directly caused by deposition of
Aβ, this time within the vasculature. Amyloid plaques formed within blood vessels
can lead to microhemmorages and in some cases instigate a stroke. Approximately
80% of individuals over the age of 65 diagnosed with AD are thought to develop
CAA.
Other aspects of this pathology have been linked to Aβ presence, though not
necessarily in compact, aggregated form. Aggregation is thought to begin
intracellularly, with Aβ1-42 fragments twisting together to form first dimmers and then
various oligomeric isoforms (Selkoe 2001). Such intracellular Aβ is thought to
15

influence phosphorylation of tau proteins (Cummings 2004). This phosphorylation
event is known to be linked to imbalances in cellular kinases and phosphatases. Tau
proteins are microtubule components that, when phosphorylated, can twist together in
α-helical pairs to form Paired Helical Filaments (PHFs). These accumulate to form
true NFTs, resulting in disruption of neuronal function and eventually cell death
(Canevari et al. 2004 and Sobow et al.2004).
Loss of cholinergic system functions is another major hallmark of AD, and
this too has been linked to Aβ activity. Aβ is thought to interact with nicotinic
receptors of cholinergic neurons, specifically by binding to α7 nACh Receptors
(Kihara and Shimohama 2004). This interaction is thought to result in inhibition of
calcium activation and acetylcholine release in these neurons, indicating a mechanism
for loss of function in cholinergic pathways. Aβ is also thought to enhance glutamate
excitotoxicity via NMDA receptor interactions. These specific interactions between
Aβ and neurons prone to dysfunction in AD strongly reinforce the importance of the
peptide in the progression of AD, as loss of memory and cognitive functions have
been linked to disruption of these pathways (Kihara and Shimohama 2004).
Further Aβ involvement via activation of caspases has also been proposed,
indicating a mechanism by which cellular apoptosis, a widespread occurrence within
the CNS in AD, may be induced (Eckert et al. 2003). Interactions between Aβ and
mitochondrial membrane transporters along with mitochondrial enzymes are thought
to be involved in decreased mitochondrial activity. This has been proposed as one
mechanism for high levels of oxidative stress found in AD (Canevari et al. 2004,
Marlatt et al. 2004).
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Aβ is also though to disrupt Ca++ transport in neurons, astrocytes, and
microglia. Alteration of Ca++ transport functionality has been linked to alterations in
neuronal signal processing, increased neuronal vulnerability to excitotoxicity, and
activation of both microglia and astrocytes (Cavevari et al. 2004). Aβ can also be
linked to production of oxygen free radical species, which occurs during oxygen
dependent formation of Aβ β-pleated sheets. Free radicals are also formed by
microglia upon activation by Aβ. These reactive species are thought to play a
substantiative role in triggering oxidative damage prevalent in AD. This damage
tends to affect mainly lipids and DNA, and is 3 times more prevalent in AD than in
normal elderly individuals (Hensley et al. 1996, Selkoe 2001). Thus, many of AD’s
pathological features can be attributed to abnormal production and function of Aβ
within the brain. However, it should be noted that there are also several lines of
evidence which suggest that the amyloid hypothesis described above may be incorrect
or at the very least incomplete.
Those malcontent with the amyloid hypothesis have emphasized an inability
of the hypothesis to explain early neurophysiological developments such as synaptic
dysfunction, neuronal loss, and decreased LTP, which occur in varying extents before
formation of Aβ plaques in AD. It has been suggested that Aβ accumulation, like
NFT formation, is truly more a consequence of a separate cellular dysfunction, not
yet entirely elucidated, which occurs before overproduction and aggregation of the
peptide. This is supported by findings in transgenic mice which indicate that synaptic
dysfunction may occur before formation of diffuse or compact amyloid plaques (Lee
et al. 2004). It has even been shown that Aβ may be involved in regulation of long17

term potentiation, indicating that the peptide is not simply a neurotoxic by-product
and that its presence in AD may be an attempt at compensating for neuronal loss, not
necessarily the cause of it (Koudinov and Berezov, 2004). It should be noted that
other studies have shown the opposite effect of the peptide in lowering capacity for
LTP (Selkoe 2002).
Other hypothesis for the actual mechanisms underlying AD focus on cell
cycling and mitochondrial enzymatic disruptions which result in oxidative stress and
neuronal loss and on abnormal levels of enzymes involved in acetylcholine synthesis
and degradation (Raina et al. 2004, Zhu et al. 2004). While it is necessary to consider
these possibilities in seeking an understanding of, and a treatment for, Alzheimer’s, it
is also important to consider in the present that previous studies have shown
correlation between Aβ levels within the CNS and extent of demetia in early stages of
AD (Bussiere et al., 2002), though Aβ load does not correlate directly to cognitive
disturbances as the disease progresses (Terry et al. 1991). Similar correlation can be
made between Aβ plaque loads and cognitive impairment in transgenic mouse models
of AD (Gordon et al. 2001). Synapse loss and neurodegeneration induced by
neurofibrillary tangles serve as better correlates to cognitive impairment (Terry et al.
1991, Arriagada et al. 1992). However, as has been shown above, these pathological
findings may be tied to and perhaps even directly caused by the presence of Aβ.
Also, as elicited above, there are numerous studies which have shown mechanisms by
which Aβ can be neurotoxic and/or can have other negative physiological impacts
within the CNS even in soluble form. Therefore, regardless of other mechanisms
involved in development of AD, there remains definite validity in searching for a
18

means to elicit Aβ clearance as a means of treatment for the disease or for preventing
Aβ formation/aggregation as a means of prevention.
Genetics of AD
Further support for the amyloid hypothesis is provided by analysis of known
genetic mutations linked to Familial Azheimer’s Disease (FAD). FAD typically
follows a similar time course to sporadic AD, which has no known genetic basis, and
differs only with regards to age of onset. FAD diagnosis typically occurs at a much
younger age, as early as 40, than sporadic AD. Each mutation linked to FAD, which
by definition is congenital and runs within families, has an in vivo effect of increasing
Aβ peptide formation, and is an autosomal dominant trait. However, only as few as
one percent of reported AD cases are currently attributed to FAD. The mutations
linked to FAD thus far include those of the APP gene itself, along with those of the
presenilin genes (PS1 and PS2) (Zekanowski et al. 2004, Selkoe 2001).
In 1984, Glenner and Wong proposed that genetic defects in Alzheimer’s
disease would be found on chromosome 21 after discovering that the amyloid protein
prevelant in both Alzheimer’s disease and Down’s syndrome pathology were
homologous (Glenner and Wong, 1984). Indeed, it has been found that mutations of
the APP gene which have been linked to FAD are located at either end of the Aβ
coding domain on chromosome 21p21. There are 16 unique mutations of the gene
which promote AD pathology and 4 which do not, though only 4-6% of FAD cases
are attributed to APP mutations. The result of each mutation is increased Aβ peptide
formation, most likely through increased processing of the APP molecule by β or γ
secretases. With regards to current research in transgenic models, two of the most
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relevant of these are the Swedish and London APP mutations. The Swedish mutation
is located at positions 670 and 671 of the APP molecule and involves a double
missense mutation, while the London mutation, which is a single missense mutation,
is located at position 717. These correlate to the domains cleaved by the β and γ
secretases. Both mutations result in dramatic increases in overall Aβ production, with
varying ratios of Aβ1-40 to Aβ1-42 produced. Specifically, the London mutation results
in an increased ratio of Aβ1-42 to Aβ1-40 while raising levels of both isoform overall,
whereas the Swedish mutation results in approximately equal increases in the levels
of both isoform (Eckman et al. 1997, Suzuki et al. 1994).
As with the London mutation, it is production of the Aβ1-42 peptide which is
most increased as a result of the presenilin (PS) mutations. It is thought that both the
PS1 and PS2 molecules are incorporated into the γ secretase complex and serve as
part or all of the active site for this complex (Farmery et al. 2003). The proteins are
generally found in endoplasmic reticulum of cells and most likely act on APP during
its processing via this organelle. The result of the presenilin mutations is increased
activity of the γ secretase complex, resulting in increased amyloidogenic processing
of APP. The PS1 gene codes for a 467aa protein and is located on chromosome
14q23.3, while the PS2 gene codes for a 448aa protein and is located on chromosome
1q31-42. The genes are highly homologous in their sequences, indicating a similar
function. PS1 mutations are the most common cause of FAD based on current data,
and more than 100 of these mutations have been identified, most of which are
missense. Only 9 PS2 mutations have been identified, all of which are missense, and
20

the prevelance of these mutations is significantly lower than those of PS1 (Kimberly
and Wolfe 2003, Gaskell and Vance 2004).
Diagnosis of AD
The predominant criteria used for the diagnosis of Alzheimer’s comes from
the National Institute for Neurologic and Communicative Disorders and StrokeAlzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA), which
specifies diagnosis as being either definite, probable, or possible based on the extent
of confirmation available. If a histological confirmation, preceded by clinical
diagnosis, is obtained, then a definitive diagnosis for AD is established. Clinical
diagnosis without histological confirmation is deemed as a probable AD case, while a
case with clinical abnormalities but no other diagnostic approaches available is
considered possible AD (Cummings 2004).
The specific clinical features looked for in diagnosing AD are the three major
behavioral hallmarks of the disease; episodic and working memory impairment and
both language and visuospatial deficits. Episodic memory is based on retrieval of
memories of one’s specific past events, typically with events which have occurred
recently being most easily forgotten (Cummings 2004, Greene et al. 1996). Working
memory, or short-term memory, is typically associated only with the ability to recall
occurrences from within minutes of the present. Loss of both episodic and working
memory, which largely correlates to general anterograde amnesia, is perhaps the
easiest of the behavioral hallmarks of AD to identify and the most important for
establishing clinical diagnosis (Welsh et al. 1992, Greene et al. 1996). There are
many tests which can be administered by clinicians in able to determine if such
21

memory loss is present and extent of impairment, including the most common, the
Mini-Mental State Exam (MMSE), which involves giving a patient number of words
to remember followed by a series of questions which serve as a distraction. An
individual’s lack of ability to retain the words given to them at the beginning of the
task (registration-recall) is an indicator of short-term memory impairment. Other
tools for evaluating mental state of potential AD patients include the 7-Minute Screen
and Geriatric Depression Scale (Langbart 2002).
Basic histological measurements which may be correlated to memory
impairment to help strengthen a diagnosis of AD include cerebro-spinal fluid (CSF)
levels of Aβ1-42 and both tau and phospho-tau (p-tau) proteins. Numerous studies
have shown that a dramatic decrease in CSF Aβ1-42 is prevalent in AD (Sobow et al.,
2004; Andreasen et al., 2003). This is thought to correlate to trapping and
aggregation of the peptide in insoluble forms within the CNS, allowing the brain to
act as an Aβ1-42 “sink”. At the same time, levels of both tau and p-tau in the CSF
increase significantly in most cases of AD (Sobow et al., 2004; Andreasen et al.,
2003). Unfortunately, CSF sample collecting is a highly invasive process, making
widespreade clinical application of these histological markers difficult. Current
research studies in the area of Aβ and tau levels in the plasma or other more
accessible fluids are ongoing (Sobow et al. 2004).
Several brain imaging techniques also serves as diagnostic tool for AD.
Computed tomography (CT) and magnetic resonance imaging (MRI) have proven to
be useful as multiple scans over time can show overall brain atrophy and localized
atrophy of the hippocampus and entorrhinal cortex (Barnes et al., 2004; Pennanen et
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al., 2004; de Leon et al., 1997). This form of atrophy is specific to AD, allowing for
exclusion of other dementia types, and can also be used to monitor the progress of the
disease. In some cases it is possible to detect this atrophy during MCI, allowing for
anticipation of an imminent diagnosis of AD. Importantly, studies of AD patients
have shown direct correlation between hippocampal atrophy and memory
impairment, specifically short-term memory (Grundman et al. 2003). Similarly,
overall atrophy of the cerebral cortices has been correlated to long-term memory and
memory retrieval impairment in AD (Bilgler et al. 2004). As discussed above, this
atrophy is likely caused by neuronal loss and restructuring common in these areas
during AD progression. More recently, positron-emmision tomogrogphy (PET) and
single-photon-emission CT scans have been applied to diagnosis of Alzheimer’s.
These scans allow for analysis of regional brain activities, and can target deficits in
activity in regions affected by AD (Cummings 2004, Minoshima 2003). Recently,
the possibility of a technique for imaging of amyloid plaques using a modified
version of the PET scan has been explored which may prove to be a very useful
diagnostic tool in the future (Klunk et al. 2003).
A diagnosis of AD, whether it be definitive, probable, or possible, in a family
with a strong history of the disease with early onset is sufficient cause for genetic
testing for FAD. Tests are clinically available for presenilin mutations, however their
application is limited and no such tests are available for APP mutations. Since there
are numerous mutations which may be present in these genes which do not result in
FAD, it is important that both physician and patient be well informed before genetic
testing results are reviewed. Extensive Genetic counseling is an important aspect of
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this education, meaning that genetic testing for FAD must typically occur through a
hospital with trained genetic counseling staff and should not be performed at a
standard physician’s office. As more FAD mutations and their resulting phenotypes
become better understood, it is likely that the availability of genetic testing will
spread. In the present, the results of genetic testing for FAD are not definitive for
diagnosis but can confirm the presence of a FAD mutation in a family, which may
prove useful for such families in preparing for the disease financially and via
preventative measures (Gaskell and Vance 2004, Zekanowski et al. 2004).
Risk Factors for AD
Certain risk factors for AD such as the most significant one, aging, are in no
way preventable. Other examples of these include sex (females run a higher risk of
developing AD than do males), having a first degree relative with AD, and carrying
the ApoE4 allele of the ApoE gene. The ApoE allele is an extremely important risk
factor for AD, with each ApoE4 allele carried resulting in a sizable increase in AD
risk and typically earlier onset of the disease if developed (Selkoe 2001, Yao et al.
2004). Other risk factors for Alzheimer’s may be prevented or treated, making them
particularly important for individuals already at a high risk for AD.
Preventable AD risk factors include head trauma (especially in young
adulthood), high blood pressure in midlife, high cholesterol levels in midlife, high
blood homocysteine levels, and a number of factors related directly to diet (Fleminger
et al. 2003, Wellington 2004, Ellinson et al. 2004). High levels of social interaction,
mental engagement, and exercise are thought to be related to lowering risk for
developing AD as well via cognitive stimulation. Diet and exercise are also indirectly
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important for regulation of blood pressure and cholesterol levels (Wang et al. 2004).
Reduction of cholesterol by use of statins has also been strongly linked to a decreased
risk for AD (Miller and Chacko 2004). Blood homocysteine levels can be regulated
by intake of vitamins B6, B12, and folic acid, which are involved in metabolism of
the molecule (Ellinson et al. 2004).
Other dietary considerations for preventing AD include decreasing caloric
intake, increasing intake of Tocopherol (Vitamin E) and other antioxidants, and/or
increasing dietary levels of Omega-3 fatty acids (Berman and Brodaty 2004, Bourre
2004). Antioxidants are important for defending the brain against oxidative damage,
and some epidemiological studies looking at dietary antioxidant levels, especially
Vitamin E levels, have shown a negative correlation between intake levels and risk
for AD development, though clinical trials have elicited mixed results (Berman and
Brodaty 2004, Sobow and Kloszewska 2003). The antioxidant properties of Vitamin
E are important in AD largely because they prevent membrane lipid peroxidation,
reducing oxidative damage in the brain.
It is thought that Omega-3 fatty acids such as Docosahexaenoic acid (DHA)
are important for neuronal health and may directly impact APP processing.
Epidemiological studies indicate that decreased dietary levels of fish, which contain
high levels of DHA and other fatty acids, can be considered a risk factor for AD
(Bourre 2004, Kalmijn et al. 1997). A diet high in fruits and vegetables along with
fish results in increased uptake of various antioxidants and n-3 fatty acids, and
patients at risk for Alzheimer’s are often encouraged by doctors to pursue such diets
both because of the direct impact of these molecular components and the indirect
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impact of such diets on cholesterol levels. Other dietetic factors which have been
linked to decreased AD risk include regular intake of nicotine, caffeine, and alcohol,
though for each of these it has yet to be determined if possible preventative
capabilities of these drugs outweigh risks associated with their use or abuse (Dall'Igna
et al. 2004, Teaktong et al. 2004, Letenneur et al. 2004).
Recently, the importance of environment with respect to AD risk has been a
major point of emphasis in Alzheimer’ research. It is becoming apparent that
education level, social integration throughout life, and engagement in mentally
stimulating activities such as writing and working puzzles has some level of
protection against AD development (Fratiglioni et al. 2004). Most risk factors for AD
have been determined through epidemiological studies, so their exact role and
mechanism of protection are difficult to define and are often tied to those of other risk
factors, such as with cholesterol, diet, and exercise. Fortunately, most actions that
individuals can take to help in prevention of AD are generally encouraged as part of a
standard healthy lifestyle and can be undertaken without a full understanding of their
effectiveness.
Current Treatments of AD
There are currently five pharmacological treatments for AD which have been
approved by the FDA. Tacrine (which is no longer used clinically due to its negative
impact on the liver), donepezil, rivastigmine, and galantamine are all
acetylcholinesterase inhibitors, while the fifth drug, memantine, is an antagonist for
NMDA-receptors (Cummings et al. 2004). Acetylcholinesterase inhibitors have been
applied clinically in the United States for many years, and are directed against lost of
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cholinergic function in AD. By inhibiting acetylcholinesterase, which breaks down
acetylcholine, cholinergic transmissions are increased due to raised levels of the
neurotransmitter in the synaptic cleft. Galantamine also acts as an allosteric ligand at
nicotinic acetylcholine receptors, further improving cholinergic function.
Rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase, which is
another cholinesterase largely associated with glial cells (Scarpini et al. 2004).
Treatment with these drugs brings about improvement or stabilization in cognitive
symptoms of mild to moderate AD, however these improvements are small and do
not typically last for more than 1-2 years. Studies are ongoing to determine whether
long-term use is at all beneficial (Scarpini et al. 2004, Sonkusare et al. 2005).
Memantine was only recently approved for treatment of AD by the FDA. By
acting as a partial NMDA-receptor agonist, this drug helps to prevent excitotoxic over
activation of these receptors by glutamate, which is thought to be present in elevated
levels in AD (Sonkusare et al. 2005). Normal levels of NMDA-receptor activation
are desirable due to their importance in long-term potentiation, however, since these
receptors allow long periods of Ca2+ influx into cells upon activation, having too
many receptors open for extended periods may lead to Ca2+ mediated neuronal
degeneration. Proper administration of memantine appears to be able to prevent this
type of excitotoxicity while allowing for normal levels of receptor activation. This
treatment leads to improved cognitive and behavioral functions in the short term over
placebo. Studies combining memantine and donepezil treatments have shown great

27

promise in short term treatment of moderate to severe AD (Tariot et al. 2004). Still,
as with the other approved treatments for AD, memantine’s effects are relatively
small and short lived, emphasizing the importance of continued research in the field
of alternative AD treatments (Scarpini et al. 2004).
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Animal Models of Alzheimer’s Disease

Various animal models for Alzheimer’s Disease have been developed based
on a persistent need for an easily reproduced and cost effective means for studying
behavioral and pathological progression of the disease. These models have since
become invaluable in evaluating potential therapeutics and preventatives. The most
commonly used method for producing these models in mice is through random
insertion of the desired gene into a fertilized mouse egg genome via microinjection or
electroporation. Mice models are desirable because they age quickly for a
mammalian animal, and are relatively easy and cheap to maintain as colonies. The
genes inserted to create these mice are mutant-type human transgenes which are
either linked to FAD, such as mutant APP and presenilin alleles, or which are known
risk factors for AD, such as the ApoE4 allele. In order for these inserted mutations to
exhibit profound effects in subsequent generations of transgenic mice, they are
inserted with strong promoters specifically activated in the mouse brain. For FAD
APP transgenes, the result is massive production of Aβ in the brains of the resulting
transgenic animals which then leads to progressive deposition of this protein fragment
to form neuritic plaques in the CNS. Models based on these mutations include the
PD-APP, Psw (APP23), and APPsw transgenic mice. Other mutations work in
conjunction with these in double transgenic models to further enhance Aβ production
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and/or deposition, but are not sufficient to induce neuritic plaque formation in single
transgenic models. An important example of this type of double transgenic model is
the APPsw+PS1 mouse.
PDAPP Model
Mice transgenic for the “London mutation” human allele of the APP gene
were initially described in 1995 and have since been termed PD-APP mice due to use
of a platelet-derived growth factor promoter for driving expression of the gene. As a
result of using this promoter, PD-APP mice express human APP (hAPP) at levels
approximately 10 times greater than expression levels in human AD brains. This
allows for pathology development during the relatively short lifetime of the mice.
mRNA expression consists of three major variants due to alternative splicing of exons
7 and 8 of the APP gene construct. Over-expression of hAPP containing the 717
single point mutation of Valine to Leucine in the PD-APP mouse brain leads to
development of pathology and behavior which correlates in many ways with that of
Alzheimer’s Disease (Games et al. 1995).
Pathological Characterization of the PDAPP Model
AD-type pathology begins to exhibit itself in PD-APP mice between 6 and 9
months when deposits of Aβ can be detected in plaques formed solely in the
hippocampus, corpus callosum, and cerebral cortex. Deposition continues past this
timepoint until plaque levels parallel or exceed those found in AD. The plaques
noted in PD-APP mice brains range from diffuse to compact, and compact plaques
consist of an Aβ core surrounded by activated astrocytes and microglia, just as is
typical for AD neuritic plaques (Games et al. 1995). While these mice do not exhibit
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cerebral atrophy or widespread neuronal loss, key features of Alzheimer’s pathology
in humans, they do exhibit a loss of both synapses and dendrites in the hippocampal
dentate gyrus coupled with overall hippocampal atrophy (Irizarry et al. 1997). This
correlates to a similar loss in this area of the human AD brain, which is thought to
contribute to short-term memory loss. Further studies of synaptic transmission in the
hippocampus of these mice have shown that there is a reduction of neurotransmission
and LTP which precedes Aβ deposition (Giacchino et al. 2000). This reduction is
also thought to play an important role in affecting behavioral impairment of these
mice.
Behavioral Characterization of the PDAPP Model
In 1999, Dodart et al. reported that PD-APP transgenic mice show ageindependent impairment in the radial arm maze task as early as 3 months of age
despite no deficit in overall motor activity.

By 6 months they were shown to be

impaired in object recognition tasks (Dodart et al. 1999). In 2000, a correlation
between object recognition and Aβ plaque loads was reported along with data
correlating deficits in both spatial and working memory to changes in synaptic
density and hippocampal atrophy (Dodart et al. 2000). That same year, Chen et al.
(2000) reported an age related deficit in working memory using a modified version of
the water maze which included use of a shifting assortment of visual cues and escape
platform locations. Alterations in platform locations after several trials required that
the mice tested learn each new location, forcing them to rely on working memory.
For all age time points, PDAPP mice took longer to learn the location of the hidden
platform than non-transgenic controls in an age-independent manner. However,
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based on last day performance at each time point, impairment was not present at a 6-9
month time point but became apparent at a 13-15 month time point and became even
more prominent at a final 18-21 month time point (Chen et al. 2000). In 2004,
Nilsson et al. tested PDAPP mice and non-transgenic controls in a full 6 week battery
of sensorimotor and cognitive based tasks starting at 2 months and 16 months for
separate groups of animals. While no differences were noted between groups at the
earlier time point, aged PDAPP animals showed impairment in the final block of
Morris water maze and in overall RAWM performance (Nilsson et al. 2004). That
same year, Leighty et al. reported a significant statistical correlation between
impairment in Morris water maze, platform recognition, and RAWM performance
and deposition of Aβ (diffuse and/or compact) in the hippocampus and parietal cortex
in 15-16 month old PDAPP mice. A correlation was also made between circular
platform escape latency and diffuse Aβ deposition in the cerebral cortex. These
patterns of impairment correlated to Aβ deposition in the hippocampus and cerebral
cortex of the mice brains indicate a direct mechanism for working memory loss in this
model of AD.
APPsw (APP23) Model
The “Swedish mutation” transgene has also been used to create hAPP
transgenic mice commonly used in Alzheimer’s research. This transgene carries a
double mutation at positions 670 (LysÆAsn) and 671 (MetÆLeu) in the APP gene, a
mutation originally discovered in a Swedish family predisposed to early onset AD
(Mullan et al., 1995). The most prevalent lines of mice carrying this mutation are the
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APPsw/Tg2576 and the Psw/APP23 mice, which carry different promoters and have
different transgene insert locations resulting in some distinct pathological features.

Pathological Characterization of the Tg2576 Model
In Tg2576 mice, the APP transgene is expressed only by neurons,
predominately in the hippocampus but with a constant, lower level of expression in
other varied cortical regions (Irizarry et al. 1997). By 6-7 months, insoluble Aβ is
present in the brains of these mice, with levels of both Aβ1-42 and Aβ1-40 isoforms
then increasing drastically through 10 months (Kawarabayashi et al. 2001). Amyloid
plaque deposition occurs by 11 months in cortical and limbic regions. Past this time
point and through 23 months of age, levels of both diffuse and neuritic plaques
increase to levels similar to those found in AD. As a result of plaque formation,
decreases in plasma and CSF Aβ levels can be noted progressively through these age
time points (Kawarabayashi et al. 2001).
Amyloid plaques in Tg2576 mice have been shown to be associated with
gliosis and neuritic dystrophy, though importantly no loss of hippocampal CA1
neurons have been reported (Irizarry et al. 1997). Aβ formation and aggregation has
also been associated with a number of other pathological and neurophysiological
features, including activation of microglia and astrocytes, induction of oxidative
stress and damage including lipid peroxidation, and impairment of LTP in CA1 and
dentate gyrus neurons (Frautschy et al. 1998, Benzing et al. 1999, Mehlhorn et al.
2000, Smith et al. 1998, Practico et al. 2001, Chapman et al. 1999). Activated
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microglia were shown to localize with Aβ depostits and increase expression of
Interlukin-1β (IL-1β) and Tumor Necrosis Factor-α (TNF-α) (Benzing et al. 1999).
Immunoreactive astrocytes directly adjacent to plaques were shown to increase
expression of IL-6 and Glial Fibrillary Acidic Protein (GFAP) (Mehlhorn et al. 2000).
These activated immunoreactive cells serve to enhance the inflammatory response
elicited by Aβ. Tg2576 mice have also been shown to have an increased risk for
development of ischemic brain damage, either as a direct result of amyloid plaque
formation or as a result of the inflammatory response process (Zhang et al. 1997).
Pathological Characterization of the APP23 Model
The Psw or APP23 model differs in pathology from the Tg2576 model in one
major respect. These mice are known to develop Cerebral Amyloid Angiopathy
(CAA), which results from amyloid plaque formation in the cerebral vasculature.
This severe pathological feature is not present in Tg2576 mice but occurs at as early
as 14 months in the Psw model. CAA in these mice is associated with loss of neurons
in areas adjacent to CAA pathology (Calhoun et al. 1999). Synaptic abnormalities,
microglial activation, and microhemorrhage are also prevalent in these regions.
Damage to the vasculature can be extreme, beginning with loss of vascular smooth
muscle cells, aneurismal vasodialation and microhemorrhages and eventually leading
to large hemotomas and in some cases hemorrhagic stroke (Winkler et al. 2001).
CAA has been noted in AD, leading some researchers to believe that the Psw mouse
provides a more realistic AD model (Calhoun et al. 1999, Winkler et al. 2001).
Behavioral Characterization of the Tg2576 Model
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Behavioral deficits have been found in both Swedish mutation transgenic
mouse models. Initial studies in Tg2576 mice showed behavioral impairment in Ymaze and Morris water maze tasks by 10-11 months of age, at the same time plaques
developed in these animals (Hsiao et al. 1996, Irizarry et al. 1997). Impaired CA1
and dentate gyrus neuronal LTP was also found to correlate to spatial working
memory impairment based on T-maze alternation impairments at 16 months
compared to non-transgenic controls (Chapman et al. 1999). In two separate studies,
Holcomb et al. showed that Y-maze impairment with regards to percent alternation
was present at 3 and 6 but not 9 months, that no impairment was present at any of
these time points for Morris water maze, and that Tg2576 mice were not impaired in a
number of sensorimotor baseline tasks (Holcomb et al. 1998, Holcomb et al. 1999).
In 1999, it was shown that impairment was present in 7 month old Tg2576 mice not
for initial application but for reversal learning of the circular platform task (Pompl et
al. 1999).
In 2002, King and Arendash behaviorally characterized the Tg2576 model at
3, 9, 14, and 19 months, providing a comprehensive overview of impairment in this
model. This was done via application of a 6-week battery of sensorimotor and
cognitive based tasks. Over all timepoints, it was shown that Tg2576 mice were
impaired in Y-maze spontaneous alternations, by nine months in visible platform
recognition, and over numerous timepoints in sensorimotor tasks such as balance
beam and string agility tasks. Continued levels of performance on par with nontransgenic mice in cognitive based tasks such as Morris water maze, circular
platform, and both passive and active avoidance through 19-months indicated that
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profound cognitive impairment is not present in this model even into old age (King et
al. 2002 (1)). Westerman et al. (2002) found that memory loss in Tg2576 mice at as
early as 6 months could actually be attributed to formation of small insoluble Aβ
aggregates, though at later time points a correlation between these aggregates and
impairment could no longer be drawn based on Morris water maze task results alone
(Westerman et al. 2002). Also in 2002, however, King et al. showed that age
dependent impairment in Morris water maze and platform recognition could be
correlated with synaptophysin staining levels present in APPsw mice through 19
months of age, indicating a connection between impairment and compensatory
measures taken by the mouse brain to combat loss of function (King et al. 2002 (2)).
In 2004, Arendash et al. reported early impairment at 5 months in APPsw
mice in balance beam but no other sensorimotor or anxiety based tasks. Between 5
and 8.5 months, these mice were significantly impaired in Y-maze percent
alternations. Impairment was also noted between 5 and 7 months in Morris maze
acquisition and retention, platform recognition, and RAWM, indicating that for these
mice cognitive impairment is present at an earlier time point than was previously
noted. This was thought to be due to actions of soluble Aβ oligomers present in the
mouse brains at these timepoints, with increased affects due to continual crossbreeding of transgenics and a resulting increased influence of the APP transgene.
(Arendash et al. 2004).
Behavioral Characterization of the APP23 Model
In the APP23 model, three recent studies have shown that cognitive
impairment is present at various timepoints in these animals. In 2003, Kelly et al.
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tested APP23 mice at 3, 18, and 25 months in passive avoidance as well as small and
large Morris water maze and platform recognition. Passive avoidance and small pool
performance impairments were shown to be age-related when comparing APP23 mice
to non-transgenic controls, while large pool performance was highly impaired across
timepoints. No impairment was noted for platform recognition performance, which
occurred during large Morris maze testing (Kelly et al. 2003). Also in 2003, Van
Dam et al. also tested APP23 mice in Morris water maze and passive avoidance at 6-8
weeks, 3, and 6 months. Impairment in Morris water maze was found to be age
related in this study as well, however passive avoidance was not found to be impaired
at these early timepoints. No significant differences between APP23 mice and nontransgenics were noted in a variety of behavioral and neuromotor measures at any
timepoint except for increased total path length for APP23 mice in open field at 6
months. It was also noted that overnight cage activity appeared to be higher for
APP23 mice than non-transgenics at various time points (Van Dam et al. 2003). In
2004, Dumont et al. tested aged (24 months) female APP23 mice in open field,
elevated plus-maze, and Morris water maze. These mice showed hyperactivity
compared to controls, decreased anxiety based on elevated plus-maze performance,
and impairment in Morris water maze acquisition, but not retention. This impairment
did not extend to probe or platform recognition trials (Dumont et al. 2004). The three
studies described above give a very general picture of spatial learning impairment in
APP23 mice and hint at some of the behavioral disturbances present in these animals,
however comprehensive assessment of impairment including application of working
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memory tasks has not been performed. Future testing may provide insight into the
exact progression of impairment in this model.

APPsw+PS1 Model
Formation of a mouse line transgenic for a FAD PS1 mutation was thought to
be the next logic step in creation of an AD mouse model based on the relatively high
frequency of PS1 mutations among FAD cases. Single transgenic mice carrying
human PS1 alleles, however, were found to be lacking significant Aβ pathology at
any time point, despite a drastic (approximately 51%) increase in Aβ1-42 to Aβ1-40
ratios in the brains of these mice as well as in overall Aβ levels (Duff et al. 1996). It
was found however, that by crossing these mice with APPsw transgenics, a double
mutant model could be created which exhibited dramatically accelerated AD-type Aβ
pathogenesis (Borchelt et al. 1997, Holcomb et al. 1998). These APPsw+PS1 mice
have been characterized by a number of groups with respect to both pathology and
behavior and have proven useful for numerous treatment and preventative studies in
AD research because of their early age of onset for Aβ pathology and correlated
cognitive impairment.
Pathological Characterization of the APPsw+PS1 Model
Early work in the APPsw+PS1 model by Borchelt et al. showed that, similar
to PS1 single transgenic mice, these mice show an approximate 50% increase in
soluble Aβ1-42 to Aβ1-40 ratios at an early timepoint (Borchelt et al. 1996). Double
transgenics were found to develop amyloid plaques prior to APPsw single
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transgenics, measured by Borchelt et al. at 12 months, and reactive astrocytes were
shown to be associated with these plaques. Many of these plaques were found to
stain mostly for Aβ1-40 at this timepoint, despite increased Aβ1-42 levels. It was also
found that double transgenics carrying a wild-type human PS1 gene did not display
accelerated Aβ deposition, indicating that the mutant allele PS1-A246E used in the
study was necessary to bring this acceleration about (Borchelt et al. 1997).
In 1998, Holcomb et al. confirmed that a dramatic increase in Aβ1-42 to Aβ1-40
ratios is present in double transgenics, this time in a APPsw+PS1-M146L line at 6
weeks of age. At 13-16 weeks, it was shown that these mice also exhibit small
numbers of deposits after thioflavin S staining, which stains for plaques containing
fibrillar and β-pleated amyloid, with dramatically increased staining appearing at 2432 weeks. Many of these deposits were also shown to be congophilic (Holcomb et al.
1998). A year later, the same group showed that by 6 months of age, all double
transgenic exhibited amyloid deposits, though none were present at a 3 month
timepoint (Holcomb et al. 1999). In contrast, Takeuchi et al. found that deposition
occurs in APPsw+PS1 mice at as early as 3M in the frontal cortex and CA1 region of
the hippocampus. At 12 months, they showed that 28.3% of the superior frontal
cortex and 18.4% of the CA1 was covered by amyloid plaques, which is
approximately 20-40 times greater than coverage levels in APPsw single transgenic
mice. It was also noted that neuronal counts did not differ significantly among
double or single transgenic from 3 to 12 months, despite apparent disruption of
neuronal architecture in doubles by compact plaques (Takeuchi et al. 2000).
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Plaque formation at 3 months was corroborated by Gordon et al. in 2002.
This group also found that compact plaques continue to form through 12 months in
both the hippocampus and frontal cortex, followed by formation of diffuse plaques in
these as well as other regions. These diffuse plaques were shown to be composed
almost entirely of Aβ1-42, while compact plaques were indicated as being composed
of both Aβ1-42 and Aβ1-40, thus providing an explanation for findings by Borchlet et
al. that plaques formed prior to 12 months showed higher ratios of Aβ1-40 relative to
Aβ1-42. Vascular Aβ was also detected by this group and was typically noted to be
Aβ1-40. Importantly, it was shown that compact plaques are associated with
dystrophic neurites, GFAP expressing astrocytes, and MHC-II immunoreactive
microglia even at early timepoints, indicating that these plaques elicit a similar
neuroinflammatory response to those in Alzheimer’s via both neuronal degradation
and direct interaction with immune cells (Gordon et al., 2002).
The effects of both soluble and insoluble Aβ in the brains of these double
transgenics appear to center on loss of neuronal function, loss of LTP in memory
centers and increases in inflammatory responses in areas surrounding deposits of Aβ.
In 1999, Wong et al. found that cholinergic synapses in the frontal cortex of the
brains of double transgenics showed a lower density than those of single transgenic
and non-transgenic groups. A lowered average cholinergic synapse size in both the
frontal cortex and hippocampus was also noted, though no changes were noted in
basal forebrain cholinergic cell body numbers (Wong et al. 1999). In 2003, Dickey et
al. reported that aged, 17-18 month-old APPsw+PS1 mice show reduced mRNA
expression of genes involved in LTP and memory formation, specifically in regions
40

where Aβ accumulation had already occurred (cortex and hippocampus). Changes in
synaptic structure, such as those noted by Takeuchi et al. (2000), were not shown to
be associated with any altered mRNA levels, however inflammatory genes were
upregulated. These findings were thought to provide an example of how memory
capacities can be affected prior to any loss of neurons via modulation of LTP and
other neuronal functions (Dickey et al. 2003). In a recent study, Trinchese et al.
(2004) delved further into the study of LTP loss in APPsw+PS1 transgenics, finding
that abnormal LTP is present at as early as 3 months, the same time point at which
plaque formation begins and abnormal short-term working memory was first
apparent, as indexed by the RAWM task. It was also shown that by 6 months, after
increases in overall Aβ loads, basal synaptic transmission is impaired, coupled with a
loss of long-term spatial learning/memory beginning at this time point in a plaque
independent manner (Trinchese et al. 2004). These connections to cognitive
impairment show correlations to many, but not all, studies focused on behavioral
characterization of this mouse line.
Behavioral Characterization of the APPsw+PS1 Model
Early testing by Holcomb et al., 1998 found a similar level of performance
among APPsw+PS1 double transgenics, single transgenic APPsws and PS1s, and
non-transgenics in sensorimotor tasks at 3-4 months, indicating no baseline
impairment in motor or sensory functions is present in these transgenics. Both the
APPsw and APPsw+PS1 groups were found to exhibit decreased Y-maze
spontaneous alternations compared to PS1 and non-transgenic mice at this same
timepoint, indicating a decrease in cognitive performance in these groups. Only
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double transgenic mice also showed an increase in overall activity in this task, which,
when coupled with decreased percent alternation performance, was thought to
correlate to hippocampal dysfunction (Holcomb et al. 1998). In 1999, Holcomb et al.
continued testing of double transgenics in the Y-maze task, as well as in Morris
Water Maze, over two additional time points. The same deficits were found in Ymaze at 6 and 9 months for these animals, though no significant differences were
noted among groups for any measure in Morris Water Maze at any time point.
Furthermore, it was noted that findings of decreased Y-maze performance at 3
months occurred prior to Aβ deposition in these mice, indicating loss of cognition did
not necessarily require plaque formation directly (Holcomb et al. 1999). As was
already shown, however, several other studies did find that some level of Aβ
deposition does occur at this early time point, including the 1998 study by Holcomb
et al., perhaps confounding interpretation of these results (Holcomb et al. 1998,
Takeuchi et al. 2000, Gordon et al. 2002; Trinchese et al. 2004.
In 2001, Arendash et al. found impairment in aged APPsw+PS1 mice in the
Radial Arm Water Maze task, and found a correlation between the level of
impairment in individual mice and the level of plaque formation. Arendash et al.
(2001) comprehensively tested the double transgenic mouse model in a full
behavioral test battery, cross-sectionally at two time points. It was noted that
transgenicity did not appear to affect cognitive performance in Y-maze, circular
platform, standard water maze, or platform recognition at 5-7 or 15-17 months, and
anxiety levels measured via the elevated plus maze task did not appear to differ
among groups. However, double transgenics did exhibit progressive increases in
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open field activity and in string agility impairment, coupled with continual
impairment in the balance beam task. Most significant, though, were findings of
cognitive impairment in both water maze and RAWM. Water maze acquisition was
found to be impaired at the later timepoint, though importantly no significant
impairment was noted during probe trials for this task. RAWM impairment was
limited to the later time point for this study as well. These findings indicate that
progressive impairment in spatial reference and working memory is present in these
mice. (Arendash et al. 2001). In a more recent report involving the same
investigators, Jensen et al. (2005) reported much earlier impairment at 4.5-6 months
in APPsw+PS1 transgenic mice in Morris water maze and RAWM (Jensen et al.
2005). This early impairment is consistent with findings of early impairment in other
studies such as Trinchese et al. (2004), in which it was reported that APPsw+PS1
mice are impaired in RAWM at as early as 3-4 months and in Morris water maze at as
early as 6-8 months (Trinchese et al. 2004). This difference from previous studies
such as Arendash et al. 2001, in which early impairment was not reported, are most
likely due to the effects of crossbreeding of APP transgene bearing mice resulting in
an increase of its effects. These effects were attributed to soluble Aβ constructs in the
brains of these mice which resulted in their earlier impairment.
Sadowski et al. (2004) reported impairment at 8 and 22 months for
APPsw+PS1 transgenics in Morris water maze as well as in Hebb-Williams maze.
Impairment in spatial memory at the 22 month time point was correlated to both a
loss of neurons (35.8%) in the hippocampal CA1 region and to reduced glucose
utilization in the hippocampus (Sadowski et al. 2004).
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Based on results from studies performed with APP transgenics, it is clear that
the resulting presence of Aβ in both soluble and insoluble form is sufficient to elicit
cognitive impairment in these mice which in many way parallels that of Alzheimer’s
Disease (Chen et al. 2000, Arendash et al. 2001). Progressive loss of short-term and
spatial memory as well as loss of long-term memory has been reported in animal
models of AD. These losses may be associated with loss of LTP and decreased basal
synaptic transmission as discussed above. This loss has been attributed to Aβ levels
(soluble and/or insoluble) as well as plaque deposition. Early decreases in LTP and
early memory impairment may result from actions of soluble Aβ oligomers including
neurotoxic protofibrils, while later deficits may be due to progressive Aβ plaque
burdens (Dickey et al. 2003, Trinchese et al. 2004). Several studies have been
conducted which have indicated that cognitive performance can be altered via
modulation of Aβ levels and/or clearance of Aβ plaques, as will be elicited in
discussion of current immunotherapeutic research in AD. These findings generate
excitement over the prospect of developing a preventative or treatment based on these
results. At the same time, however, it must be kept in mind that these models lack
complete development of all the pathological hallmarks of Alzheimer’s Disease, and
complete characterization of behavior in such models is simply not possible, making
them in many ways incomplete representations of the disease.
Mutant APP Mice as Incomplete Models of AD
Behaviorally, it is impossible to gauge all measures of disturbance in mouse
models to the extent that this can be accomplished in humans for obvious reasons.
Typical tasks for behavioral assessment in mice measure exploration, object
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recognition, anxiety and fear, and cognitive impairment with regards to spatial shortterm or long-term memory. Disparities noted during these tasks are thought to
correlate to disruptions common to Alzheimer’s, from decreased mobility and
motivation to visuospatial learning deficits to heightened anxiety (Janus and
Westaway 2001). However, it is clear that these tasks, while useful for gaining a
general picture of mouse behavior, are not specific enough to elicit findings
comparable to those obtained in humans using a wide variety of interactive tests such
as the MMSE, and even in humans diagnosis of AD is convoluted as a result of often
insufficient and sometimes contradictory data noted in such studies.
The question also arises: are the behavioral deficits noted in animal models of
AD associated with the transgene product via the same mechanism noted in humans?
Mice have different cellular machinery involved in post-translational modification of
proteins such as APP, and the exact process for neuronal production of hAPP in these
models, as well as any subsequent modifications which occur during processing to
form Aβ, has not fully been explored. Thus, the results of microinjection of such
transgenes must be elicited via pathological analysis and comparison with AD
pathology. Only the results of transgenicity can be compared, not the cause (Schwab
et al. 2004).
In APP transgenics, a number of distinct differences can be noted immediately
in comparison with human pathology. Spontaneous NFT formation has not been
noted for any APP model (tau transgenicity has been necessary to induce such
formation) despite the fact that FAD genes are known to directly result in AD
development with full pathology in humans, including NFT formation. The cause of
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this NFT formation in humans has not been entirely elucidated, but as described
above it may be associated with Aβ formation. Aβ itself is thought to act differently
within animal models as well. Although this peptide is known to be neurotoxic in
humans, perhaps resulting in the widespread neuronal loss in hippocampal and
cortical regions noted in AD, such loss of neurons simply does not occur in many
APP transgenic models, and in no model does it occur at levels similar to those
present in AD (Janus and Westaway 2001, Schwab 2004). Inflammatory responses to
Aβ once it has deposited into plaques is significantly lessened as well in mice, with
little or no complement system activation and lessened microglia activation. This can
lead to misinterpretation of results in studies such as those designed to clear plaques
from the nervous system without overactivation of the inflammatory system. These
differences may result from variations in Aβ pathology in transgenic mice as
compared to humans, such as morphological plaque density in APP models, which
tend to have less compact cores. This is most apparent in the APP23 model where
dense, congophilic plaques have also been noted to be still SDS soluble (Ashe 2001,
Schwab 2004).
It is apparent that despite similarities in Aβ pathology between transgenic
models and humans with AD, distinctions must be drawn when considering not only
the biochemical nature of plaques but their effects on cognitive performance as well.
Evaluation of these effects cognitively is made difficult for reasons outlined above.
Thus, behavioral and pathological studies in transgenic models must be limited in
application to specific and well designed treatment or prevention studies to elicit
effects, and the results of such studies must be weighed against the faults intrinsic to
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them. Nonetheless, the paradigm of repeated testing in various models followed by
subsequent staged clinical trials is still the most efficient protocol for gaining insights
in to AD therapies in a safe fashion, and thus continued behavioral testing in such
models, though found to be lacking, is still essential to AD research.
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Inflammatory Responses in AD

Neuroinflammation is a term which has evolved to specifically describe
chronic inflammation within the central nervous system involving glial cell activation
and subsequent neurodegeneration, a process for which Alzheimer’s Disease provides
a unique but complete representation (Streit et al. 2004). In AD, this inflammatory
process appears to be induced directly by Aβ, as described above, and involves
activation of glial cells, both asctocytes and microglia. Also reactive to Aβ, activated
T-cells can play a formative role in the progression and severity of
neuroinflammation in AD via direct action or through co-stimulation with microglia
and production of cytokines. This is one main distinction between
neuroinflammation in AD and other chronic forms of neuroinflammation, which do
not typically involve T lymphocytes. It may be that disruption of the BBB allows
these lymphocytes access to the AD brain, further influencing the inflammatory
cascade which occurs progressively throughout the disease. Along with the direct
affects of immunoreactive cells, cytokines and inflammatory proteins (and in some
cases complement proteins expressed by these glial cells and lymphocytes) have
widespread impact within regions of the CNS affected by AD.
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Microglia Activation
Microglia, resident phagocytes of the CNS, are thought to be derived from the
same cell lineage as macrophages and monocytes and to provide similar functions
within the brain to those provided by these cells in the periphery. In
neuroinflammation associated with Alzheimer’s, it appears that it is the nonphagocytic capabilities of these cells which play a major role in inflammation
associated with the disease, though these may only be induced after frustration of
phagocytic attempts (Streit 2004). Specifically, microglia are known to associate
with neuritic plaques in AD brains as well as in hAPP transgenic mouse brains, and it
has been shown that these cells can be activated by Aβ, especially the fibrillar,
neurotoxic form of this peptide commonly found in neuritic plaques. Other materials
associated specifically with compact neuritic plaques are also proposed to be involved
in activation of these cells, as Aβ itself does not generally elicit the exaggerated
response seen therein (D’Andrea et al. 2004). It is thought that these microglia are
induced by aggregated Aβ and these other factors to attempt phagocytosis of Aβ
aggregations; however, it is also apparent that they are largely unsuccessful at
degrading the dense plaques they are typically associated with (Streit et al. 2004).
In contrast to these findings, in human brains after postmortem analysis as
well as in transgenic mice brains taken after development of neuritic plaques, it has
been shown that microglia are indeed capable of clearing Aβ in rodent brains and that
human microglia can be induced to ingest Aβ in vitro (Frautchy et al. 1992). In
rodent models, such clearance is significantly increased by brain lesioning and by
injection of either Lipopolysaccharide (LPS) or Aβ antibody (Smith et al. 1998,
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DiCarlo et al. 2001, Bard et al. 2000). All of these factors tend to either activate the
overall immune and inflammatory systems or to interact with Aβ and microglia
directly to facilitate phagocytosis. In vitro studies have also shown that complement
system proteins such as the C1q protein may facilitate microglial phagocytosis of Aβ
(Webster et al. 2000). Furthermore, postmortem analysis from an Aβ vaccination
clinical trial indicated an association between microglia activation and amyloid
clearance in humans (Nicoll et al. 2003). These and other studies have shown that
microglia are quite capable of clearing Aβ in all configurations under the right
circumstances, however such clearance is obviously deficient for some reason in AD.
Thus it is either: 1) an overall failure of these cells to maintain clearance of plaques,
due perhaps to an inherent dysfunction of these cells 2) an overwhelming effect
following increased Aβ production later in life, or 3) the nature of the plaques
themselves, which prevents their breakdown. If the first is true, it is possible that
Alzheimer’s is due simply to a failure of microglia to maintain proper balances of Aβ
within the brain, while the last hypothesis would seem to indicate that the progressive
nature of plaque formation may allow this process to be too far along prior to
microglia activation for these cells to be effective as phagocytes after such activation
(Streit 2004). Future studies may elicit which of these is the true initial failure of
microglia, thereby allowing researchers to gain insights into how to alter this process
early on. In the present, however, it is the role of activated microglia in the
Alzheimer’s neuroinflammatory cascade which has received the most study in AD
research due to the neurotoxic potential of the cells therein.

50

As stated, the major role of microglia in exacerbating the inflammatory
damage noted in AD does not appear to be related to the phagocytic role of these
cells. Once activated, microglia often become “frustrated” due to the persistence of
the compact neuritic plaques with which they are associated, in much the same way
that immune cells of the periphery can, during certain autoimmune diseases or in
response to mitogens, be activated excessively (D’Andrea et al. 2004).

Once over-

stimulated and after failed attempts at Aβ clearance, these microglia then proceed to
produce a wide array of inflammatory factors including reactive oxygen species,
complement proteins, cytokines (such as IL-1, IL-6, and TNFα), and a number of
other factors which may be considered neurotoxic or which may stimulate further Aβ
aggregation (Akiyama et al. 2000). Local neuronal degradation causes release of
cytoplasmic inflammatory factors leading to further activation of glial cells.
Astrocytes activated by these factors, as well as by cytokines released from microglia,
are attracted to the plaque periphery where they begin to produce their own set of
inflammatory proteins and cytokines, resulting in a co-stimulatory effect with
neighboring microglia (D’Andrea et al. 2004). Inflammatory proteins such as ApoE
(produced by subsets of both glial cell types), α-ACT (produced by astrocytes),
complement proteins, and perhaps other factors all associate with neuritic plaques and
may be involved not only in promoting further Aβ aggregation, but in further
stimulating microglial response via receptor mediated activation of these cells
(Nilsson et al. 2004, Uchihara et al. 1995, D’Andrea et al. 2004). The end result is a
localized inflammatory cascade with potentially widespread repercussions due to
cytokine diffusion.
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T Cell Activation
In a general sense, T cells can be divided based on expression of either the
CD4 or CD8 co-receptor, which primarily segregates the cells into helper and
cytotoxic lines respectively. T helper (Th) cells produce a variety of cytokines when
activated which are involved in mediating inflammatory and immune responses,
while cytotoxic cells are largely involved in recognition and destruction of abnormal
or aged self cells. Helper cells can be further divided into Th1 and Th2 subsets, each
with distinct and often antagonistic roles in the immune system. The former tends to
promote inflammation and cellular based immunity via activation of macrophages
and cytotoxic T cells (TC) as well as other immune cells such as neutrophils, while the
latter tends to initiate a humoral based response via activation of B cells (Vallejo et al.
2004).
Each subtype of T cells requires a different combination of receptor mediated
activation to initiate the effects they are known to elicit. Receptor activation also
dictates if and when T cells will begin to differentiate and mature. All T cells begin
as naïve cells and remain so unless they encounter a recognizable antigen properly
presented by an antigen presenting cell (APC) for Th cells or by the majority of self
cells for TC cells. T cell recognition is dictated by variations in T cell receptor (TCR)
subcompontents, which alters initial ability of a cell to recognize antigens presented
by major histocompatibility (MHC) II complexes of APCs or to recognize peptides
presented by MHC I complexes of self cells. Antigens presented by APCs are
typically produced after breakdown of foreign peptides extracellularly via enzymatic
degradation or intracellularly after phagocytosis. The peptides presented by self cells
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are typically derived from viral or intracellular microorganisms which have infected
these cells; however aged, cancerous, or otherwise altered cells may also present
peptides which promote their own death (Vallejo et al. 2004, Crow 2004).
Coupling of the TCR with the antigen/MHC II complex or peptide/MHC I
complex initiates T cell activation and can result in differentiation into effector T
cells capable of varying functions, however further interaction of secondary cell
surface proteins is also required for induction of such activities. In many cases, such
proteins are not expressed unless secondary activation via cytokine receptors has
occurred. Thus, activation of individual T cell subtypes depends not only on
recognition of the appropriate antigen / MHC complex, but also on stimulation of
regulatory cells to produce appropriate cytokines which then mediate which specific
subtype of T cells will be activated. Once fully activated, memory T cells may
develop which proliferate and remain present in the body, awaiting reactivation or
continuing to act in the presence of persistent stimuli (Vallejo et al. 2004, Chandock
et al. 2004).
The role of TC cells in Alzheimer’s neuroinflammation is thought to be
primarily detrimental due to the ability of these cells to induce neuronal or glial
apoptosis, and thus Th1 cells activation may also be considered disadvantageous due
to subsequent activation of TC cells. At the same time, microglia can be activated by
Th1 cells resulting in a positive effect if phagocytosis of Aβ can be induced and a
negative effect if phagocytic frustration results, as discussed above. Th2 cell
activation may prove to be beneficial in Alzheimer’s if Aβ antibody formation by B
cells is then induced, enhancing clearance of Aβ, as will be discussed later, and other
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distinct capabilities of unique T cell subtypes may also be either detrimental or
therapeutic based on extent of activation and timing of such activation.
Microglia and T Cell Co-activation
As discussed above, both microglia and T cells are heavily reliant on
activation by other cell types via cytokine receptor activation or direct receptor
protein interactions with surface proteins of these other cell lines. As phagocytes,
microglia are among the few cell types capable of internalizing, digesting, and
presenting proteins in association with MHC II receptors in the CNS, thus acting as
APCs (Hickey et al. 1988). Specific lines of T cells, largely among the Th1 subtype
but also among the Th2 subtype, are capable of inducing microglia to carry out this
activity, and in certain cases microglia will remain inactive without such input. Thus,
though many other cell lines may be involved in the process, activation of microglia
and T cells can occur concurrently and can have a tendency towards exponential
propogation under certain conditions. As will be shown, however, the true
interactions which have been shown to occur between microglia and T cells in the
presence of Aβ are convoluted and often difficult to interpret.
In 2003, Monsonego et al. showed that mouse microglia primed with INF-γ
are capable of serving as Aβ APCs for both Aβ1-40 and Aβ1-42, presenting these
peptides to Aβ-specific T cells. Both Th1 and Th2 subtypes were shown to be
activated by these peptides when presented by microglia. Th1 cells were shown to be
activated in the short term, with increased expression of IFN-γ (a microglial activator
and inhibitor of Th2 proliferation) noted. Coactivation of microglia resulted in their
expression of TNF-α (an inflammatory cytokine) and IL-10. As an anti54

inflammatory cytokine, IL-10 is known to inhibit TH1 subset activation, and to inhibit
monocyte/macrophage lineage production of NO and a variety of cytokines involved
in inflammation. In contrast to this, it was shown that microglia were actually
stimulated by Th1 cells to increase their production of NO, which is a known general
T cell inhibitor. Inhibition of iNOS to reduce this production of NO resulted in
restoration of Th1 cell proliferation. Anti-IL-10 and IFN-γ antibody treatments also
elucidated that this inhibition could not be reversed simply by blocking these
cytokines without inhibition of iNOS, indicating that the normal control of IL-10 over
Th1 cell lines was not the pathway of T cell regulation in this case. Thus it appears
that the interactions between microglia and Th1 subsets in mice are in many ways
distinct from normal interactions between Th1 cells and cells of the monocyte
lineage, and that microglia are capable of inhibiting Th1 cells as a result of Th1 cells
stimulating microglia to produce NO. This high level of NO and perhaps other
mediating factors is thought to then bring about apoptosis of Th1 cells (Monsonego et
al. 2003).
It was also noted that in cultures of microglia with Th2 subset cells, there was
an increase in production of IL-4 (promotes TH2 proliferation), IL-10, TNF-α, and
granulocyte-macrophage colony-stimulating factor (GM-CSF). These T cells did not
undergo apoptosis, but were instead activated and induced to proliferate. Thus it was
assumed that the Th2 repetoire of cytokines is sufficient to block NO mediated
apoptosis of T cells, as has been shown in previous studies, despite an up-regulation
of NO which was noted in these cultures (Monsonego et al 2003).
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Based on these in vitro results coupled with those of previous studies, some of
the potential interaction which occur between T cells and microglia in Alzheimer’s
may be speculated upon and are summarized in Figure 1. The two major effectors of
microglia activation noted in the study conducted by Monsonego et al. (2003) were
IFN-γ and GM-CSF, produced by the Th1 and Th2 subsets respectively, which
promoted presentation of Aβ by microglia to these cells. Other cytokines such as IL10 were shown to decrease production of NO by microglia in vitro. Depending on the
type of interactions which occur during and following activation, however, microglia
can then act to regulate T cell activity via production of a variety of mediating factors
such as NO, as discussed above. Therefore, with development of an understanding of
the interaction which occur between these cell types, it may be possible to alter
activation of specific T cell types to promote clearance of Αβ by microglia while
preventing inflammatory damage due to secondary activities of both T cells and
microglia.
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Figure 1. IFN-γ primed Microglia cultured in the presence of Aβ are capable of
MHC II associated presentation of Aβ to both Th1 and Th2 cell types. This leads
to short term activation of Th1 cells with potential for subsequent inhibition following
release of Nitrous Oxide (NO) and IL-10 by microglia (red). Activated Th2 cells are
protected from inhibition however, perhaps via autocrine action of GM-CSF and/or
IL-4 cytokines (blue). In both instances, microglia remain active and produce
inflammatory cytokines such as TNF-α, as well as NO (green).
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Vaccination in AD Research

In the late 1990’s, in vitro studies reported that antibodies specific to various
Aβ epitopes can disaggregate amyloid plaques and prevent Aβ fibrilogenesis. It was
not long thereafter that researchers began focusing on the idea of an amyoid
vaccination as a treatment or even preventative for AD. Promising results in early
work in vitro and in vivo with animal models of AD culminated in early phase clinical
trials in humans using Αβ immunizations. These trials were halted after death of a
small number of individuals was reported due to CNS inflammation. Since that time,
intense focus has been placed on finding an immunotherapeutic strategy for fighting
AD which does not instigate the type of inflammatory response initiated by active Aβ
immunization.
In Vitro Aβ Vaccination Studies
Two of the earliest studies in vitro which contributed to initiating the current
immunotherapeutic era of Alzheimer’s research were conducted by Solomon et al. in
1996 and 1997. In the former study, it was noted that monoclonal antibodies
recognizing either aa1-28 or aa8-17 residues of the Aβ peptide are capable of
inhibiting normal in vitro aggregation of Aβ (Solomon et al. 1996). In the latter study
it was shown that the antibodies recognizing the aa1-28 residue of Aβ were actually
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capable of disaggregating insoluble Aβ fibrils into soluble Aβ (Solomon et al. 1997).
In 1998, Frenkel et al. found that these same antibodies specifically bind to aa3-6
(sequence EFRH), and it was inferred from these results that this sequence must be
involved in the Aβ aggregation process (Frenkel et al. 1998). A year later, this group
published findings which indicated that not all Aβ antibodies recognizing the region
of the peptide containing this residue were as effective at binding to it, and that low
binding affinitity antibodies were not capable of preventing Aβ aggregation (Frenkel
et al. 1999). From the results of these four in vitro studies, it was deduced that
carefully selected antibodies to Αβ had the potential to block or even reverse amyloid
aggregation, paving the way for future in vivo studies in Aβ vaccination.
Innate Immune Responses to Aβ
On a cellular level, the response of the immune system to Aβ is three-fold. B
cells can be stimulated to produce Aβ antibodies, glial cells can be stimulated to
produce a variety of inflammatory molecules and in the case of microglia to attempt
phagocytosis of Aβ plaques, and T cells can be stimulated to produce an array of
modulatory cytokines as discussed above. Prior to Aβ vaccination, these responses
are present in varying levels. Localized, high levels of glial cell activation are
common near Aβ plaques (D'Andrea 2004), and aged AD patients are significantly
more likely to exhibit strong T cell reactivity to Aβ (Monsonego et al. 2003). Finally,
Aβ antibodies are known to be produced in AD and may be involved in triggering
microglia response to plaques, thus facilitating phagocytosis (Nath et al. 2003,
Wilcock et al. 2004). These reactions to Aβ are also evoked in varying degrees
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following Aβ vaccination (Nicoll et al. 2003). The current goal of
immunotherapeutic research in AD is to establish a means of creating a balanced
response incorporating each of these responses only to the extent necessary to be
beneficial.
Active Aβ Immunization in Animal Models
A wide variety of active Aβ-based immunization studies have been reported
on since the first reports in 1999. Retrospectively, with the knowledge we now have
of consequences of standard Aβ immunization in humans, it is perhaps most simple to
divide these studies into three main categories. The first consists of those studies
which provide a general understanding of the positive pathological consequences of
Aβ immunization, which are based largely on amyloid plaque clearance and reduction
in plaque associated pathology. The second consists of those studies which provide
insight into how side-effects from such administrations in humans could be
anticipated by both characterizing the neuroinflammatory response elicited by these
or which provide alternative, less dangerous modes of eliciting an anti-Aβ immune
response. Finally, studies providing behavioral characterization of treated animals as
potentially indicative of the cognitive protection that may or may not result after
administration of an Aβ vaccine.
Pathological Benefits of Active Aβ Immunization
A number of studies focused on eliciting the pathological benefits of Aβ
vaccination while not reporting results showing the potential for negative impacts or
the behavioral consequences that result from such vaccination. In 1999, Schenk et al.
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reported results from the first attempted active Aβ immunization study in a mouse
model of AD. Injections of Aβ1-42 were performed monthly for 11 months starting at
2 months in PDAPP mice. A separate group of mice was injected with SAP peptide,
a separate component common to amyloid plaques. Initial injections contained
complete Freund’s adjuvant, while each additional injection contained incomplete
Freund’s adjuvant, a protocol used in the majority of future active Aβ vaccination
studies. Titres of antibodies to the injected antigen were measured at higher than
1:10,000 for most Aβ injected mice and between 1:1,000 and 1:10,000 for SAP
injected mice. The mice were sacrificed at 13 months, and it was found that Aβ
immunized mice were almost completely protected against development of Aβ
plaques in the CNS, while SAP immunized mice showed statistically similar levels of
plaques compared to non-treated controls. This latter data would seem to indicate
that an immune response elicited towards any Aβ plaque component is not
necessarily capable of clearing these plaques. Almost complete protection against
development of dystrophic neuritis and reduction of astrocytosis and microglia
activation was also noted in Aβ immunized mice (Schenk et al. 1999).
This group also performed additional experiments to determine if reduction of
plaque loads could be accomplished in aged mice. 11-month-old female PDAPP
mice were again immunized with Aβ1-42. Sacrifice of the mice occurred at either 15
or 18 months. At both time points, Aβ burdens were significantly reduced compared
to PBS treated transgenic controls. Reduction in both diffuse and compact plaque
counts were attributed to clearance of already formed deposits. Existing plaques were
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noted to be coated in IgG antibodies to Aβ1-42, indicating a direct mechanism of
action for these antibodies within the CNS. Lack of plaques in regions such as the
entorhinal cortex were attributed to blocked formation of plaques typically not
deposited until later time points in PDAPP mice. Aβ containing cells thought to be
microglia or monocytes were present in areas normally containing high plaque counts
at aged timepoints, indicating an activation of these cells to phagocytize existing Aβ
deposits, perhaps via antibody receptor mediated activation. Astrocytosis was noted
to be reduced in these Aβ treated mice, as were other neuritic plaque pathologies.
This second round of results would seem to indicate that while Aβ vaccination does
show potential efficacy as a treatment due to partial clearance of plaques at an aged
time point in transgenic mice and prevented formation of additional plaques, clearly
the most benefit stands to be gained from earlier, prophylactic administration of Aβ
(Schenk et al. 1999).
In 2000, Weiner et al. found that intranasal administration of synthetic Aβ1-40
peptide, as opposed to injections of Aβ1-42, between 5 and 12 months in PDAPP mice
resulted in significantly decreased neuritic plaque burden and overall Aβ1-42 levels
compared to controls treated with myelin based protein or standard controls.
Decreased microglia and astrocyte activation, decreased neuritic dystrophy as seen in
Schenk et al. (1999), and decreased reactive mononuclear cell activation was also
reported. Importantly, this study demonstrated the efficacy of intranasal Aβ
vaccination for the first time. (Weiner et al. 2000).
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In 2001, Das et al. showed that effectiveness of Aβ1-42 immunization
correlates inversely to amyloid deposition levels in Tg2576 mice. Mice with
minimal, modest, and significant Aβ deposition (7-8, 10-11, and 18 months) were
immunized with the peptide, and reductions in cerebral Aβ were noted to be highest
in mice immunized at younger timepoints. It was also noted that Aβ1-42 was reduced
at higher levels than Aβ1-40. This study clearly indicated the importance of early
vaccination as a preventative/treatment for AD (Das et al. 2001).
Further expanding on the potential benefits of Aβ vaccination, Oddo et al.
(2004) reported for the first time that Aβ immunization results in clearance of nonhyperphosphorylated (early) but not hyperphosphorylated tau aggregates in a
APPsw+PS1+Tau transgenic model, along with the normal reduction in Aβ pathology
expected after such immunization. It was also noted that Aβ pathology was necessary
for formation of tau pathology, and clearance of the former via non-immunological
methods resulted directly in clearance of the latter (Oddo et al. 2004).
Lemere et al. (2003) reported that the typical reduction in Aβ pathology
associated with Aβ immunization such as that noted in the above three studies was
coupled with a dramatic increase in Aβ levels in the serum of APP transgenic mice.
It was suggested that the main mechanism of action of Aβ immunization is thus
stimulation of Aβ antibodies largely restricted to the blood, association of these
plasma antibodies with Aβ, and clearance of CNS antibody/antigen complexes into
the vasculature, resulting in reduced Aβ levels in the CNS (Lemere et al. 2003).
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To better understand the time course for immune system reactivity to Aβ,
Wilcock et al. (2001) delved further into the specific immune responses elicited by
various numbers of Aβ1-42 vaccinations, reporting that anti-Aβ antibody titers
remained low after only 3 innoculations in APPsw+PS1 mice but were significantly
higher after nine inoculations. After 5 innoculations there was a high level of
microglia activation which tapered off by nine injections. A correlation was found
between microglia activation and reductions in congo red staining, suggesting that
microglia may be involved in clearing compact Αβ plaques in these mice. Thus this
study and that by Lemere et al. (2003) provided two distinct and probable modes of
action for anti-Aβ antibodies in clearing amyloid from the CNS (Wilcock et al. 2001).
In further examining the potential for microglial phagocytocis of Aβ plaques,
it was shown that Aβ1-42 immunization of Tg2576 mice crossed with FcRγ-/- (Fc
receptor knock-out) mice resulted in unimpaired reduction in Aβ levels according to
Das et al. (2003) compared to immunization of Tg2576, Fc receptor-sufficient mice.
This would seem to indicate that microglial, FcR-mediated phagocytosis is not
required for effectiveness of the Aβ vaccination and is not the main mechanism for
Aβ clearance (Das et al. 2003a). Das et al. (2003) also showed that B and T cell
responses to Aβ1-42 immunization vary greatly based on specific MHC class II
expression patterns, indicating that some combinations of expression among these
molecules result in better presentation of the Aβ peptide to these cells and once again
emphasized the importance of these immune cells in determining immune response to
Aβ (Das et al. 2003b).
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Along with an understanding of the reactions of the immune system of APP
transgenic mice to Aβ inoculation and the mechanisms of Aβ clearance, it is also
necessary that the impact of expression of this human transgene on the response of
these animals be understood. In comparing the immune response of APP transgenics
and non-transgenics to Aβ inoculations, Monsonego et al. (2001) reported that APP
transgenic mice immunized with either Aβ1-40 or Aβ1-42 displayed
hyporesponsiveness to these peptides immunologically. This was thought to be
associated with a lack of T cell response in these animals, perhaps due to long-term
presence of Aβ peptides in transgenic mouse brains from an early time point. It was
suggested that if the T cell response could be raised during the vaccination period,
such immunotherapy would prove more successful (Monsonego et al. 2001).
Further emphasizing the hyporesponsiveness of the the APP transgenic mouse
immune system to Aβ, Dickey et al. (2001) reported that three vaccinations with Aβ142

was necessary to elicit a significant immune response in APPsw+PS1 transgenic

mice based on IgG levels. Subsequent administrations of the vaccine resulted in
moderate immune responses through 5 months. It was also noted that the highest
immune response was to the Aβ N terminus, and it was suggested that because the
main humoral response was IgG1- and IgG2-based, a TH2 T cell subset activation was
likely to be involved in generating this response. Importantly, it was also noted that
the immunized mice displayed T-cells stimulated specifically by the Aβ peptide,
again emphasizing the potential for T-cell activation to regulate the immune response
to Aβ vaccination (Dickey et al. 2001). Both of these previous two studies provided
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insight into the importance of proper regulation of T cell activation following
immunotherapy.
Additional support for the important regulatory role of TH2 cells following Aβ
immunization in transgenic mice was provided by Town et al. (2002). It was
reported that a bias towards this T cell subset in both C57BL/6 non-transgenics and
APP mice inoculated with Aβ1-42 was found. Importantly, this bias was not noted
following Aβ1-40 immunization, indicating an altered immune response based on
antigen selection (Town et al. 2002).
In 2004, Li et al. reported that while anti-Aβ levels from Aβ immunized APP
transgenic mice are masked in ELISA measurements if not first treated with a low-pH
solution to dissociate anti-Aβ/Aβ complexes, these levels are still significantly lower
than those of non-transgenic mice of the same background following immunization
even after such treatment. Only when Aβ was administered associated with
papillomavirus virus-like particles (VLPs) were levels of anti-Aβ comparable in APP
and non-transgenic mice, indicating that self-tolerance to Aβ in APP mice results in
hypoimmune responsiveness in these mice after normal active Aβ immunization (Li
et al. 2004).
Based on findings that aged Caribbean Vervets, which are primates, often
develop cerebral Aβ plaques, Lemere et al. (2004) vaccinated a number of these
animals for 10 months with a cocktail of Aβ1-40 and Aβ1-42 in a 3:1 ratio. No plaques
were found in the four surviving immunized animals, while 11 of 13 controls showed
plaque development. It was also noted that rises in plasma Aβ were associated with
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decreases in brain Aβ levels in immunized animals, and antibodies to Aβ were noted
in both the plasma and CNS. This study was the first to report Aβ clearance
following Aβ vaccination in a non-human, non-transgenic mammal which normally
develops Aβ plaques with aging (Lemere et al. 2004).
The above studies elucidated the potential for active Aβ immunization in AD
animal models to elicit an immune response at numerous timepoints in the
development of amyloid pathology, including production of various anti-Aβ antibody
isoforms and stimulation of cellular-based immunity mediated by T lymphocytes. It
was demonstrated that such immune system activation leads to varying levels of
clearance of Aβ pathology from the CNS based on background strain interactions,
antigen selection, antigen delivery, adjuvant selection, and age. This generated
excitement at the possibility of developing a vaccination-based therapeutic for
Alzheimer’s disease. Still left to be discovered by additional studies, however, was
the potential for such immunization to also lead to devastating consequences in the
AD brain, as well as the actual cognitive benefit to be gained by Aβ vaccination.
Deleterious Effects of Active Aβ Immunization and Alternative Active
Immunization Approaches.
Two major studies in Aβ vaccination focused largely on its negative
consequences. Su et al. (1999) reported that low-level infusions of soluble Aβ1-40
intravascularly in 3 month old male rats over the course of 2 weeks resulted in blood
vessel damage including gross pulmonary hemorrhage, disruption of the BBB, and
activation of microglia and astrocytes in the CNS. While these physiological
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consequences were not coupled with impairment in water maze, they did provide
evidence that even short, low-level administrations of Aβ can result in damage to
both the vasculature and perhaps the CNS via initiation of widespread inflammation.
This again emphasized the importance of determining a method for vaccination which
does not instigate such damage (Su et al. 1999).
Furlan et al. (2003) further elucidated our understanding of the potential for
neuroinflammatory damage resulting from Aβ vaccination. Young C57BL/6 mice
immunized with Aβ1-42 were shown to display inflammatory foci in the brain and
spinal cord associated with the vasculature of these areas. These foci were noted to
contain microphages, T and B cells, and immunoglobulins. This response was
attributed to Th1 subset mediation of inflammatory events coupled with high anti-Aβ
levels. Importantly, these results were noted only when a co-administration of Aβ
and pertussis toxin (which elicits autoimmune processes) was performed; thus the
extent to which the toxin contributed to development of these foci is important in
interpretation of these results (Furlan et al. 2003).
It was apparent following the Su et al. 1999 study and based on results of
phase II clinical trials in humans that there are dangers associated with simple Aβ
vaccinations mainly associated with increased neuroinflammation, and numerous
studies which followed focused largely on searching for more unique modes of
immune system activation which do not invoke such reactions. In 2000, Frenkel et al.
attempted active Aβ immunization in both BALB/c mice and guinea pigs via either
intranasal administration and s.c. or i.p. injection of a phage displaying the Aβ 3-6
68

peptide residue EFRH. Seven days following injection, serum levels of IgG reactive
against both wt-phage and Aβ were measured for three injections spaced 14 days
apart. Mice injected i.p. with Freund’s adjuvant developed large titres of antibodies
which increased after each injection. Specific IgG and IgA antibodies were noted 7
days after only one booster injection of phages. Guinea pigs injected s.c. were noted
to develop very high titres of anti-Aβ antibodies following the same injection
protocol. The guinea pig EFRH sequence is homologous to that of humans, whereas
in mice the sequence is EFGH, so the effectiveness of the phage administration in
both species emphasized the potential of this vaccination for effectiveness in humans.
It was shown that in both animal groups, sera containing antibodies produced was
able to bind specifically to the Aβ peptide, and that this sera protected against Aβ
neurotoxicity in vitro. Also noted was the ability of this sera to disrupt Aβ fibril
formation in vitro (Frenkel et al. 2000). In 2003, Frenkel et al. again immunized mice
with EFRH presenting phages, this time in the APP transgenic model. This
immunotherapeutic approach was shown to again dramatically reduce Aβ pathology
in these mice. Importantly, it was noted that two mice receiving the phage did not
develop high titers of anti-Aβ antibodies, indicating less than perfect penetrance
(Frenkel 2003).
In 2001, Sigurdsson et al. were able to show that immunization with a
nontoxic, soluble Aβ homologue results in a similar reduction in amyloid pathology
to those noted after standard Aβ administration in APP transgenic mice. Along with
reductions in soluble and insoluble Aβ, these mice also exhibited decreased microglia
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activation, thought to be associated with an overall reduction in inflammation levels
(Sigurdsson et al. 2001). In 2004, Sigurdsson et al. carried out active immunization
in APP mice with this same nonfibrillogenic, nontoxic derivative of Aβ, K6Aβ1-30,
which was known to induce Aβ clearance in similar levels to Aβ1-42 treatments. A
primarily IgM response resulted in these mice, and Aβ pathology was significantly
reduced in inverse correlation to levels of these antibodies. IgM is not able to cross
the BBB, so it was inferred that Aβ clearance resulted from these antibodies acting as
a peripheral “sink” for these peptides.
In 2002, a study conducted by McLaurin et al. showed that antibodies
recognizing the 4-10 residues of Aβ1-42 are capable of inhibiting fibrillogenesis of
Aβ in TgCRND8 transgenic mice without invoking activation of the inflammatory
system. This antibody was shown to target protofibrillar Aβ, which is thought to be
important in formation of Aβ plaques, and provided an important mechanism for
blockage of said formation. It was further reported that the immunization which led
to this antibody formation caused a biased T cell response, downregulating
inflammatory events associated with Th1 cell activation while upregulating some
aspects of the humoral responses elicited by Th2 cells (McLaurin et al. 2002).
Koller et al. (2004) found that immunization of APP transgenic mice with
Aβ1-42 coupled with DnaK, a heat shock protein 70 analogue and strong adjuvant,
resulted in measurable levels of anti-Aβ antibodies after only one innoculation with
maximal titers of these antibodies present after the first booster inoculation. These
levels were still significantly lower than those achieved in non-transgenic controls
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receiving the same vaccination. This emphasized the importance of adjuvant in
determining the immune response elicited by active immunization, and provided a
method for reducing the total number/amount of Aβ administration necessary to elicit
an appropriate immune response. Importantly, however, these immunizations were
all administered by 3 months of age, and as a result no affect was seen on Aβ levels
and plaque burdens after sacrifice at an aged time point, suggesting that prophylactic
immunization occurring too early in life, without continuation, may prove ineffectual.
(Koller et al. 2004).
Hara et al. (2004) found that oral administration of a recombinant adenoassociated virus vector containing cDNA for Aβ resulted in expression and secretion
of both Aβ1-43 and Aβ1-21 within the intestine of hAPP transgenic mice. This resulted
in anti-Aβ antibody production through 6 months and significant decreases in CNS
Aβ levels. These decreases were not associated with any notable inflammation or T
cell response (Hara et al. 2004).
The work of Su et al. (1999), Furlan et al. (2003), and results from Aβ
vaccination clinical trials served as a warning for researchers, demanding that new
understanding of the true consequences of Aβ immunization should be gained before
any further clinical trials are conducted. Many of the studies which followed thus
searched to explore alternative Aβ vaccination methodologies to reduce
neuroinflammation and a cellular-based immune response. Even these studies,
however, are not fully sufficient to gain true understanding of the potential effects of
Aβ vaccination is AD models. Yet to be determined is the effects of Aβ vaccination
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on cognitive behavior, as most of the studies mentioned above did not seek to
correlate any pathological findings with cognitive impacts.
Behavioral Characterization in Active Aβ Immunotherapy
Due to the potential for neuroinflammatory damage associated with Aβ
immunization, it was necessary to establish that cognitive protection could be elicited
by such treatment despite these potential negative consequences. Janus et al. (2000)
reported that vaccination of young TgCRND8 mice with Aβ1-42 peptide in complete
Freund’s adjuvant resulted not only in plaque load reductions, but also in decreased
impairment in Morris water maze acquisition, though these mice still did not perform
at the same level as non-transgenic controls. 3 cohorts of mice were immunized at 6,
8, 12, 16, and 20 weeks of age with either Aβ1-42 peptide or islet-associated
polypeptide (IAPP), both in β-pleated sheet formation. This control antigen was
selected based on its similarity to Aβ, but also on the fact that it only causes
amyloidosis outside of the CNS. Both peptides were shown to induce antibody
production by 13 weeks when the first group of injected animals underwent sacrifice.
A second group of animals were sacrificed at 23 weeks and showed 2-3 fold increases
in antibody productions by this time point. These antibodies were shown to strongly
bind to dense Aβ plaques but to only weakly interact with diffuse, non-fibrillar
deposits of Aβ. Also, these antibodies did not appear to be reactive to APP, as
normal neurons were not detected by the antibody. Impacts of immunization on Aβ
pathology were noted to be similar to those from previous studies with regards to
density and size changes of dense-cored plaques, however at both 13 and 25 weeks,
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no changes in formic-acid-extractable (soluble) Aβ were noted, perhaps because of
the specificity of anti-Aβ antibodies to the β-pleated sheet formation of deposited Aβ.
Behavioral testing of mice by Janus et al. (2000) consisted of longitudinal
testing (at 11, 15, 19, and 23 weeks of age) in a reference memory version of Morris
water maze, with the submerged escape platform in a different location at each test
age. Aβ1-42 immunized transgenic mice were shown to perform significantly better
than non-immunized transgenics, however performance was not improved to the level
of non-transgenic mice. Aβ immunized mice were also shown to significantly
improve in task performance after repeated reversal testing, indicating a learning
affect in these mice. In probe trial testing following Morris water maze testing, no
significant differences were noted among groups. However, this was attributed to the
close temporal proximaty of task administration (30 minutes) to final day Morris
water maze administration. Controls studies indicated that no performance changes
were noted for non-transgenic mice following any form of PBS, Aβ, or IAPP
injection with or without adjuvant (Janus et al. 2000).
Morgan et al. (2000) and Arendash et al. 2001 found that APPsw+PS1 mice
immunized monthly with Aβ1-42 in Freund’s adjuvant (mineral oil after 3 months)
showed significant protection against impairment in the RAWM task at an aged time
point compared to controls receiving a control vaccine of keyhole limpet
haemocyanin. Behavioral assessment of double transgenic mice by Morgan et al.
(2000) and Arendash et al. (2001) consisted of pre-immunization administration of a
6-week battery of sensorimotor and cognitive based tasks between 5 and 7 months of
age followed post-immunization by Radial Arm Water Maze testing at 11.5 and 15.5
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months and balance beam, string suspension, open maze, and Y-maze tasks at 16
months. No differences were noted among groups in pre-immunization
performances, except in balance beam performance in which transgenic animals were
impaired overall. In RAWM testing at 11.5 months, transgenic animals performed at
the same level as non-transgenic controls. Results from repeated testing at 15.5
months demonstrated that Aβ immunized mice reached similar levels of performance
to non-transgenics by final trials of testing, however it was demonstrated that these
mice required more trials to reach this level of performance than these nontransgenics. Working memory was thus shown to be greatly improved in
APPsw+PS1 mice following repeated Aβ1-42 immunizations over an 8 month period
(Morgan et al. 2000).
Mice immunized with Aβ, both transgenic and wild-type, showed high antiAβ serum activity while non-Aβ immunized animals showed no such activity.
Modest to no reduction in Aβ plaque burdens in the frontal cortex and hippocampus
were noted post-immunization. Though no measures of soluble Aβ levels were noted
in these studies, it was suggested that reduced levels of soluble, toxic Aβ oligomers
may have contributed to the lack of cognitive impairment present in these Aβ
immunized animals, despite their high levels of Aβ pathology remaining in the CNS.
Based on correlation analysis of behavioral task performances and Aβ burden
measures, a number of correlations were evident in the same study’s animals
(Arendash et al. 2001). While there was no correlation between total Aβ
immunostaining (compact and diffuse plaques) and RAWM performance, T4 error
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measures did correlate with both Aβ1-40 immunostaining and congo red staining in
frontal cortex as well as with immunostaining in both the hippocampal CA1 region
and dentate gyrus. However, as Aβ reduction was modest at best it is likely the
impact of vaccination on soluble Aβ constructs in the CNS (neutralization and/or
clearance by anti-Aβ antibodies) that played a larger role in providing cognitive
benefit (Morgan et al. 2000, Arendash et al. 2001).
Jensen et al. (2005) vaccinated APP+PS1 mice with Aβ1-42 in Freund’s
adjuvant (complete for initial injection, incomplete for monthly booster injections)
from 2-16.5 months of age and determined the effect of these injections at 4.5-6
months and 15-16.5 months longitudinally via administration of a 6 week behavioral
test battery at each time point. The study cohort was divided into control transgenic,
vaccinated transgenic, and non-transgenic mice. At the 4.5-6 month time point, both
transgenic groups displayed increased open field activity, while no group differences
were noted at the 15-16.5 month time point. Only young (early time point) treatment
mice were impaired at the balance beam task, however this impairment was not
present at the later time point and no impairment was present for string agility
performance at any time point. Comparing early and late time point performances, a
significant increase in percent time spent in open arms during the elevated plus maze
task in control mice was coupled with a significant decrease in the same measure for
vaccinated mice, perhaps indicating an anxiolytic effect in the former and an anxiety
increase in the former. Consistent with open field results, vaccinated mice also
showed significantly higher plus maze and Y-maze arm entries at the young time
point. Only Y-maze entries remained higher at the aged time point, however. No
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differences among groups were noted among percent alternations in Y-maze or
circular platform acquisition, however significance was found for each additional
cognitive based task administered. In Morris water maze acquisition, vaccinated
mice were protected against impairment noted in controls at both time points. This
same trend was noticed for young mice tested in Morris water maze retention,
however both transgenic groups were impaired compared to non-transgenics at the
later testing time point. No impairment at the young time point was noticed in
platform recognition, whereas vaccinated mice showed protection against impairment
exhibited by control mice at the later time point in this task. RAWM overall and last
block performances were reported for these mice as well, and for both measures at
both time points control mice showed performance impairment. In contrast, only in
overall RAWM performance at the young time point were vaccinated mice impaired;
in last block, young time point performance and in both last block and overall aged
time point performance vaccinated mice showed were protected against this
impairment. Discriminant function analysis using direct entry method revealed
cognitive protection in vaccinated animals at the young time point. Stepwise-forward
analysis showed similar results for all measures, as well as cognitive measures, at
both time points.
At 17 months of age, mice in the study conducted by Jensen et al. (2005) were
sacrificed, and Aβ histopathology was performed on mouse brain sections. No
significant reduction in Aβ immunostaining (total Aβ) or Congo Red staining
(compact Aβ) burdens were noticed in vaccinated mice overall, though one
vaccinated mouse was noted to have significant reductions of up to 86% in Aβ levels.
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Correlation analysis between the 8 Aβ deposition measures noted and nine cognitive
measures taken at the aged time point in these mice revealed no correlations between
Aβ histopathology and cognitive performance, in contrast to previous findings by
Arendash et al. (2001) in which such correlation was made for certain measures
despite a lesser duration of Aβ administration. Still, factor analysis results from
Jensen et al. (2005) did suggest an existing relationship between Aβ deposition and
numerous cognitive measures, despite a lack of significant correlation therein. More
importantly, perhaps, is that this study demonstrated once again the potential for longterm, active Aβ vaccination to result in cognitive protection in an AD transgenic
mouse model without significant overall reductions in deposited Aβ levels (Jensen et
al. 2005).
Austin et al. (2003) showed that 4 biweekly administrations of Aβ1-42 to
APPsw+PS1 transgenic mice at 16-18 months of age did not result in improved
cognitive performance in RAWM or other tasks between 18 and 20 months compared
to cognitively intact non-transgenic mice. Serologic anti-Aβ titers in these aged mice
were measured at an approximately 10-fold lower level compared to the previous
study by Morgan et al. (2000), indicating a possible mechanism for no improvement
in cognition. Prior to immunization, RAWM and platform recognition tasks were
administered, and it was noted that impairment of APPsw+PS1 mice was only present
in trial 5 performance of RAWM as well as overall in platform recognition
performance. Following immunizations, both immunized and non-immunized
animals showed significant impairment compared to non-transgenics over a number
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of RAWM measures. Furthermore, both groups showed no pre- versus posttreatment differences in RAWM performances for any trial or block combination, and
in some instances these groups showed significant decline in performance measures.
In contrast, non-transgenic animals showed significantly better trial 4 performances
compared to testing results at a younger time point as well as stabilization of trial 5
errors at a significantly lower level compared to the high stabilization levels of
transgenic groups. Impairment also continued in platform recognition performance,
with significantly poorer performances displayed by both transgenic groups compared
to non-transgenics. Based on these findings, it seems that short-term immunization
was not effective in eliciting a strong immune response in these aged APPsw+PS1
animals resulting in no positive impact on cognitive performance. If these results can
be translated to human application, it would seem that Aβ vaccination will most
likely be most effective in AD if administration is begun at early time points in
disease development, resulting in increased administration periods (Austin et al.
2003).
Behavioral evaluation of vaccinated mice was also performed by Sigurdsson
et al. (2004) following K6Aβ1-30 immunization. Immunized mice performed
significantly better than transgenic controls in the radial arm maze task, in many
measures performing at a similar level to wild-type controls. It is clear based on these
results that cognitive protection is possible using a non-toxic, non-T cell activating
Aβ derivative such as K6Aβ1-30 as an antigen, indicating possibilities for future
vaccinations with reduced negative side-effects (Sigurdsson et al. 2004).
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The above behavioral based Aβ immunization studies directly tie the
pathological impacts of such vaccinations with cognitive benefits in AD transgenic
mice. The potential for Aβ vaccination as a therapeutic based on beneficial cognitive
impacts following reduced CNS Aβ burdens is established (Janus et al. 2000),
however, the potential of long-term vaccination to result in such benefit without
dramatic decreases in Aβ pathology is also reported (Morgan et al. 2000, Arendash et
al. 2001). Thus, the positive effects of Aβ vaccination on behavior in APP transgenic
mice appear to be mediated not simply by clearance of Aβ deposits, but by some
other mechanism such as clearance/neutralization of soluble Aβ constructs. Findings
by Austin et al. (2003) establish the necessity for long-term vaccine administrations
to achieve cognitive benefit, and it is apparent based on the overall results of the
above studies that application of Aβ vaccination as a preventative as opposed to a
treatment may result in increased efficacy. Finally, findings reported by Sigurdsson
et al. (2004) provide support for the concept of alternative immunotherapeutic
approaches to Aβ vaccination. Such results further reinforce the importance of
developing AD therapeutics targeting Aβ in the CNS, and promote Aβ
immunotherapy as a field of continued importance in AD research.
Active Aβ Immunization in Humans
The collective results of Phase I and Phase IIa Clinical Trials conducted by
Elan Pharmaceuticals in the U.S. and U.K. represent a disappointment which could
only follow the highest level of anticipation. Protocols consisted of administration of
Aβ1-42 (An1792) to humans in initial and booster shots for Phase I and, with repeated
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shots planned over a 12 month period for Phase II trials. In January 2002, reports of
nerve inflammation in four out of 298 patients in Phase II that had begun receiving
active vaccination led to further administrations being halted. Phase II was halted, in
fact, after only the initial and one booster injection (after 2 shots separated by one
month). 11 additional patients were reported to have developed similar
symptomologies a month later, and one death was attributed to affects of the vaccine.
Specifically, post-mortem analysis indicated neuroinflammation associated with T
cell activation as a possible cause of death. In the end, 18 individuals, or
approximately 6%, were found to develop symptoms suggesting subacute
meningoencephalitis (Orgogozo et al. 2003). A number of reports of findings from
these studies were still published, however. In October, 2002, Hock et al. reported on
the presence of anti-Aβ antibodies in the sera of 100% of 24 patients having received
one primary and one booster injection i.m. of Aβ vaccine containing QS-21 as an
adjuvant. These antibodies were not found to be cross-reactive with APP or any nonAβ derivatives. Sera taken from these patients were also found to bind to Aβ deposits
in post-mortem brain tissues of AD and CAA patients. CSF samples taken from 6
patients were also analyzed for Aβ reactivity, and it was reported that 4 out of 6
samples displayed positive results. Importantly, the presence of anti-Aβ in the CSF
was noted in patients with and without BBB dysfunction. It was suggested that a
combination of low Aβ antibodies and intact BBB’s resulted in prevention of these
antibodies from entering the CSF in the two negatively tested patients. Aβ titers in
serum samples ranged from 1:50 to 1:10,000, while in the CSF the highest
measurement was 1:1,000 (Hock et al. 2002).
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In March 2003, the first case report from post-mortem analysis of the lone
mortality of the Aβ1-42 vaccination trial was published by Nicoll et al.
Neuropathological analysis of this woman’s brain revealed uncharacteristically low
levels of plaques in various areas of the neocortex compared to seven unimunized AD
patient brains. It was noted that these areas still maintained levels of NFTs and CAA
common to non-treated AD patients, but that dystrophic neurite levels and astrocytic
activations typically associated with amyloid plaques were significantly reduced.
Involvement of microglia in Aβ clearance was suggested by co-associated with Aβ
immunoreactivity. Perhaps most important, however, were findings of T-lymphocyte
meningoencephalitis, indicating the potential mechanism by which
neuroinflammation occurred in patients receiving the Aβ vaccine (Nicoll et al. 2003).
This provides insight into the major disparity between immune reactivity to Aβ1-42 in
mice and humans. In mice, evidence suggests that hyppoimmune responses to Aβ
may be due to low levels of T cell activation; however it is clear based on the above
findings that heightened T cell response is present in at least some humans receiving
the vaccine.
In May of 2003, Hock et al. reported on some of the positive cognitive effects
of Aβ vaccination in humans. 19 of the 28 patients administered the vaccine in Phase
I trials showed decreased decline in cognitive functions compared to non-treated
individuals. These patients were also noted to be the individuals who developed
antibodies against Aβ. Cognitive stability was determined via administration of tests
such as the MMSE and Visual Paired Associates Test of delay recall from the
Wechsler Memory Scale. Declines in activities of daily living were also diminished
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in treated individuals as determined from Disability Assessment for Dimentia results.
Importantly, overall results from the 300 patients tested in Phase II AN1792 clinical
trials did not parallel these findings, with no significant differences in cognitive
decline noted between groups. More information on the time course for antibody
development was also relayed in this publication. It was reported that both IgG and
IgM levels against aggregated Aβ1-42 increased significantly in the first month
following initial Aβ inoculation, and that maximal titers were reached by a month
after the booster injection (Hock et al. 2003).
The various findings resulting from vaccination studies in humans reinforce
the potential for variations between mouse model systems and human systems to
result in imperfect translation of results from one to the other. Important to consider,
however, is the evidence shown that cognitive benefit and Aβ clearance can result
from Aβ administration in humans. Thus, while the risks associated with standard
Aβ immunization outweigh potential benefits, it is clear that Aβ immunotherapeutic
approaches to AD warrant further investigation.
Passive Anti-Aβ Immunization in Animal Models
Pathologic Effects of Passive Anti-Aβ Immunization
Due to its neurotoxic properties, it is clear that the concept of Aβ inoculations
should elicit some level of concern. Passive administration of Aβ antibodies allows
for introduction of these molecules without any need for Aβ inoculation or for
immune system activations associated with antibody production. The major methods
proposed for vaccine efficacy are direct solublization of Aβ, peripheral sequestration
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of Aβ by circulating antibodies, and antibody facilitated phagocytosis of Aβ by
microlgia. Thus, the potential for Aβ clearance based solely on the administration of
Aβ antibodies is viable. Bard et al. (2000) performed the first study involving passive
immunization in a mouse model of AD. It was shown that peripherally administered
antibodies to Aβ are capable of entering the CNS of PDAPP mice to induce clearance
of amyloid plaques by as much as 93%. Two of a set of four monoclonal antibodies
along with polyclonal antibodies from Aβ1-42 immunized mice were shown to induce
this effect in 8-10 month-old mice. No T-cell reactivity was seen to be evoked as a
result of these procedures. Analysis of microglia showed numerous Aβ containing
vesicles, indicating a major phagocytic mechanism of plaque clearance. Internalized
Aβ was shown to be degraded by these cells, and the internalization process was
shown to be Fc receptor mediated. Additional work with 13 month old mice showed
that modest reduction in existing small plaque counts could be seen as early as 3 days
after treatment, while 35 days after treatment up to 60% of small and diffuse plaques
had been cleared. Large, compact plaques appeared to resist clearance. Importantly,
no correlation existed between binding affinity of antibodies to soluble Aβ and plaque
clearing capabilities of these antibodies, indicating that affinity to deposited Aβ may
play the larger role (Bard et al. 2000).
DeMattos et al. (2001) also showed that anti-Aβ antibodies are able to prevent
Aβ deposition in PDAPP mice, however it was shown that the antibodies used in this
study were not capable of binding to existing Aβ deposits. It was found that these
antibodies sequestered large quantities of Aβ in the serum, indicating that in this case
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the ability of these molecules to act as a peripheral Aβ sink was the driving force
behind protection against development of Aβ pathology. CSF levels of Aβ were also
found to increase, which was attributed to increasing levels of solublized Aβ
(DeMattos et al. 2001).
Lambert et al. (2001) showed that antibodies generated in vivo against
inoculated Aβ1-42 oligomers were capable of binding preferentially to Aβ constructs
in vitro. These antibodies were also shown to block toxicity of Aβ oligomers in vitro.
As mentioned earlier, a study conducted by McLaurin et al. in 2002 showed that
antibodies recognizing the 4-10 residues of Aβ1-42 inhibit fibrillogenesis of Aβ in
TgCRND8 mice. Again, the antibody was shown to target protofibrillar Aβ, an
important Aβ plaque precursor. These studies provide a clear mechanism for
prevention of plaque formation via anti-Aβ administration which may potentially
occur without modulation of Aβ levels. (McLaurin et al. 2002).
In 2002, Chauhan and Siegel reported that a single ICV injection of anti-Aβ
antibodies led to reduced plaque loads in the cerebrum and decreased astrocytosis in
10 month-old Tg2576 mice. In 2003, this same group reported that this same
treatment was associated with reduction in activated microglia levels in areas
surrounding existing Congophilic plaques- the study, however, only involved
qualitative assessments of these levels. Nonetheless, it was further reported that no
signs of microhemorrhage were found in these mice (Chauhan and Siegel 2003).
Wilcock et al. (2004) also showed that significant reduction in amyloid was possible
in Tg2576 mice, this time in 19 month-old animals. It was shown in this study that
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microglia activation between 3-7 days after injection correlated to this clearance, but
that other mechanisms were involved as clearance began as early as 24 hours postinfusion. Finally, a study by Lombardo et al. (2003) in aged PDAPP mice indicated
that, along with clearance of Aβ as early as 4 days following a single administration
of anti-Aβ antibodies, neuritic alterations attributed to neurotoxic properties of Aβ
were reversed as a result of this administration. This again emphasized the
importance of achieving Aβ clearance from the CNS in AD.
Pfeifer et al. (2002) produced the first results indicating the possibility for
negative consequences to passive anti-Aβ administration. 21 month-old APP23 mice
showed reduced amyloid pathology following such treatment, mainly due to
clearance of diffuse Aβ plaques, but also displayed increased levels of
microhemorrhages. It was also shown that CAA levels were not affected, only
hemorrhages associated with this pathology were shown to increase in occurrence.
CAA development appeared to be a requisite for this pathology to occur, as 6 monthold APP23 mice lacking CAA did not develop these hemorrhages. One suggested
mechanism for triggering of these hemorrhages was that anti-Aβ antibodies are
capable of binding to amyloid deposits in blood vessel walls, potentially causing an
inflammatory event that served to weaken such amyloid-bearing blood vessel walls.
It was suggested that because approximately 80% of AD patients over 65 develop
CAA, and because only APP23 mice develop CAA at levels comparable to those
found in AD, that results from other passive anti-Aβ studies may not be a perfect
indicator of the response such treatment would elicit in humans (Pfeifer et al. 2002).
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Behavioral Effects of Passive Anti-Aβ Immunization
Along with those studies focused solely on pathological impacts of passive
anti-Aβ immunotherapy, a few studies also investigated behavioral impacts. Dodart
et al. (2002) reported that 24 month-old PDAPP mice treated i.p. with m266 anti-Aβ
antibodies for six weeks showed performance in object recognition tasks similar to 8
month old wild-type mice and significantly better than non-treated PDAPP mice or
IgG1 isotype treated controls. No significant reduction in Aβ pathology was noted in
these mice, in contrast with previous findings from this same group in younger
PDAPP mice, and task improvement was therefore attributed to reduced levels of
soluble Aβ in the CNS. This was supported by correlation analysis showing no
correlation between Aβ burdens and behavior in m266 treated mice and by findings
that 8 month old non-treated PDAPP mice were significantly worse than aged, treated
PDAPP mice at recognizing novel objects despite having lower levels of Aβ
deposition.
Further work by Dodart et al. (2002) studied the impact of acute, single
administrations of m266 on 11 month old PDAPP mice. Again it was shown that
these mice were better at recognizing novel objects than age-matched transgenic
controls after receiving only one m266 administrations. To further explore the effect
of acute, single-dose m266 therapy on behavior in 11 month old PDAPP mice, 4 days
of the holeboard task were administered. It was reported that treated mice made
significantly fewer errors in this task during the final two days of testing (data not
reported for initial two days of testing), again emphasizing the potential for learning
and memory benefits based on m266 therapy. Finally, statistical analysis showed a
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dose dependent correlation between object recognition performance and m266
therapy dosage, and only mice receiving maximal dosage (250 µg) showed
performance above chance levels in this task. The antibody used in this study was
known to not decorate existing Aβ plaques and was thought to not cross the BBB,
however a dose-dependent correlation was made between plasma concentrations of
Aβ isoforms and m266 therapy. Based on these findings, it was suggested that the
major mechanism of action for m266 therapy was for these antibodies to act as a
peripheral Aβ “sink”, binding and sequestering peripheral amyloid and causing an
equilibrium shift of CNS to peripheral Aβ. Thus, according to this theory, cognitive
protection can be gained via modulation of CNS soluble Aβ levels without reductions
in Aβ plaque burdens. (Dodart et al. 2002).
Kotilinek et al. (2002) reported similar results to those seen by Dodart et al.
(2002). It was shown that administration of the monoclonal anti-Aβ antibody BAM10 (which recognizes the N terminus of Aβ) did not lead to plaque clearance in the
CNS of 9-11 month old Tg2576 mice, but that reversal of memory loss did correlate
to such administration. Baseline performance was measured just prior to
immunization and consisted of administration of the visible platform task followed by
hidden platform coupled with three intermittent probe trials (a variation of Morris
water maze application). Mice were divided into treatment groups based on mean
probe trial performances. 4-5 days after baseline evaluation, treatment mice
underwent 3 separate injections of BAM-10 over a period of one week. 11-12 days
following baseline testing, hidden platform testing was administered using the same
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protocol; however a different set of visual cues were arranged around the testing pool
and a unique platform location was used. Major differences among groups based on
treatment revolved around probe trial results. It was shown that percent time spent in
the target quadrant for this task was significantly increased in BAM-10 treated mice;
in specific probe trials, however this trend was not noted in overall percent time
measures (averaged from all probe trials) and no significant difference was measured
between BAM-10 treated mice and IgG treated control mice overall. No
improvements were noted for hidden platform performances. The interpretation of
this data by the authors was that BAM-10 treated mice showed a reverse of memory
loss following treatment. As there were not significant alterations in Aβ levels in
these mice, the authors contributed this reversal of impairment to neutralization of Aβ
assemblies in the CNS resulting in decreased neurotoxicity of these constructs. It was
shown that BAM-10 treatment eliminated the negative correlation between soluble
brain Aβ and probe trial scores, indicating that this treatment did in fact reduce the
impact of existing Aβ in the brains of Tg2576 mice (Kotilinek et al. 2002).
Wilcock et al. (2004) administered weekly doses of anti-Aβ antibody to
Tg2576 mice for either 1, 2, or 3 months, with treatment beginning so that all mice
finished the treatment regimen at 22 months of age. Behavioral assessment of these
mice consisted of a single, 8 minute administration of the Y-maze task 1 day before
sacrifice. Mice were treated with IgG antibody to Aβ28-40 with controls receiving an
anti-Drosophilia amnesiac protein IgG1 antibody. Only mice treated with Anti-Aβ
for 3 months were shown to have significantly higher spontaneous alternation in Ymaze performance compared to transgenic control groups. Performance for mice
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treated for 3 months was at the same level as non-transgenics, with reduced
performances following lesser treatment periods. However, after 1 or 2 months of
treatment, immunized mice were not significantly different in performance from
either non-transgenics or controls transgenics. Hyperactivity based on Y-maze arm
entries was noted in non-treated APP controls but was not noted in 2 or 3 month
treated animals.
Antibodies administered for all treated mice were shown to decorate plaques
within the CNS, with direct proportionality between immunostaining and plaque
density. Following 1 month of anti-Aβ treatment, transgenic animals were noted to
have slight but not significant reductions in Aβ deposition. Following both 2 and 3
months of treatment, however, significant decreases in Aβ immunostaining were
found in hippocampal and frontal cortex regions, with both compact and diffuse
plaque burdens reduced. It was further shown that microglia Fcγ receptor expression
was upregulated after 1 month of anti-Aβ antibody treatment, CD45 molecules after 2
months, and that expression levels of both marks then returned to normal after three
months, indicating temporal activation of these cells. Based on these findings, it was
suggested that Aβ clearance was thus mediated via a number of mechanisms,
including solublization of deposited Aβ by antibodies, sequestering of Aβ in the
plasma, as well as by microglia activation and phagocytosis of Aβ. Furthermore, it
was said to be this reduction in Aβ burden in the CNS which resulted in improved Ymaze performance for treated Tg2576 mice (Wilcock et al. 2004), although no
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correlation between Aβ deposition and Y-maze alternation was done for Aβ antibody
treated mice.
The speed with which acute administration of anti-Aβ antibodies result in
cognitive benefit in AD transgenic mice (based on findings by both Kotilinek et al.
2002 and Dodart et al. 2002) and the lack of Aβ pathology decreases in these animals
would seem to support the theory that these antibodies are acting more through either
alterations in CNS:sera Aβ levels or neutralization of toxic Aβ constructs. The rapid
behavioral benefits reported by Dodart et al. (2002) and Kotilinek et al. (2002) could,
however, result from alleviation of secondary effects of Aβ (a known vasoconstrictor)
in the blood resulting in increased cerebral blood flow. In any event, findings by
Wilcock et al. (2004) still support the concept of cognitive protection following
reductions in Aβ pathology due to passive Aβ immunization.
Passive Anti-Aβ Immunization in Humans
While no data has been reported on passive Aβ immunization in humans, the
potential exists for such studies to occur based on results noted above in assessment
of such immunization in transgenic models of AD. In the wake of findings from
active immunization trials in humans, however, the climate for research along
immunotherapeutic lines in humans with AD has changed dramatically in the last few
years. Findings such as those noted by Pfeifer et al (2002) suggest that inflammation
following anti-Aβ administration can occur in transgenic animals which develop
CAA, and it is not unreasonable to assume that similar side-effects would occur in
humans following such treatment. As Anti-Aβ antibodies have been shown to
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sequester amyloid in the blood, it is also possible that increased development of CAA
or other vasculature dysfunctions may occur. Other side-effects from
continual/repeated administration of antibodies in humans may result from eventual
immune response to injected antibodies, resulting in accumulation of immune
complexes and potentially further disruption of the vasculature (serum sickness)
(Sigurdsson et al. 2002). Such activation of the peripheral immune system may also
lead to development of inflammation within the circulatory system. Although many
results from passive Aβ immunization in animal models of AD have been positive, it
is clear that the immune environment of transgenic models is extremely variable even
based solely on background differences among mice, and the major lesson to be taken
from the human vaccination trials is the potential for differences between immune
responses in these mice and in humans to result in devastating side-effects. Until a
valid and long-lasting therapeutic for Alzheimer’s Disease is discovered, however, it
is likely that the need for such treatments will eventually outweigh other concerns,
and immunotherapeutic approaches such as passive Aβ immunization will
undoubtedly be assessed in human subjects at some point.
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Other Immunotherapeutic Strategies for Alzheimer’s Disease

Based on our current understanding of immunotherapeutic approaches to
Alzheimer’s Disease, it is clear that the most probable means of reducing Aβ
pathology in the CNS is limited to two mechanisms. The first is humoral based and
involves clearance of Aβ from the CNS via two separate routes. Solublization of Aβ
in the CNS by direct actions of anti-Aβ antibodies can result in clearance of both
soluble and insoluble forms of the peptide, while sequestration of the Aβ by anti-Aβ
antibodies in circulation can lead to an equilibration shift of Aβ into the serum and
out of the CNS. The second is cellular based and relies on activation of key immune
system cells within the CNS to clear Aβ by phagocytosis and internal degradation of
the molecule or by production of extracellular peptidases capable of breaking down
aggregated Aβ. Aβ immunization, both active and passive, is known to initiate
reduction of Aβ levels within the CNS, both soluble and insoluble, via both pathways
as described above.
Alternative immunotherapies attempt to achieve similar results without
instigating inflammatory damages associated with Aβ vaccination. Currently, two
potential immunotherapies in particular show promise. The first involves
development of non-antibody Aβ binding agents which can be administered
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peripherally and serve to sequester Aβ in a similar fashion to anti-Aβ antibodies,
again resulting in increased traffic of Aβ out of the CNS. As discussed previously,
these agents thus serve as peripheral Aβ “sinks” by increasing serum levels of Aβ via
this mechanism. The second involves either stimulation of an appropriate T cell
response via various mechanisms or direct infusion of specifically activated T cells to
elicit a desired immune response.
Alternative Peripheral Aβ Sinks
In 2002, Matsuoka et al. reported that peripheral administration of two
separate Aβ binding molecules, gelsolin and GM1, in young APPsw+PS1 mice
resulted in significant Aβ clearance from the brains of these mice. These bloodlimited molecules were thought to sequester Aβ in the periphery, causing a shift in
Aβ equilibrium away from the CNS, as described for anti-Aβ treatments. Gelsolin in
particular is unable to cross the BBB, and so its affects are attributed solely to
peripheral binding of Aβ. Importantly, it was noted after treatment that plasma levels
of Aβ did not increase at anywhere near the levels seen after passive Aβ
immunization, making the exact mechanism of action for Aβ sequestration in the
periphery difficult to interpret. Administration of these compounds in aged PDAPP
mice did not result in significant reduction of amyloid plaques, apparently indicating
once again that amyloid plaque burdens are more difficult to reduce in older animals
(Matsuoka et al. 2002). This resiliency of established plaques in aged mice against
reduction following immunotherapy has been established in numerous studies
(Morgan et al. 2000, Arendash et al. 2001, Dodart et al. 2002, Kotilinek et al. 2002).
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In 2003, Deane et al. showed that sRAGE, derived from the RAGE Aβ binding
protein, can also act to sequester Aβ in the periphery, providing another potential for
Aβ-binding protein therapy.
The exact mechanism by which Aβ is transported across the BBB to the
periphery is thought to be mediated by the LRP clearance receptor for Aβ, while reentry of the peptide into the CNS appears to be mediated by RAGE receptors. Other
carrier proteins such as albumin and transhyretin are also thought to be involved in
this process. Modification or inhibition of certain aspects of these pathways or
treatments may provide a mechanism for altering sera:CNS Aβ ratios, providing
another mode of Aβ clearance from the CNS (Zlokovic et al. 2004).
T-cell Based Therapy
As indicated above, immunotherapeutic treatments for neurodegenerative
diseases such as AD result in varied levels of activation among separate T helper cell
subtypes. The actions of these reactive T cells then bias the overall immune response.
In the most general terms, Th1 T cells cause a cellular based response and Th2 cells a
humoral response (Vallejo et al. 2004). Either response, if elicited in an appropriate
fashion, may have a beneficial effect in the AD brain; the former via activation of
phagocytes, the latter via activation of antibody-producing B cells and/or
downregulation of neuroinflammation. The potential for such bias to result in
negative consequences has also been well established, for instance it has been
indicated in vaccination studies that a Th1 biased immune response results in
increased inflammation, potentially leading to an aberrant auto-immunee reaction
(Furlan et al. 2003). These responses are the most general aspects of T cell activities,
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however, and, especially with regards to active immunization, it is unclear to what
extent undesirable T cell activation and the neuroinflammatory events which result
are due simply to the unique reactions elicited by the antigen and/or adjuvant used.
Modulation of the T cell response via alterations in antigen/adjuvant vaccine
components, as well as delivery routes/vehicles, could potentially result in benefit
without neuroinflammation (Cribbs et al. 2003), and certain immunological
treatments have been shown to elicit such benefit without any T cell activation
(Schenk et al. 2004). However, it is important to consider that T cell subsets as a
whole are not anathema. The potential activities of these cells in response to antigen
based activation are wide ranging, and it remains to be seen whether such activation
in the context of a non-immunized system is beneficial or detrimental. Infusion of
Aβ reactive T-cells has never been attempted in any animal model of AD, however
the concept of such adoptive immunotherapy has been established for some time in
other fields of study. In individuals with lowered immune system efficacies or hyporesponsiveness to specific antigens, T cell infusions act to prime these systems to
counterbalance such deficits.
Donor Lymphocyte Infusion For Non-CNS Diseases
Infusion of activated T cells has been used in the treatment of a number of
disorders and diseases, with benefit gained due to actions of both CD4+ and CD8+ T
cells individually and in concert. There is great potential for such adoptive transfers
to serve as anti-tumor treatments due to the activity of both cytotoxic cells
recognizing tumor specific antigens and memory T helper cells capable of sustaining
an immune response to malignant cells (Vonderheide and June et al. 2003). Findings
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that graph-versus-leukemia anti-leukemia affects were more likely to occur following
transplant of non-T-cell-depleted bone marrow transplants resulted in a number of
studies being conducted to test the efficacy of T cell Donor Lymphocyte Infusions
(DLI), or selective infusion of non-patient lymphocytes, in treating various leukemias
(Kolb et al. 1995, Collins et al. 1997, Slavin et al. 1996) as well as myelodysplastic
syndrome (Bressoud et al. 1996), multiple myeloma (Lokhorst et al 1997), and nonHodgkin’s lymphoma (Bernard et al. 1999). Complications were most prevalent
following bone marrow transplant-based treatments and consisted mainly of marrow
aplasia, or failure of the bone marrow to thrive, though this was resolved in as many
as 80% of patients (Collins et al. 1997). The potential for T cell infusions to serve as
a treatment for numerous cancers, especially for recurrent hematalogic cancers postbone marrow transplant, has thus been established (Szer et al. 1993).
Continuing research in immune system diseases have shown that T cell
infusions serve to re-establish immune functions in patients with Epstein Barr Virus
(EBV), cytomegalovirus, and Human Immunodeficiency Virus (HIV) infections,
though not always without some adverse affects (Heslop and Rooney 1997, Walter et
al. 1995, Levine et al. 2002). This research elicits the potential for recharging of the
immune system following DLI in immune compromised individuals or in
counteracting hypo-immuneresponsiveness to a toxic self peptide such as has been
implicated in AD.
Priming of the CNS Immune System With T Lymphocytes
APP transgenic mice display a tolerance-based effect after immunization with
Aβ which results in a decreased immune system response (Monsonego et al. 2001).
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To elicit an immune response to Aβ in humans, it was deemed necessary to
administer an adjuvant in concert with the peptide (Hock et al. 2002). Otherwise the
Aβ peptide, which is formed via proteolytic processing of the endogenously
expressed APP molecule found in all humans, would not likely elicit a significant
immune response until late in AD development when it is associated with
neuroinflammation. This self tolerance may affect the ability of Aβ vaccination to be
effective as a treatment, especially as immune system activation in AD is largely
restricted to local, glial based, non-systemic types (Streit 2004, D’Andrea 2004). An
exploration of the ability of T cells to prime the immune systems of AD models is
thus warranted to determine the potential for such cells to overcome or reverse self
tolerance to Aβ, inducing either microglial phagocytosis of Aβ or B cell anti-Aβ
antibody production.
As described above, APP mice display a lessened immune response following
Aβ immunization compared to wild-type controls, most likely due to self tolerance.
As both APP and Aβ are present under normal conditions in humans throughout
aging, it is likely that a certain level of tolerance is present in humans as well
following similar vaccination. DLIs have been used to combat deficient immune
systems in murine models as well as humans, whether these deficiencies be
congenital or due to an infectious disease of the immune system. It has been
suggested a deficiency in the immune system may be present in AD which prevents
the immune cells of the CNS from taking appropriate action against the insults
inflicted therein during the course of disease. Both microglia and T lymphocytes are
likely to be drawn to areas of inflammation associated with Aβ pathology in AD
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brains (D’Andrea 2004, Farkas et al. 2003). However, these cells may not be
appropriately activated early enough along the course of the disease to be affective, or
may be deficient in their activity (Streit 2004, Monsonego et al. 2001). Prior to
compact neuritic plaque formation, microglia could potentially be stimulated to clear
deposited Aβ. At the same time, activated T cells can both regulate the immune
response to Aβ associated damage and, as will be elicited later, potentially play a
neuroprotective role against further damage. If activated too late, however,
frustration and continual stimulation of microglia and T cells (via co-stimulation)
may occur, resulting in exacerbation of the inflammatory cascade rather than
protection.
Aβ-sensitive T cells are unlikely to be found in large numbers in APP
transgenic mice or in humans due to selection against thymocytes reactive to self
proteins which occurs during T cell development. As AD progresses and Aβ
becomes more prevalent and is associated with inflammation and cellular damage,
however, is likely that Aβ-senstive T cells would be activated and proliferate. This is
supported by findings by Monsonego et al. (2003) that Aβ-sensitive T cells are
common in both elderly, healthy individuals and AD patients, with AD patients more
likely to possess these cells. What is not clear, however, is if this immune response to
an endogenous peptide is beneficial but is simply deficient in AD patients, or is a
detrimental autoimmune dysfunction.
If T cells do possess the potential to combat the damage associated with
amyloid pathology, it is possible that Aβ-sensitive T cells themselves could serve as a
potential therapeutic in AD. These cells may then play a role in activating other
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immune system cells as described above, causing an upregulation in immune system
activity, or a “charging” of the AD immune system. The potential drawback of such
activation, of course, is that an incorrectly balanced immune reaction can lead to a
strong bias towards a cellular or humoral based response, and under certain
conditions this can lead to increased neuroinflammation, as seen in human clinical
trials for Aβ vaccination (Nicoll et al. 2003). Careful study of the effects of
Aβ−sensitive T cell infusions in AD models will be necessary to determine the true
potential of such cells.
Neuroprotective Actions of T Lymphocytes
It is thought that in AD, immune hyporesponsiveness to Aβ prevents
effectiveness of some Aβ immunotherapies, as would be true for any endogenously
expressed peptide due to self-tolerance. To overcome this deficit, adjuvant coupled
administration of Aβ peptide was used in human clinical trials, and it was found that
this led to potentially lethal inflammation in the CNS of immunized individuals. This
may have occurred in part due to activation of cells sensitive to a “self” peptide.
Autoimmunity of this type is typically associated with a negative connotation due to
such devastating effects, which are not un-similar to those noted in autoimmune
disorders. However, new research in this field has begun to reveal that autoreactive
cells, specifically T cells, are actually capable of providing neuroprotective benefits
in areas of CNS inflammation and neuronal damage. Understanding and harnessing
of this potential may lead to potential new therapeutics for neurodegenerative
diseases such as AD, in which neuroinflammation plays a key role.
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Extensive research in neural injury repair has shown that T cells can play an
essential role in modulating repair in neuroinflammatory-based damage. Specifically,
myelin-specific Th1 cells (the same proinflammatory, encephalitogenic cells capable
of instigating onset of autoimmune diseases) seem to be capable of providing
protection following neuronal injury. It appears that these autoreactive T cells,
capable of causing neuronal damage and inflammation when inappropriately
activated, are also capable of being drawn to an area of injury and in some way acting
as neuroprotectants under the correct neurophysiological paradigm (Kipnis et al 2002,
Schwartz et al. 2003).
One pathway of this protection appears to be regulation of microglia activity.
Microglia, known to both be activated by and activators of T cells as discussed above,
can contribute to continued neuronal damage following initial insult if left unchecked.
T cells do possess the ability to prevent frustrated microglia from continuing to cause
neuronal damage (Avidan et al. 2004). A second route of action for T cell mediation
of CNS damage may be production of neurotrophins. Infused autoimmune T cells are
capable of producing such factors after reactivation due to antigen presentation. Both
Th1 and Th2 subsets of autoimmune cells have been shown to produce these factors
following injury to the CNS, resulting in neuroprotective effects. These effects can
be blocked via inhibition of NT-receptor activity, indicating that it is the direct
interactions of these factors with neurons which is providing protection, and these
receptors are known to be upregulated on injured neurons (Moalem et al. 2000).
Finally, the work of Michal Schwartz and associates in the past two years has
displayed the ability of T cells to protect against glutamate neurotoxicity. Excessive
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activation of neurons and/or glutamate release by activated cells such as microglia
can result in such toxicity, and the potential of T cells to lessen glutamate toxicity
based damage is another potential mechanism by which these cells are capable of
providing protection following CNS damage. The mechanism of action for this
protection appears to be two fold. In response to neuronal damage associated with
glutamate toxicity, self-specific T cells directly decrease damage following glutamate
exposure. This is attributed to the neuroprotective capabilities of autoreactive T cells
as discussed above. Secondly, regulatory T cells reduce cytotoxic-type microglial
activation, reducing neuroinflammatory damage associated with such activation
(Schwartz et al. 2003).
These findings seem to imply an important, direct route by which T cells
typically associated with inflammation in the CNS are actually important in
combating damage under appropriate conditions. The damage and associated
neuroinflammation present in AD may thus also be regulated and counterbalanced by
the same T cell subsets which might otherwise be involved in propagating
neuroinflammatory events. As has been illustrated earlier, microglia associated with
neuritic plaques in the AD brain are known to instigate neuronal damage if left
unchecked due to phagocytic frustration. However, microglia have been shown to be
capable of acting as Aβ APCs for T cells, indicating a mechanism by which Aβsensitive T cells may be reactivated local to these plaques (Monsonego et al. 2003).
In 2003, Farkas et al. reported that Aβ mediated break-down of the BBB followed by
infusion of activated T cells resulted in migration of these cells into the brains of male
Wistar rats. Based on these results, it is reasonable to assume that in murine AD
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models, peripherally infused Aβ-sensitive T cells would migrate across the BBB into
the brain, allowing them to associate with microglia in amyloid containing regions of
the CNS.
Microglia express MHC-II in order to interact with T cells, allowing microglia
to participate in T cell activation, and thus indirectly in neuroprotection. Suppresed
expression of MHC-II is thought to be present in AD and may prevent early actions
of microglia in clearing amyloid plaques, and it has been suggested that localized TH1
cells may be able to stimulate such expression at an earlier time point (Schwartz et al.
2003). In the presence of inflammatory factors released by damaged neurons, and
following co-stimulation with microglia, these T cells may then be stimulated by the
same mechanisms outlined above to both reduce local gliosis and counteract neuronal
damage associated with Aβ deposition. As a caveat, it should again be noted that TH1
subset cells have been implicated in playing a major role in neuroinflammation in AD
and other CNS disorders (Furlan et al. 2003). Interestingly, however, it appears that
microglia and T cell co-activation in the CNS results in upregulated production of
anti-inflammatory cytokines such as IL-10 by T cells, resulting in decreased
production of neuroinflammation-inducing cytokines and other inflammatory factors
by microglia and TH1 cell lines (Chabot et al. 1999). Mallat et al. (2003) produced
results emphasizing the potential benefit to be gained via this mechanism. It was
shown that adoptive transfer of ovalbumin-specific Tr1 subtype T cells (which are
capable of downregulating Th1 cells) reduced development of atherosclerosis in
Apolipoprotein E knockout mice. Injection of these cells along with ovalbumin in
complete Freund’s adjuvant resulted in activation of infused lymphocytes and a
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significantly reduced overall Th1 response (based on cytokine profiles). It was
suggested that this bias against a cellular based immune response resulted in
decreased inflammation, which is thought to play a major role in development of
atherosclerosis in these ApoE KO mice (Mallat et al. 2003). Importantly though, this
study focused on overall Th1 subset activities, not on the potential for specific
autoreactive Th1 subsets on the CNS side of the BBB.
Th2 subsets may also be capable of playing a neuroprotective role. Benner et
al. (2004) demonstrated that Cop-1 (a Th2 phenotype specific stimulator) activated
immune cells adoptively transferred into MPTP-intoxicated mice (a model for
Parkinson’s disease) are capable of migrating into the inflamed nigrostriatal
dopaminergic regions of these mice. Once localized to the site of inflammation, these
cells were shown to be capable of suppressing microglia actions and of stimulating
production of neuroprotective products such as glial cell line-derived neurotrophic
factor (GDNF) by astrocytes to result in significant neuronal protection (Benner et al.
2004). Thus, without serving to reduce Aβ pathology, infused Aβ autoreactive T
cells, including both Th1 and Th2 subsets, may be capable of protecting against Aβ
associated damage if they too are able to produce neuroprotective agents and to
combat neuroinflammation.
Perhaps the most persuasive study indicating the potential for T cell therapy in
AD was conducted in 2004 by Avidan et al. This study reported that T cells specific
to neuronal self antigens are capable of reducing damage associated with neurotoxic
properties of Aβ. Intraocular Aβ1-40 injections in C57BL/6J mice resulted in
significant death of retinal ganglion cells. In mice immunized prior to Aβ injection
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with interphotoreceptor retinoid-binding protein (antigen specific cells in the eye),
loss of neurons was significantly less. To verify that this reduction was T cell
induced, interphotoreceptor retinoid-binding protein and S-antigen specific T cells
were passively transferred into C57BL/6J mice immediately following Aβ intraocular
injections, resulting once again in retinal ganglion cell protection. Further findings by
Avidan et al. (2004) would seem to downplay the potential for neuroprotection
following infusion of Aβ-sensitive T cells in APP transgenic mice. It was noted that
T cells specific to non-aggregated Aβ1-40 are capable of inducing only slight
reductions in Aβ-induced retinal ganglion cell loss. This was attributed to a lack of
microglial capacity for expressing MHC-II in response to aggregated Aβ1-40 exposure
based on unpublished results by Butovsky et al. However, the authors do suggest that
memory T cells specific to self antigens should be capable of activation and downregulation of cytotoxic microglia actions. This is more in agreement with findings by
Monsonego et al. (2003) which indicate that presentation of Aβ and direct activation
of Aβ specific T cell subsets by activated Microglia can occur. Furthermore,
additional findings published by Monsenego et al. demonstrate the presence of Aβsensitive T cells in AD patients, and it is suggested that processing of Aβ in the CNS
by APC cells followed by migration of APCs to lymph nodes leads to eventual
peripheral activation of Aβ reactive T cells (Monsonego et al. 2003-2). The potential
for Aβ-sensitive T cells to be activated via MHC-II presentation is thus established in
both murine systems as well as in humans.
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There appears to be potential for adoptive T cell transfer to serve as a
therapeutic for neurodegenerative diseases. The pathways by which such protection
may occur in AD, as discussed above, are outlined in Figure 2. The first pathway is
based on the ability of certain T cells to stimulate the immune system early in Aβ
pathology development via either a cellular (stimulation of microglial phagocytosis of
Aβ) or humoral (stimulation of anti-Aβ antibody production) based response. In
addition, there is the potential for T cells to provide protection against neuronal
damage resulting from development of Aβ pathology later along the course of the
disease via both production of neurotrophins and down-regulation of glial-based
neuroinflammation. This form of protection may also extend towards prevention of
glutamate based neurotoxicity. No studies to date have established the behavioral
effects of T cell infusions into a neurodegenerative disease model, nor have the
pathological effects of such infusions been explored in a model of Alzheimer’s
Disease. Elucidation of the actions of various T cell subsets once within the CNS of
AD models may provide insight into the potential for T cell therapy in AD.
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Figure 2. Mechanisms of T cell based neuroprotection. Following re-activation in
the CNS via interactions with APCs such as microglia, infused auto-reactive T cells
sensitive to Aβ may act therapeutically in the AD brain via three mechanisms: 1)
Early activation of the immune system to promote both humoral and cellular based
immune responses to soluble and deposited Aβ (red). 2) Suppression of “frustrated”
cell (microglia, astrocytes, etc.) actions in the region of Aβ mediated neuronal
damage to prevent excessive neuroinflammation and associated glutamate toxicity
(blue). 3) Production of neurotrophic factors which promote neuronal health and
help protect against neuronal loss/dysfunction while also protecting against glutamate
neurotoxicty (green).
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Specific Aims

The specific aims of this thesis are:
1) To isolate, culture, and prime with human Aβ1-42 peptide, spleenocytes
isolated from young, Aβ1-42 immunized wild-type mice, and to inject
these activated, multi-subset, T cell enriched spleenocytes into AD
transgenic mice.
2) To determine the effects of Aβ-sensitive T cell enriched spleenocyte
infusion on cognitive performance in Radial Arm Water Maze, Platform
Recognition, and Y-maze tasks compared to placebo-infused transgenic
and wild-type mice.
3) To determine post-mortem the pathologic effects of Aβ-sensitive T cell
enriched spleenocytes within the CNS of AD transgenic mice through
analysis of Aβ burdens and distribution/activation levels of microglia and
T cells therein.
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4) To determine effects of Aβ-sensitive T cell enriched spleenocyte infusions
on blood cytokines levels, specifically with regards to levels of pro and
anti-inflammatory cytokines.
5) To perform correlation analysis to determine if behavioral task
performance measures correlate to any specific pathologic or biochemical
measures.
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Materials and Methods

Animals
To obtain the APPsw+PS1 mice used in this investigation, male heterozygous
APPK670N,M671L transgenic (APPsw) mice were crossed with female, homozygous PS1
mice of the 6.2 transgenic line. Female heterozygous PS1 transgenic offspring were
then crossed with APPsw males of the parental generation to obtain the nontransgenic and heterozygous APPsw+PS1 mice used for this investigation. Mouse
backgrounds for this generation consist of a 56.25% C57, 12.5% B6, 18.75% SJL and
12.5% Swiss Webster heterogeneous background. Mice were genotyped after
weaning, and then singly housed throughout the course of the study in standard 12hour light-dark cycle conditions, with free access to water and rodent chow.
Behavioral assessment and immune cell infusions occurred during the light phase of
the circadian cycle.
General Protocol
As indicated in the Timeline in Fig. 3, baseline cognitive performance for 10
non-transgenic and 15 APPsw+PS1 mice was established via a 12 day administration
of the RAWM task for working memory at eight months of age. Transgenic mice
were then divided into two groups balanced in RAWM performance based on overall
latency and error averages so that pre- vs. post- infusion comparson could be made
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between groups. Seven transgenic mice were designated as recipients for Aβsensitive immune cells, and 8 transgenics (as well as all 10 non-transgenics) were
designated as controls, to be given PBS. To generate Aβ-sensitive immune cells, 3
additional congenic non-transgenics were repeatedly immunized with Aβ1-42 at 3-4
months of age. Spleenocytes and lymphocytes isolated from these animals were then
cultured for 4 days prior to infusion into immune cell recipient mice. Infusion of
immune cells into these mice along with injection of PBS into both control groups
occurred two days following completion of RAWM testing (Fig. 3). After a one
month delay, mice underwent additional behavioral assessment consisting of RAWM,
Platform Recognition, and Y-maze task administrations (9, 4, and 1 days
respectively). A neurological assessment battery was also used to test for motor
and/or neurological deficits prior to sacrifice. Plasma samples and brains were taken
at sacrifice. Plasma cytokine levels were evaluated via immunoassay, and half brains
(bisected mid-sagitally) were coronally sectioned and used for quantification of brain
Aβ deposition levels via direct Thioflavin S staining, as well as by 6E10
immunostaining. Finally, statistical analysis was conducted to determine group
differences in cognitive task performances, plasma cytokine levels, and Aβ load
determinations. Correlation analyses, factor analysis, and discriminant function
analysis were also be used to evaluate overall group differences across these
measures.
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Figure 3. General protocol time line for the adoptive transfer study.
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Immune Cell Infusion Protocol
Three non-transgenic mice from the same generation as the study cohort were
vaccinated with human Aβ1-42 to elicit an immune response. One day prior to
injection, the site of injection on the backs of these mice was shaved. The following
day, 3 separate endodermal injections of human Aβ1-42 peptide (Bachem) in
complete Freund’s adjucant (CFA) were administered to each mouse following
isofluorane anesthesia.

Each mouse received a total of 250 µg of non-fibrillar,

soluble Aβ in 100µl of adjuvant divided equally over the three injections to induce
proliferation of Aβ sensitive immune cells. Each mouse then received additional
injections of 200 ng pertussis toxin 1 and 3 days post-immunization. Mice were
monitored for signs of distress and paralysis for these 3 days and for 7 days thereafter.
Following this 10 day period, these mice were sacrificed for harvest of spleen tissues
and lymph node fluids. Tissues from all 3 mice were pooled and homogenized with a
loose fitting 15 mL dounce, followed by filtration through a 70µm sieve filter,
centrifugal pelleting, and resuspension in red blood cell lysis buffer. After five
minutes, cells were again gently pelleted, then resuspended in full media and counted.
Cells were then cultured in full media containing 8-10 µg/mL Aβ1-42 and for 4 days.
After culturing, cells were once again pelleted, resuspended in phosphate buffered
saline (PBS), and viable cells were counted by trypan blue exclusion. Immune cell
recipient APPsw+PS1 mice were then administered approximately 2x107 viable
immune cells in 0.5 mL PBS by tail vein injection. Control transgenic and nontransgenic mice received tail vein injections of 0.5 mL PBS. All animals were then
monitored daily for signs of discomfort or paralysis.
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Behavioral Assessment
Radial Arm Water Maze
The RAWM task for working (short-term) memory was administered for all
mice at two time points as indicated on the study timeline. Testing occurred in a
100cm diameter pool of water divided by an aluminum insert which establishes 6
evenly spaced radial arms surrounding a central open area. Each arm was 30.5 cm in
length and 19 cm wide, while the central circular swim area was 40 cm in diameter.
A transparent 9 cm diameter platform at a 1.5 cm depth was used as an escape
platform for mice placed in the maze, and was placed approximately 15 cm away
from the end of the randomly assigned goal arm of the maze each day of the task.
Numerous visual cues surrounded the pool to provide spatial references for
navigation of the maze. For each trial of the task, mice were placed in the water at
the entrance of a novel start arm of the maze for that day, facing the central swim
area. The start arm was never the arm containing the submerged escape platform, and
both start arm sequences and goal arm location were semi-randomly changed each
day. The mouse was allowed to navigate the maze freely until fully entering an arm
of the maze. If the arm selected by the animal did not contain the escape platform, an
error was recorded and the animal was pulled gently back to the start location for that
trial. This procedure, including counting of an error, was also used if no arm
selection was made within 20 seconds. If after 60 seconds, an animal did not find the
escape platform, it was guided gently to it. Latency to find the platform up to 60
seconds and number of errors were recorded for each trial. The RAWM task
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consisted of five daily trials, the first four of which were administered with only a 30
second delay between them during which the mouse was left on the escape platform.
The fifth trial was administered 30 minutes later, and the animal was returned to its
cage during this delay interval. For animals which did not make at least 3 choices
during a trial and did not find the escape platform, a penalty error was recorded for
that trial. The penalty error was calculated by averaging trial one errors for the first
three days of testing for animals which did not find the escape platform but did make
at least three arm choices during these trials.
Platform Recognition
The platform recognition task was administered following completion of the
RAWM task to determine the ability of the mice to recognize a visible platform
placed at various locations in an open, 100cm diameter pool. This required a strategy
switch, as the RAWM task required that the animals search for a submerged platform
hidden in a divided pool based on orientation of visual cues around the pool, whereas
the platform recognition task only requires identification of the visible escape
platform. Thus, this task also tested the ability of these animals to adapt to a new
escape strategy. For this task, a 9 cm circular platform with a conspicuous 10 x 40
cm black and white conical visual cue attached was used, with the surface of the
platform raised .8 cm above the water’s surface. Mice were placed in the same
location in the pool for each of 4 daily trials. For each trial of a given day, the visible
platform was moved to a central part of one of four established quadrants in the pool.
The mice were allowed 60 seconds to find the platform before being guided to it

114

during each trial, and a 30 second stay on the platform was allowed between each
trail. Latency up to 60 seconds for each trial was recorded for 4 days of testing.
Y-maze
Mice were given 5 minutes to explore a black, three-armed Y-maze in order to
test both general activity (based on total number of arm entries) and basic mnemonic
processing (based on spontaneous percent alternation). Mice were placed facing the
center of the maze at the opening of the maze arm designated arm two. During the
five minute test period, the number and sequence of are choices was recorded.
Percent alternation was calculated by subtracting two from the total number of arm
entries and dividing this value into the total number of spontaneous alternation events
(consecutive choice of each of the 3 Y-maze arms, without re-entry into a previously
chosen arm) for each animal.
Neurological Battery
19 sensorimotor measures were taken from a neurological battery derived
from the Irwin Test (Irwin 1968). Qualititative assessment ratings of the following
were obtained for each mouse: transfer arousal after placement in a new
environment, ataxia, hypotenic gait, pelvic elevation (while walking), tail elevation
(while walking), palpebral closure, approach to Q-tip (novel object), withdrawl from
invasive Q-tip, response to touch, response to audible startle stimulus, corneal reflex,
righting reflex, visual placing (reaching for paw hold while hanging), grip strength
(while hanging), recognition of visual cliff, response to toe pinch, and response to tail
pinch. Quantitative measures were also obtained for the following: latency to move
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to the edge of an elevated platform and number of head pokes over the edge of an
elevated platform in one minute.
Brain Collection and Sectioning
Two days following behavioral testing all study mice were anesthetized with
Nembutal (1 mg/10 gm body weight). Blood (.2 ml) was collected from the heart,
mixed with .5M EDTA, and centrifuged. Plasma and red blood cells were then
separated, flash frozen, and stored at -80°C. Following blood collection, all mice
were pericardially perfused with .9% saline. Brains were excised and halved midsagitally. The left half was fixed in 4% paraformaldehyde for 24 hours at 4°C,
followed by graded sucrose solutions (10, 20, and 30% (w/v) sucrose in 0.1×
Sorenson's phosphate buffer) prior to sectioning. Frozen 25 µm coronal sections were
then collected on a sliding microtome and stored in PBS. These sections were
immunostained with 6E10 antibody (for diffuse Aβ) or stained with Thioflavin S (for
compact Aβ deposition).
Plasma Cytokine Level Measurements
Relative cytokine level determinations were obtained using a custom RayBio
Mouse Cytokine Antibody Array. Briefly, provided membranes bearing ten separate
anti-mouse-cytokine antibodies were treated with blocking buffer and then incubated
with 1 ml of 1:10 diluted plasma samples for one hour. The membranes were then
incubated with 1x secondary biotinylated antibodies diluted in blocking buffer for one
hour, followed by a two hour incubation with 1,000 fold diluted labeled-strepavidin in
blocking buffer to complete the conjugated secondary antibody complex. The
membranes were washed following each incubation with provided 1x wash buffer
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solutions. Detection signals for each membrane were detected using Fujifilm AR xray film following a seven second incubation with provided detection buffers. Backlit photographs were taken of the developed film with a Kodak DC290 digital camera.
Mean signal intensities minus background signal intensity for duplicate readings were
determined using Kodak 1D Image Analysis Software and standardized to a zero to
one scale based on minimum and maximum mean intensity readings for each
cytokine. This was necessary because of the naturally occurring large variability
(100x-1000x) in levels (based on signal intensities) among various cytokines.
Resultant standardized signal intensities were then used for relative cytokine level
comparisons among animal groups.
Αβ Deposition Determinations
6E10 Immunostaining
6E10 immunostaining was performed on mouse brain sections at the level of
the dorsal hippocampus. Three 25µm coronal sections spaced approximately 600700µm apart were used to analyze diffuse Aβ deposition in sections of the dorsal
hippocampus and overlaying parietal cortex. Sections were floated in 10% ethanol
and mounted on pre-treated slides. For the following steps, all incubations were
carried out at room temperature on a rotating platform shaker unless otherwise noted.
In order to induce epitope retrieval, slides were first placed in a 85ºC 25mM citrate
buffer (pH 7.3) bath for five minutes, washed at room temperature in PBS, placed in
88% formic acid for five minutes, and then washed under low pressure running deionized water for 10 minutes. Slides were then incubated at room temperature with
pre-mixed DAKO blocking solution [49.5% DAKO (catalog #X0909; Dako,
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Carpinteria, CA), 49.5% PBS, .3% H2O2 by volume] for 15 minutes to block
endogenous peroxidase activity, with M.O.M. anti-mouse IgG antibody for 60
minutes to block non-specific binding, with a Triton X solution (.4% by volume) in
two 2.5-minute PBS baths to induce permeability, and with protein concentrate
solution for 5 minutes to further block non-specific binding. Slides were placed in
PBS baths for 5 minutes following both DAKO and Triton X applications. Slides
were then incubated with 6E10 primary antibody overnight at 4ºC. Following this
incubation, slides were placed in three successive PBS baths at 60ºC for 3.5 minutes
each. Slides were then incubated with secondary IgG antibody in PBS with Triton X
and protein concentrate. Slides were then incubated for 30 minutes with ABC
complex solution from a NovaRed (Vector) substrate kit, which was pre-mixed and
allowed to incubate for approximately 30 minutes prior to application. Three 3minute PBS baths were done following both incubation steps. Slides were then
incubated with NovaRed detection reagent mixture for three minutes, followed by a
five minute water bath. Slides were then washed in 45%, 60%, 80%, 95%, and 100%
ethanol baths for approximately 20 seconds each or until no colors from Nova Red
staining ran. A final, four second xylene bath followed by immediate application of
cytoseal and coverslipping completed the staining procedure.
Thioflavin S Staining
Thioflavin S staining was used to detect compact Aβ plaques in the same
brain regions used for 6E10 immunostaining. Slides were immersed for five minutes
in 1% Thioflavin S in 50% ethanol. The same graded alcohol washes and xylene
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wash scheme used for 6E10 protocol was applied, followed by application of cytoseal
and coverslipping.
Image Analysis
All 6E10 and Thioflavin-s stained sections were analyzed on a Nikon Eclipse
E1000 microscope at either 4x (Thioflavin S) or 10x (6E10) magnification with Plan
Four objective lenses. A Retiga 1300 CCD with QImaging RGB LCD-slider was
used to capture images of these sections. A Nikon BV-2B fluorescence fliter cube
was used for thioflavin S staining. Image Analysis was performed using customized
software written in Visual Basic 6.0 (Microsoft) that used Auto-Pro function calls to
segment and quantify images according to the established protocols used by Costa et
al (2004). Aβ deposition was quantified as a percent of area of interest (=Area
stainedtotal/Area Measuredtotal).
Statistical Analysis
Behavioral Statistical Analysis
Inter- and Intra-group comparisons in pre/post infusion RAWM performance
(errors and latency) and post infusion Platform Recognition (latency) and Y-maze (%
alternation and arm entries) performances were obtained using standard one-way
ANOVAs. Two-way repeated measure ANOVAs were also used to compare groups
in multi-day tasks (RAWM and Platform Recognition). Daily averages over 4 days in
Platform Recognition were used for this measure, and three 3-day block averages
were used for RAWM. Using the Fisher LSD test, pos-hoc pair-by-pair differences
between groups (planned comparisons) were then obtained. Swim speed in RAWM
was approximated for each animal by dividing overall Trial 4 + Trial 5 average errors
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into overall Trial 4 + Trial 5 average latencies. Non-performers (e.g. repeated circlers
etc.) for a given task were not used for statistical analysis in that task. 16 of the 19
sensorimotor tasks comprising the Neurologic Screen were analyzed nonparametrically using the Kruskal–Wallis test and Mann–Whitney U-test. The
remaining 3 measures (visual cliff, head poke latency, and number of head pokes)
were analyzed using ANOVA.
Pathological/Histochemical Statistical Analysis
Standard one-way ANOVAs were used to determine group differences for Aβ
load determinations (6E10 and Thioflavin S) and relative cytokine signal intensities.
Using the Fisher LSD test, pos-hoc pair-by-pair differences between groups (planned
comparisons) were then obtained for each measure.
Correlation Analysis
To determine if a direct relationship existed between behavioral and
pathological measures, correlation analysis was performed using Systat software. A
correlation matrix was established between 18 RAWM behavioral measures and 4 Aβ
histochemical measures, as well as between these same behavioral measures and 10
plasma cytokine measures. Finally, Y-maze % alternation and arm entry measures
were correlated to Aβ histochemical measures.
Factor Analysis
Factor Analysis (FA) was performed using Systat software to group
behavioral measures into common, distinct factors. Each factor corresponds to a
discrete component of behavior or cognition such as sensory motor function or
working memory. This allows for the relationship between behavioral measures to be
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determined, and also indicates how individual task performances may correlate with
other task performance levels. FA was performed for 13 behavioral measures
obtained.
Discriminant Function Analysis
Discriminant function analysis (DFA) was performed using 11 similarly
loading measures from FA analysis as well as with all 13 behavioral measures used
for FA analysis to determine if experimental animal groups (Tg+/T cell, Tg+/PBS,
and NT) could be distinguished from one another behaviorally. All DFA analyses
were performed using Systat software using both direct entry and stepwise forward
DFAs. The direct entry method attempts to discriminate between groups using all
behavior measures available, while the stepwise-forward method sequentially selects
measures based on their variance contribution to best discriminate between the three
groups.
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Results

Behavior
RAWM
Pre-Infusion Testing. In pre-infusion RAWM testing (Fig. 4),
transgenic (Tg+) mice were significantly impaired in working memory, as evidenced
by an overall group effect for average combined Trial 4 and Trial 5 errors over 4
blocks of testing [F(1,23)=6.6823, p<.02]. After completion of pre-infusion testing,
animals in the Tg+ group were divided into two groups for infusion of Aβ-sensitive
immune cells (Tg+/T cell group) or PBS (Tg+/PBS group). Pre-infusion RAWM
performance of these two sub-groups were identical prior to infusion (data not
shown).
Post-Infusion Testing. Looking at overall post-infusion RAWM
performance, Tg+/PBS mice made significantly more Trial 4+5 errors than Tg- mice (
p<.05), while Tg+/T cell errors were not significantly different from either Tg- or
Tg+/PBS mice (p=n.s.). Thus, overall Tg+/T cell animals performed at a level
between that of Tg+ and Tg- control groups in RAWM working memory. Looking at
individual blocks, Tg+/PBS mice maintained high Trial 4+5 errors during block 1 of
post-infusion testing (Fig. 5), whereas Tg+/T cell mice made significantly fewer Trial
4+5 errors (p<.05) and performed identically to Tg- mice (p=n.s.). No group
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Figure 4. Pre-infusion overall working memory performances. Tg+ mice
averaged significantly more errors in overall Trial 4+5 testing than Tg- mice prior to
their division into treatment groups, indicating a clear transgenic impairment in
working memory. * = significant difference between Tg- and Tg+ groups (p<.02).
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Figure 5. Post-infusion Block 1 RAWM errors. In contrast to Tg+/T cell mice,
which performed similarly to Tg- mice, Tg+/PBS mice averaged significantly more
errors in Block 1 Trial 4+5 post-infusion testing. * = significant difference between
Tg+/PBS and both Tg+/T cell (p<.05) and Tg- mice (p<.02).
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differences were evident on the semi-random Trial 1 (Fig. 5). Additionally, no group
differences were noted for Trial 1 or Trial 4+5 errors in either block 2 or 3 of testing
(data not shown). For Block 3 post-infusion testing (Fig 6) however, both Tg+/T cell
mice (p<.05) and Tg- mice (p<.05) were able to significantly reduce their combined
Trial 4+5 errors from Trial 1 “naive” performance levels, whereas Tg+/PBS mice
were not (p=n.s.). Neither Tg+/T cell nor Tg+/PBS mice were able to improve Trial
1 vs. Trial 4+5 performance in Block 1 and Block 2, whereas Tg- mice showed
improved Trial 1 vs. Trial 4+5 performance for all 3 blocks of testing (data not
shown).
To ensure that post-infusion performance differences were not attributable to
differences in time taken by animals to navigate the RAWM apparatus, an average
number of seconds per arm choice in overall Trial 4+5 was calculated for each group
by dividing overall Trial 4+5 latency by overall Trial 4+5 errors. No group
differences in number of seconds per choice were noted for this measure (Tg+/T cell:
10.9 ± 1.2, Tg+/PBS: 9.8 ± 1.1, Tg-: 11.2 ± 1.0 sec.).
Pre-Infusion vs. Post-Infusion Testing. To further determine the
effects of immune cell infusion on working memory performances in Tg+ mice, a
block by block comparison of pre-infusion vs. post-infusion performances in the
RAWM task was performed for all groups (Fig. 7). It was determined that Tg+/PBS
mice did not significantly lower their number of errors for any individual block of
testing (p=n.s.). In contrast, Tg+/T cell mice did significantly lowered their number
of errors from Block 1 pre-infusion testing to Block 1 post-infusion testing (p<.01) as
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Figure 6. RAWM during post-infusion Block 3 Trial 1 vs. Trial 4+5. Both Tg+/T
cell and Tg- mice were able to significantly reduce their number of Trial 4+5 errors
compared to Trial 1 “naive” performances. In contrast, Tg+/PBS mice failed to
obtain a significantly lower number of errors for Trial 4+5 compared to Trial 1. * =
significantly lower Trial 4+5 errors compared to Trial 1 errors (p<.05).
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RAWM: Pre vs. Post-Infusion
Trial 4+5 Combined
6
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Figure 7. RAWM pre-infusion vs. post-infusion comparisons for Trial 4+5
combined errors by group. Tg+/PBS mice did not significantly lower their errors
for any block of post-infusion testing. In contrast, Tg+/T cell mice were able to
significantly lower their errors for both Block 1 and Block 2 of post-infusion testing
compared with Trial 4+5 error averages for these blocks from pre-infusion testing.
Tg- mice maintained relatively low errors throughout and thus also lacked significant
improvement post-infusion. * = significantly lower Trial 4+5 error in post-infusion
testing vs. pre-infusion testing (p<.05 or higher level of significance).
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well as from Block 2 pre-infusion testing to Block 2 post-infusion testing (p<.05] but
did not show this error reduction for Block 3 performance (p=n.s.). Tg- mice did not
show significantly decreased errors for any block comparison, most likely due to
relatively good pre-infusion performance levels. Comparisons of Trial 4+5 errors
during the final block of pre-infusion testing vs. the first block of post-infusion testing
showed that Tg+/PBS mice became significantly worse (p<0.05) during initial postinfusion testing (Fig. 8). By contrast, Tg+ mice that received T cell infusions
maintained their final pre-infusion performance level, as did Tg- controls, on the
initial post-infusion block (Fig.8).
Y-Maze
Post-infusion performance in the Y-maze task revealed a significant overall
effect indicating a direct treatment effect on basic pneumonic processes
[F(2,18)=6.8962; p<.01] (Fig. 9). Tg+/PBS mice demonstrated significantly lower
percent spontaneous alternations than Tg+/T cell mice (p<.01) or Tg- mice (p<.005).
In sharp contrast, Tg+/T cell mice performed identically to Tg- mice. No group
differences were noted in number of Y-maze arm entries (data not shown).
Platform Recognition
Analysis of average latencies for individual days and over all 4 days of
Platform Recognition testing found no group differences in performance for this task
(Fig. 10). There was a highly significant day effect [F(3,66)=7.02; p<.0005),
indicating that all animals collectively improved their performances across the 4 days
of testing.
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RAWM:
Last Block Pre- vs. First Block Post-Infusion
Trial 4+5 Combined
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Figure 8. RAWM Trial 4+5 performance for pre-infusion (final block)
vs. post-infusion (first block). Tg+/PBS mice significantly worsened their working
memory performance from pre- to post-infusion testing, whereas Tg+/T cell and Tganimals maintained lower levels of errors in post-infusion testing. * = significantly
higher post-infusion RAWM errors compared to pre-infusion performances (p<.05,
paired t-test).
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Figure 9. Post-infusion Y-maze spontaneous percent alternation performances.
Tg+/PBS mice displayed significantly lower percent alternations compared to Tganimals, whereas Tg+/T cell mice performed identically to Tg- controls. * =
significantly lower percent alternation compared to Tg- and Tg+/T cell mice (p<.01
or higher level of significance).

130

Platform Recognition

Latency (sec)

60

Tg+/PBS
Tg+/T cell
Tg-

50
40
30
20
10
1

2

3

4

Days
Figure 10. Post-infusion Platform Recognition latencies by day. No group
differences were noted for any day or overall in Platform Recognition
performance.
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Neurologic Battery
While no group differences were noted between Tg+/T cell and Tg+/PBS
groups for the 19 measures of our Neurologic Battery (data not shown), direct
comparison between these groups and Tg- animals did elicit group differences.
Tg+/PBS animals showed significantly decreased transfer arousal upon placement
into a novel environment compared to Tg- mice [p<.05]. Tg+/Tcell mice showed
decreased transfer arousal as well [p<.05], and also scored significantly lower in
evaluation of pelvis [p<.01] and tail elevation [p<.05] compared to Tg- animals.
Finally, Tg+/T cell mice showed an increased score for hypotonic gait qualifications
compared to the Tg- group [p<.01]. The lack of differences between Tg+/T cell and
Tg+/PBS groups may indicated that infusion of T cells did not result in any
deleterious neurologic effects in Tg+ mice.
Pathology
Brain Aβ Deposition Quantification
6E10 Immunohistochemistry/Thioflavin S Histochemistry. Tg+/T cell
and Tg+/PBS mice showed no group differences in % area Aβ plaque deposition,
staining either for diffuse deposits (6E10) or compact deposits (Thioflavin S) (Fig.
11). Comparisons were made between groups for both hippocampal and parietal
cortex Aβ burdens; no significant differences were noted for either brain region
(p=n.s).
Plasma Cytokine Analysis
For the ten cytokine measures taken (Fig. 12), there were no group differences
between Tg+/Tcell and Tg+/PBS mice or between Tg+/PBS and Tg- mice (p=n.s).
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Figure 11. Quantification of 6E10and Thioflavin S Aβ burdens. No group
differences between Tg+ groups were noted for either Aβ burden measure in either
hippocampus or parietal cortex.
.

133

Standardized Mean
Signal Intensity

0.8

Tg+/T-Cell

Tg+/PBS

Tg-

0.6

0.4

*

*

*

0.2

0.0

IL-1α

IL1-β

IL-2

IL-4

IL-6

IL-10

IL-12

TNF-α

IFN-γ

GM-CSF

(p70)

Figure 12. Standardized mean signal intensities for 10 plasma cytokines. Tg+/T
cell mice showed significantly lower levels of plasma IL-10, TNF-α, and GM-CSF
compared to Tg- mice. * = significantly lower mean signal intensity compared to Tganimals (p≤.05).
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However, the Tg+/Tcell group did display significantly lower plasma cytokine levels
than Tg- mice for GM-CSF ( p≤.05), IL-10 ( p<.05), and TNF-α (p≤.05). Thus, T
cell infusion into Tg+ mice did not result in a sustained, global increase in plasma
pro-inflammatory cytokines.
Multi-metric Statistical Analysis
Correlation Analysis
RAWM vs. Aβ Burdens. A correlation matrix comparing Aβ
deposition quantifications in hippocampus and parietal cortex vs. RAWM
performances uncovered numerous correlations between these measures. All
correlations were positive unless otherwise noted (e.g. higher RAWM errors/latency
associated with higher Aβ deposition). For all 15 Tg+ animals combined (Table 1),
these correlations were found exclusively between 6E10 hippocampal measures and
the following 8 RAWM working memory measures: overall Trial 4 errors (p≤.05),
Block 1 Trial 4 errors (p<.01), Block 1 Trial 4+5 errors (p<.01), overall Trial 4
latency (p<.05), overall Trial 4+5 latency (p≤.05), Block 1 Trial 4 latency (p≤.001),
Block 1 Trial 5 Latency (p<.05), and Block 1 Trial 4+5 Latency (p≤.005). No
correlations were found between Thioflavin S burdens in either brain area and
working memory. Thus, lower hippocampal levels of diffuse Aβ deposits correlated
with improved working memory.
A strong correlation was noted between RAWM Trial 4+5 errors for Block 1
of post-infusion testing and hippocampal 6E10 burdens when considering all Tg+
mice (p<.01). This correlation is of particular interest because Block 1 performance
for Tg+/T cell mice was identical to that of Tg- mice, while Tg+/PBS mice made
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Table 1. For all Tg+ animals, a correlation matrix of RAWM error and latency measures vs. 6E10/Thioflavin S measures of
Aβ plaque burdens in the parietal cortex and hippocampus.
RAWM Errors
Overall
Trial 4

Overall Trial
5

Overall Trial
4+5

Block 3 Trial
4

Block 3 Trial
5

Block 3 Trial
4+5

Block 1 Trial
4

Block 1 Trial
5

Block 1 Trial
4+5

6E10:
Hippocampus
Thioflavin S:
Cortex

r
p
r
p
r
p

0.092
0.745
0.512
0.051
-0.133
0.637

0.166
0.554
0.422
0.118
-0.001
0.997

0.134
0.635
0.502
0.057
-0.078
0.783

-0.199
0.477
0.135
0.631
-0.091
0.748

0.261
0.347
0.272
0.326
0.089
0.751

0.022
0.939
0.236
0.398
-0.006
0.982

0.218
0.436
0.713
0.003
-0.226
0.418

0.243
0.382
0.497
0.059
-0.042
0.882

0.248
0.373
0.665
0.007
-0.154
0.583

Thioflavin S:
Hippocampus

r
p

0.238
0.393

0.076
0.789

0.175
0.533

0.11
0.698

0.45
0.092

0.319
0.247

-0.017
0.951

-0.028
0.922

-0.024
0.933

Overall
Trial 4

Overall Trial
5

Overall Trial
4+5

Block 3 Trial
4

Block 3 Trial
5

Block 3 Trial
4+5

Block 1 Trial
4

Block 1 Trial
5

Block 1 Trial
4+5

0.19
0.497
0.589
0.021
-0.027
0.924
0.287
0.299

0.094
0.738
0.384
0.158
-0.156
0.578
0.182
0.517

0.15
0.594
0.51
0.052
-0.093
0.743
0.246
0.376

0.048
0.864
0.379
0.163
-0.024
0.932
0.151
0.591

0.24
0.389
0.337
0.219
0.025
0.929
0.396
0.144

0.162
0.565
0.394
0.146
0.001
0.996
0.305
0.269

0.309
0.263
0.772
0.001
0.028
0.92
0.169
0.546

0.232
0.405
0.515
0.049
-0.093
0.741
0.238
0.394

0.287
0.299
0.687
0.005
-0.029
0.919
0.211
0.451

6E10: Cortex

RAWM Latency
6E10: Cortex
6E10:
Hippocampus
Thioflavin S:
Cortex
Thioflavin S:
Hippocampus

r
p
r
p
r
p
r
p

Correlations (bold font) were noted between 6E10 diffuse plaque burdens in the hippocampus and several overall and Block 1 RAWM measures of working
memory. Most of these correlations were also noted when looking at only Tg+/T cell animals, however none were found when considering Tg+/PBS animals
(data not shown), indicating the Tg+/T cell animals as the driving force behind correlations between working memory and diffuse Aβ depostion. r = Pearson
product-moment correlation coefficient. p = probability.
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significantly more errors than either group. Looking at the graph for this
comparison (Fig. 13), it is apparent that Tg+/T cell mice are driving the correlation
between working memory performance and hippocampal diffuse Aβ burdens.
Interestingly, it appears that this correlation occurs as a result of segregation of the
Tg+/T cell group into two subgroups. Of the seven total Tg+/T cell mice, a group of
four mice maintained low errors in Block 1 and displayed low diffuse Aβ burdens in
the hippocampus, whereas the remaining three Tg+/T cell mice made a high number
of errors in testing and displayed high hippocampal burdens. In contrast, seven of
eight Tg+/PBS mice displayed high errors and diffuse Aβ burdens. This stark
difference between Tg+/T cell and Tg+/PBS animals clearly illustrates not only how
Tg+/T cell animals are driving correlations between RAWM and 6E10 measures, but
would also seem to indicate that a treatment effect is apparent in the majority of
Tg+/T cell animals. It should also be noted that even the remaining three Tg+/T cell
animals with higher Block 1 RAWM errors were able to reduce their errors by Block
3 of testing, indicating that good working memory performance was not limited to
only a portion of the Tg+/T cell animals.
When considering only T cell recipient mice (n=7), correlations were also
exclusive to hippocampal 6E10 burden when compared to the following measures:
overall Trial 4 errors (p<.05), Block 1 Trial 4 errors (p<.05), Block 1 Trial 5 errors
(p<.05), Block 1 Trial 4+5 errors (p<.05), Block 1 Trial 4 latency (p<.05), and Block
1 Trial 4+5 latency (p<.05). The lack of correlations between Tg+/PBS mouse
RAWM measures and hippocampal 6E10 measures once again indicates that it is the
Tg+/T cell mice which are driving these correlations for all Tg+ mice combined.
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Correlation: RAWM vs. 6E10
6
5

r = 0.665
p = 0.007

Errors
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3
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Tg+/T Cell
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Figure 13. For all Tg+ mice, a correlation between RAWM Block 1 Trial 4+5
Errors and Hippocampal 6E10 burden. A strong correlation between diffuse
hippocampal Aβ burden and working memory impairment in Tg+ mice is apparent. This
correlation is clearly driven by the Tg+/T cell group, which show a distinct segregation
into two subgroups, one with good working memory performance and low Aβ burdens
(left side of the graph), and one with poor working memory performance and high Aβ
burdens (right side of the graph).
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This is especially true for 6E10 vs. overall and Block 1 measures where correlations
were found when considering all Tg+ mice as well as Tg+/T cell mice alone, but not
when considering Tg+/PBS mice alone. When considering PBS recipient transgenic
mice only (n=8), correlations noted were between hippocampal Thioflavin S burdens
and the following behavioral measures: Block 3 Trial 5 errors (p<.05), Block 3 Trial
5 latency (p<.01), and Block 3 Trial 4+5 latency (p<.05).
Y-maze and Platform Recognition vs. Aβ Burdens. No correlations
were observed between Aβ burdens in the hippocampus and parietal cortex vs. Ymaze percent alternations for Tg+/T cell mice or for all Tg+ mice combined (p=n.s.).
Similarly, no correlations were noted between Aβ burdens and Day 4 or overall
Platform Recognition Latencies for these groups of animals.
RAWM vs. Plasma Cytokines. A correlation matrix between plasma
cytokine levels and RAWM performance measures was established for all mice, for
Tg+ mice combined, and for both PBS recipient Tg+ mice and T cell recipient mice
alone. All correlations noted were negative (e.g. higher plasma cytokines associated
with less RAWM errors). For all mice combined, 9 negative correlations were found,
including one between Block 3 Trial 5 errors and plasma GM-CSF levels (p≤.05).
Negative correlations were also found between IL-1β levels and the following
measures: overall Trial 4 errors (p<.05), overall Trial 4+5 errors (p<.05), Block 1
Trial 4 errors (p<.05), and Block 1 Trial 4+5 errors. As for IL-1β correlations, the
same negative correlations were also noted for plasma TNF-α levels: overall Trial 4
errors (p<.01), overall Trial 4+5 errors (p<.05), Block 1 Trial 4 errors (p<.005), and
Block 1 Trial 4+5 errors (p<.05).
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For all Tg+ mice combined, only 2 negative correlations were noted: between
IL-4 levels and overall Trial 5 errors (p<.05) and between IL-1β and Block 1 Trial 5
errors (p<.05). When considering only PBS recipient Tg+ mice, the only (negative)
correlation noted was between IFN-γ and Block 1 Trial 5 errors (p<.05). In sharp
contrast, numerous negative correlations (13) were noted between levels of plasma
cytokines in T cell recipient Tg+ mice and RAWM measures (Table 2). IL-1α was
found to correlate negatively with Block 3 Trial 5 errors (p<.05). IL-1β was found to
correlate negatively with overall Trial 4 errors (p≤.05) and Block 3 Trial 5 errors
(p<.05). IL-2 was found to correlate negatively with Block 3 Trial 4 errors (p≤.001).
IL-4 was found to correlate negatively with overall Trial 4 errors (p<.05), as well as
with Block 1 Trial 5 (p<.05) and Block 1 Trial 4+5 (p<.05) errors. IL-12 was found
to correlate negatively with both overall Trial 4 (p<.05) and Block 1 Trial 5 errors
(p<.05). Finally, TNF-α was found to correlate negatively with overall Trial 5 errors
(p<.005), overall Trial 4+5 errors (p<.05), and Block 1 Trial 4+5 errors (p<.05).
The strong negative correlations noted between RAWM measures and both TNF-α
and IL-1β when considering all animals as well as T cell animals alone were not
noted when looking at all Tg+ animals alone. This would seem to indicate that both
T cell and Tg- mice are driving these negative correlations, implicating plasma IL1-β
and TNF-α levels as being particularly important in terms of RAWM performance.
Other cytokines such as IL-4, IL-1α, and IL-12, which were only negatively
correlated to RAWM performance when considering Tg+/T cell animals, may also
have an impact. However, the lack of such correlations for all animals combined
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Table 2. Correlation matrix for RAWM errors vs. plasma Cytokine measures for Tg+/T cell animals.
Overal Trial 4
r
p

Overall
Trial 5

Overall Trial
4+5

Block 1 Trial
4

Block 1
Trial 5

Block 1 Trial
4+5

Block 3 Trial
4

Block 3
Trial 5

Block 3 Trial
4+5

0.345
0.503

0.456
0.363
-0.147
0.781
0.369
0.471
0.390
0.444

0.239
0.648
-0.858
0.029
-0.695
0.125
-0.692
0.128

0.452
0.369
-0.750
0.086
-0.322
0.533
-0.307
0.554

-0.337
0.514
-0.170
0.747
0.108
0.838
0.450
0.37

-0.354
0.492
-0.533
0.276
-0.414
0.415
-0.273
0.6

-0.374
0.466
-0.393
0.441
-0.183
0.729
0.071
0.894

r
p
r
p
r
p

0.057
0.915
-0.613
0.195
-0.234
0.655
-0.48
0.335

-0 883
0.020
-0 556
0.252
-0.582
0.225

0.203
0.699
-0.765
0.076
-0.402
0.429
-0.544
0.264

IL-1α

r
p

-0.581
0.227

-0.735
0.096

-0.674
0.142

0.185
0.726

-0.732
0.098

-0.458
0.361

-0.434
0.39

-0.820
0.046

-0.690
0.129

IL-1β

r
p

-0.806
0.053

-0.681
0.137

-0.763
0.077

-0.307
0.554

-0.798
0.057

-0.797
0.058

-0.618
0.191

-0.813
0.049

-0.780
0.067

IL-2

r
p

-0.515
0.296

-0.454
0.366

-0.497
0.316

-0.433
0.391

-0.411
0.418

-0.572
0.236

-0.972
0.001

-0.762
0.078

-0.929
0.007

IL-4

r
p

-0.688
0.131

-0 854
0.030

-0.790
0.062

-0.278
0.594

-0.844
0.035

-0.815
0.048

-0.566
0.242

-0.761
0.079

-0.723
0.104

IL-6

r
p

-0.235
0.353

-0.439
0.384

-0.464
0.354

0.499
0.314

-0.680
0.137

-0.235
0.654

0.367
0.474

-0.377
0.461

-0.031
0.954

TNF-α

r
p

-0.827
0.060

-0 950
0.004

-0.892
0.017

-0.369
0.471

-0.790
0.061

-0.827
0.042

-0.437
0.386

-0.643
0.169

-0.591
0.217

GM-CSF
IL-12
IFN-γ
IL-10

Negative correlations (bold font) were noted for numerous measures when considering Tg+/T cell animals alone; correlations which did not exist when
considering Tg+/PBS mice alone, or both groups of Tg+ mice together. (data not shown).
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would seem to indicate that they are not universally associated with behavioral
performance in this task.
Factor Analysis
Factor Analysis of 13 post-infusion behavioral measures from RAWM, Y-maze,
and Platform Recognition was performed to determine the underlying relationships
between these measures/tasks (Table 3). FA involving all 13 behavioral measures
resulted in 11 of those measures loading on a common first factor, which accounted for
58.2% of the total variance (a measure was considered “significant” for loading on a
factor if it’s component loading value exceeded 0.65 for that factor). Factor 1 was thus
considered the primary cognition-based factor, as nearly all cognitive measures
contributed to it. The two Platform Recognition measures used in this analysis co-loaded
in factors 1 and 2. Only one RAWM measure (Block 1 Trial 5 errors) and Y-maze
percent alternations did not load in the cognition-based factor 1. Block 1 Trial 5 errors
did not load in any factor, where as Y-maze percent alternations loaded alone in factor 4.
Discriminant Function Analysis
DFA was utilized to determine if behavioral performances of the three groups
(Tg-, Tg+/PBS, and Tg+/T cell) could distinguish the groups from one another during
post-immune cell infusion testing. Both “direct entry” and “stepwise-forward” DFA
methodologies were employed. The direct entry method included all behavioral
measures evaluated, while the “stepwise-forward” selects behavioral measures from the
total number evaluated based on their contribution to the variance. For each
methodology, all 13 measures used in Factor Analysis were included. Additionally, both
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Table 3. Factor loadings of behavioral measures.
Factor
1

Variance
(%)
(58.2)

2

(12.3)

3
4

(9.6)
(8.7)

Did not
load:

-

Post-Infustion Behavioral Measures
RAWM:
Overall Trial 4+5 Errors
Overall Trial 4 Errors
Overall Trial 5 Errors
Block 1 Trial 4+5 Errors
Block 1 Trial 4 Errors
Block 3 Trial 4+5 Errors
Block 3 Trial 4 Errors
Block 3 Trial 5 Errors
Y-maze:
Arm Entries
Platform Recognition:
Overall Latency
Day 4 Latency
Platform Recognition:
Overall Latency
Day 4 Latency
None
Y-maze:
Percent Alternations
RAWM:
Block 1 Trial 5 Errors

Eight of nine RAWM measures loaded with Y-maze entries and two Platform Recognition measures in
factor 1- the primary cognitive factor. Both Platform Recognition measures co-loaded in factors 1 and 2.
Only Y-maze alternations loaded in a separate factor (factor 4), whereas Block 1 Trial 5 RAWM errors did
not load in any factor. Percent of total variance explained by a given factor is indicated in bold type within
parentheses.
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forms of DFAs were run using only the 11 measures that loaded on factor 1 of Factor
Analysis. Results of these DFA’s are summarized in Table 4. Direct entry DFAs, both
for all 13 measures and factor 1 measures only, could not discriminate between the three
groups based on their behavioral performance (p=.19; p=.48, respectively). In sharp
contrast, the stepwise-forward DFA method (for both behavioral measures sets) was very
effective in discriminating between Tg+/PBS mice and the other 2 groups. When all 13
behavioral measures were analyzed, RAWM Block 1 Trial 4+5 errors and Platform
Recognition Day 4 latencies were retained in step-wise forward DFA. 86% of Tg+/PBS
animals were correctly classified by this analysis, whereas only 50% of Tg+/T cell mice
and 60% of Tg- mice were correctly classified. A similar pattern was noted for step-wise
forward analysis of factor 1 behavioral measures, for which RAWM Block 1 Trial 4+5
errors was retained. 88% of Tg+/PBS animals were correctly classified by this analysis.
In contrast, only 48% of Tg+/T cell and 50% of Tg- mice were correctly classified by this
procedure. Thus, while step-wise forward DFAs were capable of discriminating between
Tg+/PBS groups and the other 2 groups, this analysis could not effectively discriminate
between Tg- and Tg+/T cell groups, indicating that behavioral performances in these
latter two groups were too similar for distinction between them to be made.
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Table 4. Summary of discriminant function analyses.
Measures
All 13
Factor 1

Direct Entry
Significance:
N.S.
N.S.

Significance:
*p < .01
*p < .05

Stepwise Forward
Measures Retained:
RAWM Block 1 Trial 4+5 Errors
PR Day 4 Latency
RAWM Block 1 Trial 4+5 Errors

p-values are from Wilks’s λ. * = significant for Tg+/PBS vs. both Tg+/T cell and Tg- groups.
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Discussion

General Summary
In the present study, we evaluated the behavioral and pathological effects of
adoptive transfer of Aβ-sensitive immune cells into AD transgenic mice. These cells
consisted of spleenocytes and lymphocytes taken from Aβ-immunized, congenic wildtype mice. The cells were cultured to enrich for T cells prior to infusion into recipient
animals. We determined that such an infusion of T cells led to reversal of working
memory impairment and also improved basic mnemonic processing at a 1-1½ month
post-infusion time point. While overall no reductions in brain Aβ deposition were found,
strong correlations between diffuse hippocampal deposition and RAWM working
memory performances in T cell infused mice were noted, indicating that cognitive benefit
was likely Aβ dependent.
It is also important to note that cognitive benefit in immune cell infused animals
was not accompanied by increases in plasma pro-inflammatory cytokines. This would
seem to indicate that a systemic inflammatory response was not evoked by adoptive
transfer of immune cells into AD transgenic mice. Results of our Neurologic Battery
would seem to confirm this, with no differences noted between transgenic controls and T
cell recipient mice. Considering the lack of differences between transgenics noted in the
Neuorologic Battery, as well as the presence of cognitive benefit extending over several
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domains following only one immunotherapeutic infusion of T cells, such adoptive
immunotherapy shows great promise for future human application in treating AD.
Behavioral Results
Immunotherapeutic techniques directed against Aβ have been tested in AD
transgenic mice since 1999, however only a handful of these studies incorporated
comprehensive behavioral testing of treated animals. In 2000, Morgan et al. found that
repeated immunizations with Aβ1-42 in Freund’s adjuvant over an 8 month period
resulted in protection against impairment in the RAWM task for working memory,
though the 15 month old APPsw+PS1 mice tested did take more trials to learn the task
than non-transgenic controls. In 2003, Austin et al. found that short term (4 biweekly
injections) administration of this same vaccine to aged APPsw+PS1 mice did not result in
reversal of impairment in the RAWM task.. In a longitudinal study, Jensen et al. 2005
reported that APPsw+PS1 mice immunized with Αβ1-42 from 2-16.5 months of age were
protected against impairment in RAWM testing performed at both 5 and 16 months of
age. Thus it has been established that protection against impairment in RAWM can be
incurred via active Aβ immunization in APPsw+PS1 mice. However, it is also clear that
repeated administrations over an extended time period are necessary to establish this
behavioral benefit. In the current study, we show that a single immunotherapeutic
administration of Aβ-sensitive T cell results in improved RAWM performance at a 1
month post-infusion time point.
In pre-infusion RAWM testing, Tg+ mice were clearly impaired in working
memory performance compared to Tg- mice, making significantly higher Trial 4+5 errors
overall. In post-infusion RAWM, Tg+/PBS mice maintained a poor level of working
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memory performance, with significantly higher Trial 4+5 errors overall compared to Tgmice. In contrast, Tg+/Tcell mice were not significantly different from either Tg- or
Tg+/PBS mice for this measure, indicating an overall improvement in working memory
performance to a level between that of Tg- and Tg+ controls. Indeed, for Block 1 of
testing, Tg+/T cell mice performed identically to Tg- animals in Trial 4+5 errors, while
Tg+/PBS mice made significantly more errors than either group. Further demonstrating
that improvement in working memory performance was present in Tg+/T cell animals, it
was noted that these mice showed a significant learning effect from Trial 1 to Trial 4+5
during the final block of RAWM testing. This effect was not noted for Tg+/PBS mice for
any block, whereas Tg- mice showed a significant learning effect for each block of postinfusion testing.
To further demonstrate the level to which Tg+/T cell animals were able to
improve their working memory performances from pre-infusion levels, a block by block
comparison of pre- vs. post-infusion RAWM errors was performed. This analysis
revealed an inability of Tg+/PBS animals to improve their performance for any block. In
contrast, Tg+/T cell animals did show significant improvements in this measure for both
Block 1 and Block 2 of post-infusion testing. One final analysis of the RAWM task
comparing final block pre- vs. first block post-infusion also demonstrated this effect.
Tg+/PBS animals significantly worsened their working memory performance following
PBS infusion and a 1½ month hiatus from testing, whereas Tg+/T cell animals as well as
Tg- animals maintained significantly low levels in post-infusion testing. Post-infusion
and pre-vs. post-infusion analysis revealed that overall and for each block of postinfusion RAWM testing, Tg+/T cell animals displayed either an improvement in working
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memory performance from pre-infusion performances, and/or an ability to perform at a
level greater than that of Tg+/PBS controls. In many cases, this performance level was
identical to Tg- animals. This benefit was most prominent during the initial phase of
post-infusion testing, but was evident throughout the entire post-infusion treatment
period. Thus, post-infusion analysis confirms the potential for a single Aβ-sensitive
immune cell infusion to reverse cognitive impairment in transgenic animals. Trinchese et
al. (2004) found impairment in APPsw/PS1 mice in RAWM at as early as 3-4 months of
age, while our laboratory has found impairment at as early as 5.5 months (Jensen et al.
2005) but has found no impairment at a 3 month time point (unpublished observation).
These findings combined with pre- vs. post-infusion analysis from the current study
confirm that the treatment effect noted above was a reversal of cognitive impairment,
specifically in the domain of working memory.
In the Y-maze task of spontaneous alternations, Tg+/PBS animals displayed
significantly lower alternations than both Tg+/T cell and Tg- animals. Therefore, it can
be said that T cell infused animals were clearly protected against basic mnemonic
processing impairment found in un-infused transgenic controls. Thus Y-maze, which is a
relatively insensitive task, was still capable of eliciting a treatment effect in 10 month old
mice. The results demonstrate how both working memory (RAWM) and basic
mnemonic processing (Y-maze) benefited from T-cell infusion in Tg+ mice. In early Ymaze studies, Holcomb et al. (1998; 1999) found decreased Y-Maze alternations in 3-4
month, 6 month, and 9 month old APPsw/PS1 mice, whereas other studies did not find
impairment at multiple time points through 16 months (Arendash et al. 2001, Jensen et al.
2005). Thus, the direct treatment effect observed confirms that T cell infusion promotes
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improved performance in the Y-maze task, but does not provide insight into whether this
is due to prevention or reversal of impairment. In 2004, Wilcock et al. showed that 3
monthly infusions of anti-Aβ antibodies were required to see behavioral improvement in
the Y-maze task in 22 month old Tg2576 mice. The improved performance noted for this
task in the current study occurred one month post-infusion of a single dose of Aβsensitive T cells. This again underscores the potential of this immunotherapeutic
technique to provide cognitive benefit without numerous administrations.
No differences were noted between treatment groups in Platform Recognition
performance. The relatively poor performance of all 3 groups compared to prior studies
(Arendash et al. 2001, Jensen et al. 2005) may have resulted from Platform Recognition
testing immediately following post-infusion RAWM. All groups may have had difficulty
adjusting to the new, working memory-independent strategy of this task. However, it
should be noted that, for all groups collectively, there was an overall learning effect, with
significantly improved latencies from first to last day of testing.
Importantly, no differences were found when comparing the Neurologic Battery
results of Tg+/PBS and Tg+/T cell animals. This would seem to indicate a lack of EAE
(Experimental Allergic Encephalomyelitis) in T cell animals, which can occur following
adoptive T-cell transfer (Kipnis et al. 2002). However, differences noted between Tg+/T
cell animals and Tg- animals may indicate potential for some hind-leg motor control
difficulties in T cell animals, beyond those found in control Tg+ mice. Future studies
must look further into the effects of adoptive immunotherapy on neurological function to
determine if these effects are consistent and, if so, to identify their cause.
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Pathology
No group differences were noted for 6E10 or Thioflavin S burdens in the
hippocampus or parietal cortex, indicating no overall reduction in diffuse or compact
(insoluble) Aβ depostion following T cell infusion into APPsw/PS1 mice. Potential does
exist for reductions in soluble Aβ levels, which would go a long way in explaining the
behavioral improvement noted in Tg+/T cell animals. Previous immunotherapeutic
studies in AD models have found improved behavior associated with reduced insoluble
Aβ levels (Janus et al. 2000, Wilcock et al. 2004). Additionally, it has been noted in
several studies that behavioral improvement can be independent of overall reductions in
Aβ deposition (Morgan et al. 2000, Arendash et al. 2001, Jensen et al. 2005) following
immunotherapy, as noted in the current study. This may be due to reductions in soluble
Aβ levels, as other immunotherapeutic studies have reported reductions in soluble Aβ
levels in the CNS following immunization (Sigurdsson et al. 2001, Sigurdsson et al.
2004). Future studies must be conducted to analyze soluble forms of this peptide, most
importantly the Aβ1-40 and Aβ1-42 isoforms, to determine if reduced soluble amyloid
levels contribute to the cognitive improvement noted in Tg+/T cell animals.
The lack of significant difference between Plasma cytokine levels in Tg+/T cell
and Tg+/PBS groups suggests that T cell infusion into Tg+/T cell mice did not result in a
sustained, global immune response. Thus, cognitive benefit associated with such an
infusion was found to occur independently of an enhanced systemic immune response,
although strong correlations were evident between plasma cytokines and cognitive
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performance (see below). However, it should be noted that these cytokine measurements
are for plasma only, and may not be indicative of regional brain cytokine profiles. Future
studies must be conducted to analyze brain specific cytokine levels to determine if this
trend for reduced cytokine levels is carried over into the CNS following infusion of Aβsensitive T cells. Compared to Tg- mice, there was a trend for Tg+/T cell mice to display
reduced plasma cytokine levels, with significance noted for IL-10, TNF-α, and GM-CSF
vs. Tg- controls. This reduction in cytokine levels may indicate an overall immune
system inhibition by immune suppressive regulatory T cells (T regs), or down regulation
of specific immune cell types by T helper cell subsets. The lack of significance between
cytokine levels in Tg+/PBS and Tg- animals suggests no overt immunological response
to Aβ in Tg+ animals. This may be indicative of an established immune tolerance to this
human peptide, as would be expected for any peptide produced endogenously at high
levels throughout the life of these mice. In 2002, Town et al. found that APPsw mice
immunized with Aβ1-42 displayed decreased IFN-γ and increased IL-10 plasma cytokine
levels. Levels of IL-2 and IL-4 were deemed immeasurable in this same study. Based on
these findings, the authors proposed that Aβ1-42 immunization elicited a Th2 biased
response in APPsw mice. Microglia and astrocytes are known to display increased
expression of IL-1β, TNF-α, and IL-6 in the brains of Tg2576 animals, however this is
not necessarily indicative of plasma levels of these cytokines (Benzing et al. 1999,
Melhorn et al. 2000).
Correlations
Correlations to RAWM measures were limited specifically to hippocampal 6E10
diffuse brain Aβ burdens when considering all Tg+ mice. The majority of these
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correlations were shown to be driven by the Tg+/T cell group however, as strong
correlations also exist when considering only these animals. Analysis with Tg+/PBS
animals only showed correlations with hippocampal Thioflavin S compact brain Aβ
burdens exclusively. Thus it is clear that hippocampal Aβ burdens do have an impact on
cognition, and diffuse hippocampal burdens seems to play the most important role
following infusion of Aβ-sensitive T cells into AD transgenic mice. Without such
infusion, compact plaques seem to take on a more important role in determining level of
impairment.
Perhaps the best example of the overall correlation effect involved correlation
data between Tg+ animals in RAWM Block 1 Trial 4+5 errors vs. hippocampal 6E10 Aβ
burdens. Clearly, Tg+/T cell animals drove this correlation, with 4 animals displaying
low errors and low burdens, and 3 animals display higher errors and higher burdens. In
contrast, all but 1 Tg+/PBS animal displayed high errors with high Aβ burdens. This
correlation may also demonstrate one mode of action for T cell adoptive immunotherapy.
Clearly the four Tg+/T cell animals with lower RAWM errors displayed decreased Aβ
burdens, and it may be possible that these infused animals benefited behaviorally due to
clearance of hippocampal diffuse Aβ, thus explaining why this measure was of particular
importance.
We have previously demonstrated that cognitive performance in a number of
tasks can correlate with brain Aβ burdens in AD transgenic mice (Leighty et al. 2004,
Gordon et al. 2001, Arendash et al. 2001b), though these correlations are not always
present (Jensen et al. 2005). When present, correlations often involve the RAWM task,
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although they can also involve Morris Water Maze and Platform Recognition (Leighty et
al. 2004). RAWM is a task for working memory, thus performance in this task is heavily
hippocampus dependent. This directly explains the cognitive benefit noted during Block
1 of post-infusion testing in 4 out of 7 Tg+/T cell animals. What these correlations do
confirm is that both diffuse and compact Aβ burdens in the hippocampus can contribute
to cognitive impairment in Tg+ animals, and also that modest reductions in diffuse
hippocampal Aβ burden are associated with improved performance in the RAWM task.
Several correlations were noted between RAWM measures and plasma cytokine
levels when considering all animals. Higher plasma cytokine levels correlated with better
cognitive performance. All but one of these correlations were between either IL-1β or
TNF-α and RAWM measures. These and several other correlations were also found
when looking at Tg+/T cell animals alone, but not when looking at Tg+ animals
combined or Tg+/PBS animals alone. Clearly then, these negative correlations are being
driven by both Tg- and Tg+/T cell animals. These correlations were all negative (e.g.
higher plasma cytokines with lower RAWM errors). Therefore, it would seem that
despite a trend for decreased plasma cytokine levels in Tg+/T cell animals, higher levels
of individual cytokines (especially IL-1β and TNF-α) may play a role in improving
cognitive performance capabilities. It is interesting that the two key cytokines driving
these correlations are pro-inflammatory cytokines which have been found to be overexpressed by microglia local to Aβ plaques in transgenic models of AD (Benzing et al.
1999, Akiyama et al. 2000). In humans with AD, CSF levels of both cytokines are
increased (Cacabelos et al. 1991, Tarkowski et al. 1999). However, several lines of study
suggest that while these cytokines are involved in the neuroinflammatory cascade of AD,
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under situations of appropriate immune activation they may actually act beneficially in
the CNS to reduce inflammatory damage (Correale and Villa, 2004). This may indicate
that the actions of certain cytokine producing cells may be important in determining
extent of behavioral improvement. Once again, this emphasizes the importance of
analyzing brain cytokine levels, and perhaps also quantifying levels of activated immune
cells such as microglia, astrocytes and T cells that would contribute to production of
these cytokines in the brain.
Factor Analysis/Discriminant Function Analysis
All but one RAWM measure loaded in Factor 1 of FA, as did both PR measures,
indicating this factor as cognitively-based. Stepwise forward DFA results for all
behavioral measures as well as Factor 1 measures alone indicate that Tg+/T cell animal
performances could not be separated from Tg- performances, whereas Tg+/PBS animal
performance levels were poor enough that they were clearly distinguished from the other
two, better performing groups. Our laboratory has shown in the past that “stepwise
forward” DFA analysis is capable of distinguishing not only between transgenic
treatment groups and wild-type mice, but also between different strains of transgenic
mice (Jensen et al. 2005, Leighty et al. 2004). Thus, the lack of discrimination between
Tg+/T cell animals and Tg- animals when applying this methodology across multiple
cognitive measures strongly emphasizes the similar performance levels of these two
groups. This reinforces the hypothesis that infusion of Aβ-sensitive immune cells leads
to normalization of Tg+ animal performances in RAWM to that of Tg- levels.
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Proposed Mechanisms of Aβ-Sensitive T Cell Mediated Cognitive Improvement in
APPsw/PS1 Mice
Although the current literature is limited with regards to application of adoptive
immunotherapy in neurodegenerative diseases, it is possible to speculate as to the
mechanisms by which infused T cells could act therapeutically in a mouse model for AD.
It has been shown that immuno-tolerance to Aβ is present in APP transgenic mice
(Monsonego et al. 2001), and it is therefore necessary to administer Aβ vaccinations in
adjuvant designed to activate the immune systems to elicit an effect. One mechanism of
action for Aβ-sensitive T cells infused into such an immuno-tolerant environment could
be to break this tolerance and initiate an immune system-based clearance of Aβ from the
CNS. Neuroinflammation is thought to be a major contributor to the progression of AD,
and is present to a large extent in AD mouse models. A second mechanism for T cell
action could be for regulatory T cells and/or Th2 cells to down-regulate this type of
cellular-based neuroinflammatory response. Finally, it is possible for T cells and the
cells they activate (astrocytes, microglia etc.), provide neuroprotection via a number of
mechanisms.
Stimulation of the immune system against an endogenous ‘self’ peptide, Aβ
T helper cells play a central role in determining the type of immune response elicited
against a given immunogen. Depending on the major sub-type of T cell involved in
stimulating such an immune response against Aβ, it is likely that one of two reactions,
either cellularly or humorally based, would be elicited against this peptide. If Th1 T
helper cells were the major contributor towards developing this reaction, a phagocytic
immune cell activation would be anticipated. This would potentially result in clearance
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of deposited amyloid via phagocytic mechanisms, a mechanism of clearance found to be
present in several active immunization studies in AD models (Das et al. 2003a, Das et al.
2003b). In the CNS, the primary phagocytic cells are the microglia, and thus such a
reaction would most likely be associated with increased microglial activation in the areas
of Aβ plaques (Wilcock et al. 2001). While correlation data from the current study
suggests that decreased diffuse hippocampal Aβ may mediate RAWM improvement in
some T cell infused mice, no overall reductions in Aβ pathology were noted, indicating
that this effect was not widespread in Tg+/T cell mice. In futures studies, it will be
important to determine to what extent microglia and other components of the cellular
immune system are activated in the CNS of T cell infused mice.
If following T cell infusion a Th2 biased response was elicited, in contrast to the
cellular based response to Aβ promoted by Th1 cells, a humoral response would be
anticipated instead. This would be mediated by the ability of Th2 subset cells to
stimulate B cells to produce antibodies, in this case antibodies specific to Aβ. Based on
the results of passive immunizations studies in models of AD (DeMattos et al. 2001,
Wilcock et al. 2004), it is likely that such a humoral based immune response would also
trigger the clearance of insoluble as well as soluble Aβ from the CNS via standard
clearance mechanisms for antigen-antibody immune complexes. A down-regulation of
cellular immunity present in Th1-biased immune reactions would also be expected in a
Th2-biased response, perhaps leading to decreased neuroinflammation as discussed
below. To determine if these effects were present in T cell animals, it may be beneficial
to look at antibody titers and regional brain cytokine levels in future studies.
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Overall down-regulation of the immune system, or of specific immune cells which
may contribute to neuroinflammation.
As previously mentioned, microglia and other cellular components of the CNS
immune system may be down-regulated by the Th2 subset of T helper cells. This would
be especially beneficial in the Tg+ animal brain paradigm, in which immune cells such as
microglia are perpetually activated by Aβ and Aβ associated neuronal damage. Without
the influence of regulatory cells, this form of activation may result in a state of “frustrated
phagocytosis”, which results in production of neuroinflammatory mediators involved
both in inappropriately activating other cells (such as astrocytes) and in directly causing
damage/dysfunction in adjacent neurons (Streit et al. 2004, D’Andrea et al. 2004). Th2
subset cells could down-regulate such activation, blocking perpetuation of the AD
neuroinflammatory cascade. Regulatory T cells may also be involved in this process,
down-regulating numerous immune cell types indirectly via de-activation of T-cells or
directly via interactions with microglia and other components of the cellular immune
system (Avidan et al. 2004). Again, in future studies, looking at regional cytokine
profiles would be beneficial to determine if such an effect was present. Analysis of
activated immune cell levels in the CNS would also be extremely beneficial in
determining the exact actions of adoptively transferred T cells.
Neuronal protection
The potential for T cells to enhance neuronal health and protect against neuronal
damage has been established in the current literature (Moalem et al. 2000, Benner et al.
2004, Avidan et al. 2004). This could involve a down-regulation of immune cells which
instigate neuroinflammation (and resulting neuronal damage) as described above, or a
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direct production and/or induced production of neuroprotective agents by astrocytes.
Whether cells in the Aβ-sensitive T cell populations infused into Tg+ animals possess
this potential is unknown, and analysis of either neurotrophic factor levels in the CNS
would indicate if this is a viable method by which T cells provide cognitive benefit in
these animals.
Clinical Implication of T cell Study Findings and Proposed Future Investigations
As with all immunologically based protocols, special care must be taken before
application of such protocols in humans. Further investigation into the potential for Aβsensitive immune cells to promote EAE or other deleterious auto-immune type reactions
is of the utmost importance, especially in lieu of the adverse effects resulting from
clinical application of active Aβ immunotherapy (Orgogozo et al. 2003). Additionally, to
help elucidate the exact mechanism of cognitive improvement/protection provided by
immune cell infusion, it may be beneficial for futures studies to look at the effects of
infusion of specific T cell subsets into transgenic animals. Analysis of the effects of
these subsets on behavior and pathology, as well as added analysis of brain cytokines,
activated immune cell (such as microglia) stains, and neurotrophic factor levels may
provide insight into the mechanisms by which Aβ-sensitive immune cells improve
cognitive-based performances in these AD transgenic mice. In addition, a comparison of
neuronal health and activity, especially in the hippocampus, in treated vs. untreated Tg+
animals may elucidate the exact mechanism by which cognitive performances in tasks
such as the RAWM are being improved. These and additional studies would be desirable
before application of this procedure in humans is initiated.
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From a methodological standpoint, Aβ-sensitive T-cells could be isolated from an
AD patient’s blood, or even spleen, expanded in vitro and returned to the patient on a
periodic basis. While invasive, this process is not unprecedented and has been used in
donor lymphocyte infusion protocols for many years (Kolb et al. 1995). Only one
infusion of T cells into AD transgenic mice was necessary to observe cognitive
improvement 1-1½ months later in this study. Future studies would be necessary to
determine if these effects would continue without additional infusions. If such followups were unnecessary or could be spaced far apart, this immunotherapeutic approach may
prove to be less invasive than other immunotherapeutic approaches to AD (specifically
active and passive immunization therapies against Aβ), which require regular injections
of either Aβ in adjuvant or anti-Aβ antibodies. Both of these forms of treatment have
potential for side effects as elucidated by studies both in animal models of AD and, for
active immunotherapy, in humans. Both active and passive immunotherapeutic
approaches have been shown to induce meningoencephalitis (Lee et al. 2005) due to
excessive immune system activation. This form of inflammation may not be present
following a single infusion of Aβ-sensitive T cells independent of adjuvant. Findings of
reduced levels of cytokines in the plasma of T cell infused mice would seem to suggest
that inflammation such as that noted in human active Aβ immunization trials is not
present, though further work will confirm or refute this hypothesis. Thus, adoptive
immunotherapy may provide a means of providing long term cognitive benefits in AD,
with decreased potential for negative side-effects.
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